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Nanomedicine includes detection, diagnosis and treatment of diseases at the 
cellular level and can be a valuable tool for highly specific medical interventions by 
utilising nanoscale objects. Cancer nanomedicine is one of the most successful 
research fields for exploring cancer at the cellular level. To find a suitable candidate 
for cancer theranostics (therapy and diagnosis) at an early stage and post-treatment 
(remission), the cytotoxicity, imaging, and therapeutic capabilities of various classes 
of nanoparticles were investigated.  
Firstly, various nanoparticles were first obtained from WOx and iron oxides 
being processed under hydrogen (H2) + argon (Ar) gas heat treatment and membrane 
filtration. A colouration process from yellow to blue colour was obtained for WO3 
nanoparticles (NPs) and an oxygen reduction process that led us to obtain metallic Fe 
NPs from γ-Fe2O3 NPs. Additionally, membrane filtration methods using ultrathin 
nanoporous membranes in microfluidic platforms were performed on γ-Fe2O3 
polydisperse NPs. This novel application showed a consistent reduction in size 
distribution from these magnetic polydisperse NPs after filtration at 37 nm and 60 nm 
membrane pore sizes. Tangential and normal flow filtration (TFF and NFF, 
respectively) were used with ethanol and water solvents which showed the need to 
work at low concentrations for dense nanoparticles. TFF presented a higher degree of 
filtration at the cost of complexity, time and price.  
Secondly, these NPs were then investigated for their incorporation as the core 
in core-shell structures. Novel core-shell NP structures were designed with an 
intermediate tunable SiO2 layer (3-60 nm) using the Stober process and also a tunable 




the Turkevich method. WO3-SiO2-Au NPs were synthesised which are a new class of 
NP that contains a first in it class WO3 core with potential electrochromic functionalities. 
Coherent anti-Stokes Raman spectroscopy (CARS) and near-infrared (NIR) surface-
enhanced Raman spectroscopy (SERS) were performed as a proof of concept for 
potential medical imaging to locate the nanoparticles achieving single-cell resolution. 
SERS enhancement factor (EF) using 785 nm was approximately 103 for a 30 nm thick 
Au shell in a silicon wafer. Additional Raman signals were measured in liquid samples 
to evaluate obtaining a SERS EF of 771 with WOx core and 33 using γ-Fe2O3 core. It 
presented low toxicity at concentrations under 100 µg/mL after 24 h using human 
isolated at M D Anderson from a pleural effusion of a patient with invasive ductal breast 
carcinoma breast cancer cells (MDA-MB 231)  in vitro.  
Finally, monodisperse γ-Fe2O3-SiO2-Au nanoparticles displayed a promising 
negative contrast for MRI in both T1 and T2 modes along with strong contrast under 
microcomputed tomography (μCT). Monodisperse γ-Fe2O3 cores, which have an 
average diameter of 11 nm following a gaussian distribution with a standard deviation 
of 3 nm, in γ-Fe2O3-SiO2-Au structures outperformed in all these imaging tests to 
polydisperse γ-Fe2O3 cores, which have a mode value at 31 nm following a Lorentzian 
distribution with a scale parameter of 29 ± 7  nm. Magnetic hyperthermia was achieved 
using γ-Fe2O3 cores confirmed the potential therapy functionality in water using AMFs 
at 515 kHz and 170 Oe, obtaining an increment of 7 °C in 23 min, which adds in total 
4 functionalities with potential application for cancer nanotheranostics. Moreover, cell 
viability assays using monodisperse γ-Fe2O3-SiO2-Au nanoparticles showed almost 
negligible cytotoxicity in different nanoparticle concentrations (0-2000 µg/mL) and cell 




In conclusion, the thesis was able to demonstrate that WO3-SiO2-Au NP and γ-
Fe2O3-SiO2-Au NP have the potential for further development as a tool in 
nanomedicine, although systemic toxicology and excretion pathways will have to be 
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Cancer is a disease of the genome in cells which typically leads to a reiterative 
process of clonal and subclonal expansion, genetic diversification, clonal selection, 
angiogenesis and tissue invasion[1–3]. When the tumour cells metastasise and migrate 
from a primary site to a distant organ, the survival rate of the patient with cancer is 
much lower. Hence, early diagnosis and treatment is a crucial element to minimise the 
impact of the malignancy. Current clinical in vivo diagnostic tools such as magnetic 
resonance imaging (MRI), X-ray computed tomography (CT), and positron emission 
tomography (PET) do not achieve a single-cell resolution. This issue prevents them 
from succeeding in early in-situ detections of tumours and validation after treatment 
for cancer patients in remission. They can only detect tumour tissues with a high 
number of tumour cells. Also, the effectiveness of most of these techniques is limited 
to certain types of cancer.  
Raman spectroscopy is a powerful analytical technique that can measure the 
biochemical changes at a molecular level of complex biological samples, such as 
biofluids, cells and tissues [4]. Recent advances in the field of point-of-care medicine 
include in vivo Raman fiber-optic needle probes that measure the molecular 
fingerprints of the region where the needle tip is located to determine the presence of 
any type of cancer [5]. This minimally invasive Raman approach can reach deeper 
regions in the body and involve the use of either transmission illumination and 
collection geometries. Another approach is spatially offset Raman spectroscopy 
(SORS) in which the illumination and collection points are on different points of the 
tissue surface and can reach up to a few centimetres deep which has many application 




higher precision in vivo and ex vivo by measuring biomarkers in the microscale, such 
as microcalcifications in breast cancer tissue [9].  
Alongside with these novel techniques, even more, precise diagnostic 
measurements are possible by obtaining images of labelled nanoscale contrast agents, 
achieving single-cell resolution via surface-enhanced Raman spectroscopy (SERS) 
for truly early-stage cancer detection [10,11]. Furthermore, an improved method to 
optimise the signal intensity is surface-enhanced resonance Raman spectroscopy 
(SERRS) which looks to match the wavelength of the excitation and the wavelength 
of an electronic transition within the reporter molecule used on the metal surface of 
the nanoparticles. Alternatively, fluorescent can also be used for single-cell detection 
but not for in vivo measurements in deeply buried tissue. However, its signal is several 
orders of magnitude weaker than those obtained in SERRS, although it is much 





Figure 1.1 | Statistics of cancer treatments in England from 2013 to 2016 obtained by 
the National Cancer Registration and Analysis Service (NCRAS) in partnership with 
Cancer Research UK (CRUK)  [12].  
Once the diagnosis locates the tumour tissue and identifies the cancer type, 
clinicians choose the best available therapeutic procedure to treat the malignancy. 
Among potential therapies, the most common approaches are surgery, radiotherapy 
and chemotherapy or a combination of them depending on the pathological context 
and local regulation. Figure 1.1 shows statistics of the percentages of tumours 
diagnosed in England in 2013 - 2016 recorded as receiving radiotherapy, 
chemotherapy or tumour resection (surgery).  Cancer surgery is not only the oldest 
oncological discipline but also the gold standard for localised tumours by excising the 
tumour with a surrounding margin of healthy tissue, such as lumpectomy in breast 
cancer [13]. Surgery is the most common line of defence against cancer, but often also 
requires to be used in combination with other therapies (as shown in Figure 1.1) due 
to potential extravasation of the tumour.  
Radiotherapy aims to deliver as much dose to the localised tumour whilst 
sparing healthy tissue; however, there are intrinsic risks of developing additional 
tumours due to using ionising radiation [14]. X-rays were first used as a cancer 
treatment by Emil Grubbe who used against a recurrent breast carcinoma in 1896, 
called Roentgen rays at that time. This type of technique was called radiotherapy or 
radiation therapy because it is a therapy based on the exposure of cancer cells to high 
doses of X-rays radiation (ionising radiation) which damages the DNA of the cell and 
leads to cell death and miotic failure [15]. This damage can be direct or indirect 




that ionising radiation induces DNA breaks, particularly, double-strand breaks in the 
chromosome. It also generates reactive oxygen species that oxidise proteins and lipids, 
and induce several damages to DNA, like the generation of abasic sites and single 
DNA strand breaks. In radiotherapy, DNA damage is targeted to only the cancer cells. 
Usually, it includes the use of multiple X-rays beams at a lower intensity that converge 
into the tumorous area to maximise the dose received in the cancer cells while 
minimising the exposure of healthy cells. This technique aims to shrink the tumour 
mass or eliminate residual tumour cells. 
A similar approach was also adopted in 1896 by Niels Finsen in the so-called 
phototherapy whose first trial in skin cancer used UV light which is also ionising 
radiation, but much less energetic than X-rays. Sixty years later, thanks to previous 
satisfactory clinical electric muscle stimulation, electrotherapy appeared published in 
Science to combat skin cancer cells with reported total tumour destruction in the 60% 
of the subjects in 1959. Furthermore, in 1985, Edwin Smith precisely described the 
concept of hyperthermia, for the first time in history. However, hyperthermia has not 
an agreed definition yet [16]; it has been defined as a core temperature above 38.2 °C, 
irrespective of the cause. In the context of treatment, it is defined as temperatures 
ranging between 40–48 °C [17]. Examples of external stimuli are shown in Figure 2.6.(2). 
Chemotherapy is the most common line of treatment for metastasised tumours 
and blood cancer due to their usually high growth and cancer cell division rates along 
with tumour delocalisation [18]. This type of therapy in most cases uses combinations 
of chemotherapeutic drugs with critical anticancer effects such as preventing drug 
resistant cancer cells, inhibiting angiogenesis and disrupting all possible stages of the 




other treatments such as surgery, radiotherapy and immunotherapy. Unfortunately, 
most chemotherapy drugs are highly dependent on the type of tumour and cannot be 
applied to other types. Therefore, in case of facing specific unexpected behaviour or 
high heterogeneity in the cancer cells, the therapy might fail for a subset of cells and 
require a second round of chemotherapy or an alternative treatment. Survivor cancer 
cells will have adaptive advantages that will make them harder to kill, the longer it 
takes to start a secondary effective therapeutic approach. Multifunctional 
nanoparticles (NPs) can address most of these demanding tasks for either detection, 
imaging or diagnosis by interacting at the nanoscale with single cells. There has been 
keen interest during the last decade in finding different NPs that tackle specific clinical 
limitations, including in vivo single cancer cell imaging and treatment of aggressive 
brain cancers such as glioblastoma [21]. 
Nevertheless, the interest has been even more substantial in finding those that 
can provide multiple highly valuable functionalities in the same device. Some very 
promising magneto-plasmonic NPs, those that have both magnetic and plasmonic 
behaviour, have previously been presented over the last years by other authors as 
multifunctional platforms [22–26]. However, most of these do not provide multiple 
translational applications to the clinic and are limited to only the areas of the body 
where the diagnostic technique is effective and safe. For instance, for MRI, different 
regions have different MRI contrast for both T1 and T2; consequently, the nanoparticle 
needs to be tuned to be distinguishable in the desired region in a particular mode [27]. 
Raman signals from nanoparticles can only be measured up to a penetration depth of 
approximately 15 mm in the best-reported scenario using SORRS [28], due to light 
attenuation in complex media, which is not enough to detect deep regions. Also, to 




nanoparticles to match the maximum absorption peak with the excitation wavelength. 
For similar reasons, effective photothermal ablation from NPs is only available for skin 
cancer and the heating rate is typically very high which limits the control in the 
hyperthermia region and the laser beam diameter tends to be 3 mm which provides 
low precision. Organs are susceptible to potential toxicity after exposure to NPs; some 
of the most critical areas are the respiratory system[29], the renal system[30] and the 
brain [31].  
Additionally, there is a lack of cytotoxicity tests with different cell types - 
including healthy and malignant – for most NPs; they are usually performed in one cell 
type only.  And many impactful studies on NPs for cancer diagnosis and treatment 
[24,25,32–39] did not include or discuss the effects of NP aggregation since it is an 
unwanted scenario, despite being a recurrently reported case during NP synthesis. It 
may happen in a diverse physiological environment as found in the human body; with 
changes in pH, pressure and temperature [40,41]. 
Moreover, most magnetoplasmonic structures use magnetite (Fe3O4) magnetic 
components that display powerful magnetic properties useful for faster and stronger 
responses to external magnetic fields, particularly with SPIONs [42–45]. Unfortunately, 
these strong magnetic properties also lead to a tendency to aggregate, even when 
coatings are used to reduce this effect [46]. In the worst scenario, the presence of NP 





Figure 1.2 | Statistics of publications on nanomedicine/NPs used to find and treat 
cancer cells.  
Figure 1.2 presents the number of publications per year listed in PubMed under 
the search query “nanoparticles treatment diagnosis cancer cells”. There is a clear 
exponential trend that represents the growing interest, development implementation 
and lately maturation of NPs for both diagnosis and treatment of cancer. Some of the 
breakthroughs in the field of NPs for cancer diagnosis and treatment include selective 
cell targeting, immunotherapy, fluorescent imaging, SERS imaging, surface-enhanced 
SESORS, computed tomography (Computer tomography) contrast agents, MRI 
contrast agents, magnetic drug targeting, photothermal hyperthermia and magnetic 
hyperthermia [49–54]. These functionalities arising from NPs have provided a better 
understanding of what can be introduced during the design of a nanoscale agent to 
overcome some current clinical limitations. However, most of these technological 
solutions are vaguely presented in the clinical context, yet with just a few undergoing 
clinical trials that are not fully approved for commercial use. In these examples, the 





















NPs involved are very simple, with minimal biomedical functionalities. Most initial 
clinical trials are blind controls or double-blind randomization to compare the evaluate 
dosage, and then efficacy and side effects. The main evaluated aspects for NPs are 
clearance and toxicity for specific NP concentration, which are mainly dependent on 
the size, shape, density, hydrophobicity, pH stability, surface charge and surface 
chemistry [55]. In terms of NP clearance, hydrophilicity (charge-polarized and capable 
of hydrogen bonding) usually leads to direct excretion by the kidneys, while the 
hydrophobicity undergoes biotransformation before excretion. 
To get NPs approval by regulatory agencies, NPs need to undergo product-
specific technical assessments, taking into account the effects of NPs in the particular 
biological context and pharmacodynamics of each product and its intended use. To 
regulate medical NPs, the US Food and Drug Administration (FDA) implements two 
regulatory pathways as mandated by the Medical Device Regulation Act of 1976: the 
most common is the 510 (k) process, and the other is the PMA process. The PMA 
process requires clinical trials to demonstrate the safety and effectiveness of NPs. 
Before beginning clinical research, an Investigational New Drug (IND) application must 
be submitted to the FDA, which must include: animal study data and toxicity data, 
manufacturing information, clinical protocols for studies to be conducted, data from 
any prior human research and information about the investigator. The 510 (k) process 
requires a submission to the FDA demonstrating that the NP to be sold is similar to, 
and at least as safe and effective as, a previously legally marketed NP that is not 
subjected to PMA [56]. For the European Medical Agency (EMA), the only route for the 
NP approval is performing human clinical trials whose data are evaluated by EMA 




of medicinal products for humans. The clinical trials can be performed outside of the 
EU, but they need to adhere to equivalent standards.  
In this thesis, experimental work is primarily presented with the aim to design, 
synthesise, and evaluate multifunctional core-shell composite NPs for combined 
cancer imaging and treatment capabilities. The main focus of this work is obtaining 
high quality and biocompatible nanomaterials that combine as many functionalities as 
possible, with the capacity for cancer diagnosis along with therapeutic capabilities that 
are externally activated and effective for many types of cancer. This thesis also aims 
to obtain materials suitable for in vivo single-cell imaging applications using SERS in 
conjunction with contrast imaging from clinically available diagnostic tools for cancer 



















2.1. Single-cell detection 
Single-cell detection is essential for early diagnosis of health conditions that 
can quickly escalate if not detected early enough. Figure 2.1 shows the different 
methods used for single-cell detection. 
  
 Figure 2.1 | Current approaches under investigation to single-cell detection for 
disease diagnosis. 
While microfluidic cell isolation (detection) and subsequent single-cell 
sequencing (analysis) are relatively common oncological techniques in the clinic, the 
in vivo and ex vivo single-cell detection approaches are still under investigation.  
In vitro methods are very popular to isolate cells and subsequently perform 
advanced analysis, including cell genomics and surface cells proteomics. 
Unfortunately, these methods require a sample biopsy from the patient, which is 
always invasive, with different degrees depending on the sample origin. This 
requirement makes in vitro systems less appealing for cell detection, especially when 
the exact tumour location is unknown. 
For in vivo measurements, both microparticles and NPs overcome this problem 
by being able to target cells in any region of the body without the need for a biopsy 
from the patient. However, injecting micro- and NPs into a human body is a highly 




objects. These features are usually not achieved by microparticles due to their size, 
which is in the same order of magnitude as the human cells, which are 4-40 µm. NPs, 
on the other hand, can achieve higher excretion percentages if their size is tailored 
appropriately to be in the size range of human proteins and virus (5-120 nm), enabling 
their ability to travel. However, only NPs smaller than 5 nm are readily excreted by the 
kidneys into the urine. Invasiveness can be minimised by localising a region of interest 
where the suspected disease exists, which is highly effective in the case of cancers 
since most of them exist in specific locations and display features characteristic of 
those regions. An example of this is the microcalcifications which are detected in 
breast cancers. These are biomarkers that indicate a potential malignancy, which can 
be further confirmed by using NPs in the breast area. 
Diagnosis is the most critical aspect in oncology. The prognosis of patients 
whose cancer is detected early is drastically improved compared to those with later 
detection. Besides the fact that there are some cancer biomarkers that can be 
detected just by taking blood or urine samples, a comprehensive diagnosis is usually 
required to fully understand the illness or disease and follow with the treatment that 
has the highest likelihood of success. For this reason, there exist a wide range of 
molecular imaging options for this purpose that includes magnetic resonance imaging 
(MRI), computer tomography (CT), positron emission tomography (PET), single-
photon emission CT, ultrasounds imaging, fluoroscopy and recently Raman 
spectroscopy (via SESORRS). 7-T MRI machines can resolve up to 0.5 mm, while 
21.1-T high-resolution MRI (HRMRI) can resolve as small as 120 μm[57]. 
Microcomputed tomography (microCT) can have a resolution of 1 μm. However, in 
vivo, human CT imaging is restricted to a voxel size of 82 μm (with an actual spatial 




considerations [58]. Positron emission tomography (PET) can obtain a resolution of 
0.67 mm for pre-clinical studies (small non-human animals) and 1.83 mm for clinical 
imaging [59]. All these values are beneficial for clusters of cells or tissues, but they 
cannot detect single human cancer cells which typically range from 20 to 30 µm and 
even reach sizes smaller than 6-7 µm to navigate through blood vessels [60]. Therefore, 
these techniques cannot provide a single-cell resolution. For most types of cancer, 
detection in the early stage is the key to success in the treatment. Particularly in cancer 
research, early diagnosis has become the focus of attention in the scientific community.  
There are some commercially available techniques to destroy cancer locally at 
the cellular level, but not for in vivo imaging. Most cancers are diagnosed when there 
is a significant volume of tumour tissue, and therefore the malignant cells are likely to 
have spread around the whole body, which decreases notably the probability of 
success for most treatments. Hence, single-cell detection is essential to find and 
analyse cancer at its earliest stage possible. However, single-cell detection has some 
physical barriers for most commercially available traditional techniques which make it 
not possible to achieve. Here is where nanotechnology comes to bring a new set of 
tools for unlocking the cellular and subcellular scale, particularly with the use of NPs.  
NPs are objects smaller than 1 µm, usually in the range of approximately 1 to 
100 nm, much smaller than any human cell (4-40 µm). Their relatively small size is 
what makes them so desirable for cancer cell imaging. Depending on the antigens 
expressed on the cancer cell surface (e.g. oestrogen, progesterone, her2, egfr), there 
is a unique type of antibody that links to each cancer cell antigen. Antigens are typically 
proteins, peptides, or polysaccharides. Different antibodies can be used to target the 




different cells. With protein antigens, the antibody molecule contacts the antigen over 
a broad area of its surface that is complementary to the surface recognised on the 
antigen. Functionalisation of the NP surface with the right antibody enables it to target 
the surface of the malignant cells that present the binding antigen, which can occur as 
a consequence of electrostatic interactions, hydrogen bonds, van der Waals forces or 
hydrophobic interactions [61]. This targeting brings the possibility of performing 
diagnostics in single cells.   
One essential point to consider is the biocompatibility and circulation time in the 
bloodstream of these NPs. This includes cytotoxicity but expands the considerations 
to NPs accumulation in undesired areas, inflammation, and cellular behavioural 
changes such as oxidative stress. These aspects must be considered while designing 
the nanomaterial for single cell detection. In this regard, gold nanoparticles (AuNPs) 
are truly biocompatible and non-cytotoxic at low concentrations for a wide range of 
scenarios because of their high stability and being a noble metal.  
2.1.1. Raman spectroscopy 
Spontaneous Raman spectroscopy, usually referred as Raman spectroscopy 
in the literature, is a molecular spectroscopic technique based on an inelastic light 
scattering, which provide spectroscopic information of the energy transitions of 
electrons that are excited from the molecular valence state to virtual molecular states 
and subsequently decay inelastically. This technique, combined with surface 
plasmons generated near the vibrating reporter molecules, results in the so-called 
surface-enhanced Raman spectroscopy (SERS). In SERS imaging, AuNPs have been 
widely used because of their ability to generate plasmons with visible and NIR light 




nm of the NPs surface. Raman reporter molecules are molecules are used to provide 
a known signal spectrum which are typically amplified using SERS. Plasmons are 
collective sinusoidal oscillations of the electron clouds in metals which boost the 
intensity of the Raman reporter molecular vibrations up to 106 on average and 1010 or 
higher in localised areas for low wavelengths such as UV light while using SERRS and 
matching the plasmon resonance frequency. SERRS is one step beyond SERS in 
which the analyte has a chromophore with the excitation energy of its electronic states 
close to the respective the frequency of the excitation that is utilised to excite the 
surface plasmons in SERS. Another approach is deep Raman spectroscopy; this type 
of Raman uses spatially offset Raman spectroscopy (SORS) to collect the Raman 
photons that have been generated more deeply in complex media when NIR 
illumination is used. SORS has been demonstrated for the detection of Raman spectra 
from calcifications (breast cancer biomarkers) and cancerous tissues under a deep 
soft tissue but at much higher concentrations than the required for a SERRS signal to 
be detected. Recently, silicated RGD-coated gold nanostars with an average diameter 
of 120+/-9 nm and a silica shell of 23 ± 4 nm have been used to perform a combination 
of SERRS and SORS called SESORRS obtaining measurable signals through stacked 
plastic barriers of 4.5, 6 and 7.5 mm thick each and being dispersed in ethanol [28]. By 
changing the offset, there is a substantial change in the depth of the detected signal. 
This can be used to obtain a higher contrast when displaying a heat map of the signal. 
Larger offsets provide weaker signals due to photons penetrating longer paths in the 
plastic barrier. 
Figure 2.2 summarises the underlying physical principle of Spontaneous 
Raman spectroscopy which is commonly used to describe the molecular band energy 




state [62]. This type of Raman-scattering receives the name of spontaneous because it 
takes place spontaneously, i.e., this scattering occurs randomly, and only a small 
number of scattered photons undergo this process. The potential vibrational energy 
states that the molecules can go to or depart from can be obtained by solving the 
vibrational Schrödinger equation.  
 
Figure 2.2 | Jablonski diagrams of Spontaneous Raman Spectroscopy. The 
fundamental physical principle of the Raman scattering in terms of energy levels. The 
Stokes mode is described in the left side, and the Anti-Stokes mode is described on 
the right side. 
The Raman spectra contain the intensity of each decay present in Figure 2.2, which 
are expressed in terms of Raman shifts: 
Δω = (ωpump −ωRaman) (2.1.1) 
where Δω is the Raman shift, ωpump is the excitation wavenumber and ωRaman 




In Raman spectroscopy, a monochromatic laser beam interacts with the 
molecules of the sample and produces scattered light. This scattered light contains 
spectroscopic information of the molecular interactions. However, most of the 
scattered photons are elastically scattered via Rayleigh scattering. This type of 
scattered photons contains no information about the light-matter interaction. Only a 
small fraction of the scattered radiation has a different frequency from the frequency 
of the monochromatic incident radiation. This small contribution of scattered radiation 
constitutes the Raman spectra. In Raman scattering, there is a molecular excitation 
caused by the incident radiation and a decay via inelastic photonic scattering through 
its interaction with vibrating molecules[63]. A Raman spectrum is presented as an 
intensity-versus-wavelength shift with a typical Raman spectra range of 4000-400 
cm−1 which is the region of Raman active normal modes of vibration for organic 
molecules[64]. 
Low sensitivity due to weak Raman scattering is the major problem associated 
with this technique. However, sensitivity can be enhanced using Resonance Raman 
Spectroscopy (RRS) and SERS. The basic idea of RRS consists of matching the 
frequency of incident radiation with an electronic transition of the molecule, which 
increases the intensity of the obtained Raman spectrum drastically. RRS also allows 
working with very diluted samples. 
For in vivo imaging of cancer cells, Raman spectroscopy should be performed 
in the NIR to penetrate human soft tissue deeper, red light (650 nm) is extinguished at 
4–5 mm penetration depth and shorter wavelengths penetrate even less. Detection of 
NPs that target cancer cells using NIR SERS requires larger spherical NPs to redshift 




enhancement factor (EF). However, the problems related to toxicity associated with 
large NPs and their low excretion rate make them less ideal for safe diagnosis. 
Moreover, large NPs tend to aggregate more quickly due to potential larger 
electrostatically charged surfaces, to be more massive than smaller counterparts and, 
if magnetic, to presenting ferrimagnetic behaviour that attracts other magnetic 
nanoparticles around. For these reasons, they eventually can form aggregates heavy 
enough to undergo gravitational decantation inside of the human body if they are in an 
area with a slow or null flow which will lead to potential tissue damage and will prevent 
their excretion. Furthermore, different shapes of nanoparticles also provide different 
absorption profiles which can be tuned for the optimal maximum of localised surface 
plasmon resonance (LSPR) absorption.  
There are other methods for single-cell detection, such as NIR fluorescence. 
For instance, Dong et al. 2019 successfully developed NIR-to-NIR two-photon excited 
fluorescent CaF2: Tm3+, Yb3+ NPs (with a diameter of 11 nm and size dispersion of ±2 
nm) for highly penetrating fluorescence bio-imaging which were tested using in vitro 
HeLa cells which are an immortal cervical cancer cell line [65]. Additionally, 
autofluorescence in the NIR region from human tissue is very low. This low NIR cellular 
autofluorescence background allows this technique to perform in vivo fluorescence of 
the entire body. This is particularly relevant in pharmacokinetics and guided tumour 
surgery [66]. Unfortunately, this technique does not provide molecular information from 
the fluorophores. For detailed molecular information, additional ex vivo studies can be 




Hence, finding the right NP that brings reliable single-cell detection in vivo, while 
causing minimal or zero toxicity, is the main goal in terms of diagnostic properties in 
this thesis. 
2.1.1.1. SERS imaging and detection 
Raman spectroscopy is a spectroscopic technique that shows the inelastic light 
scattering after interacting with the vibrational bands in the targeted molecules. These 
transitions between vibrational levels in molecules provide information of their 
chemical structure in the form of peaks for specific wavenumbers whose distribution 
is unique for every molecule. The Raman spectra can be understood as the “molecular 
fingerprints” of any molecule. This revolutionary discovery made in 1928 by 
Chandrasekhara Venkata Raman about the analysis of molecular structure resulted in 
his Nobel prize in physics in 1930 ‘for his work on the scattering of light and for the 
discovery of the effect named after him’.  
SERS is a powerful method to measure the vibrational band fingerprints of 
single molecules which are adsorbed on top of a jagged metal (see Figure 2.3). SERS 
can stand for either scattering to emphasise the optical effect or spectroscopy to 
emphasise the technique and its applications. The signal obtained from Raman 
scattering is enhanced by surface plasmons that move across the metal substrate of 
noble metals such as Au, silver (Ag) and copper nanostructures. However, other 
plasmons can also be generated in periodic 2D structures such as graphene. These 
plasmons are activated by the coupling between photons and charge density 
oscillations of the electrons in the conduction band in metals. On the other hand, 
spectroscopy is a measurement technique of the interaction between matter and light. 




radiation is using light beams in the form of laser with approximately one single 
wavelength or by using white light. For Raman spectroscopy, a laser is used to excite 
the vibrational bands with different wavelengths depending on the purpose.  The range 
of lasers commercially available involves ultra-violet (UV) from 244 nm to 364 nm, 
visible from 457 nm to 660 nm and near-infrared from 785 nm to 1064 nm. Conversely, 
it is an important issue to assess the appropriate laser power to ensure the NPs are 
activated strongly enough to enhance the Raman signal but not so high that they 
produce heat. 
 
Figure 2.3 | Diagram of SERS effect where the Raman molecule reporter is a thiol (4-
Mercaptobenzoic acid) on top of an Au layer that acts as a metallic substrate, and the 
laser photons are in the Near-Infrared. 𝜆 refers to the incident light and 𝜆 ± Δ𝜆 are the 




Figure 2.3 shows the very well-known bond between AuNPs and the sulphur of 
the thiol molecule obtaining a self-assembled surface structure of thiol-capped AuNPs. 
The selection of 4-mercaptobenzoic acid (4-MBA) among all the other possible 
thiolated marker provides the potential benefit of both a strong SERS signal and a 
peak shift with pH. Despite the fact that the bonding between one single sulphur atom 
and Au is robust, other chemical structures contain more than one sulphur that can 
bind with the same AuNPs and, therefore, can produce a much more stable final 
material. Also, 4-MBA only contains one aromatic ring that generates much weaker 
peaks than other thiols with several rings.  
SERS is a surface spectroscopy technique, by definition. Hence, the reporting 
molecules must be close to the surface (<10 nm). This means that a bond or 
attachment between the metallic surface and the molecules is required for continuous, 
reproducible and optimised signals. To implement SERS in many practical 
applications, transferring the molecules from the bulk to a surface is needed and can 
be achieved in different ways that can affect the final enhancement efficiency. This 
step must be taken into careful consideration in advance to ensure the best 
performance for each case. The surface can present a variety of shapes, SERS can 
be performed from redispersed metallic colloids in a solution to uniform substrates 
fabricated by nano-lithography. However, roughened surfaces providing points of 
electric field enhancement, related to the lightning rod effect, provide areas of greatest 
enhancement. 
The enhanced signal is due to plasmon resonances in the metal substrate. For 
both applied and fundamental SERS approaches, measuring how much the signal can 




quantified by using the enhancement factor (EF). On average, the best enhancements 
in a sample can be up to 106, usually called ‘average SERS’; while in localised areas 
it is possible to obtain an EF of 1010 or higher using UV light. However, there are some 
issues to compare and predict EFs of different SERS substrates for a specific 
application. Due to the significant number of possible scenarios in which SERS can 
appear, a single general definition for the EF is impossible. There has been a growing 
controversy during the last 15 years about the possible contribution for the origin of 
the SERS enhancement due to the effect of the electronic interactions between the 
metal and the adsorbate, typically called chemical enhancement factor [67]. While the 
electromagnetic enhancement makes it possible to see the enhancement in the signal, 
the chemical mechanism determines what is observed. When the molecule is directly 
attached to the surface, the highest EM enhancement is obtained. This enhancement 
is differential across large molecules, with a higher enhancement for the molecules 
closer to the metal surface. Then, there is a possibility of including in this enhancement 
a multiplicative contribution due to the excitation into a charge transfer (CT) excitation 
between the metal and the adsorbed molecules which can provide an enhancement 
of ∼102 in the peaks [68]. SERS spectrum contains the information about the adsorbate, 
its environment and its interaction with the enhancing NP, its spatial orientation, and 
the polarization properties of the local electric field.  Almost 20 years after the initial 
ideas about the physical origin of the magnitude increment in SERS, the possibility of 
single molecule (SM) Raman spectroscopy via SERS was proposed [69]. Since then, 
SERS became a dominant tool for SM laser spectroscopy competing with the 
traditional well-established fluorescence. Still much remains to be learned about SERS, 
in recent years, a better understanding of the SERS background was studied 




on plasmons, the identity of the adsorbate, adsorbate coverage and electrochemical 
potential [70]. 
By using NIR lasers, non-dissipative light transmission in tissues can be 
achieved while keeping a strong SERS effect. This is the foundation of deep tissue 
Raman imaging for cancer cells. An excellent example of this is the SERS-active gold 
nanoshells (AuNSs) of 100 nm in diameter with built-in hotspots with SERS EF higher 
than their gold sphere counterparts of the same size for 633, 785, and 830 nm [71]. 
These structures reached NIR SERS EF over 200 for diluted colloidal samples in water 
using acquisition times of 10 s and 5 mW of power. 
The key concept behind the SERS signal peaks’ boost is the coupling of electric 
fields from the plasmon waves with the vibrational modes in the molecules. These 
electric fields are a consequence of the dielectric environment formed by the electron 
cloud oscillation around the metallic nucleus, i.e. plasmons. Therefore, a dipolar 
localised surface plasmon resonance (LSPR) is responsible for the excitation of the 
metallic NP (see Figure 2.4). One crucial aspect is the fact that plasmons are in 
principle only generated in metals due to the need for conductive electrons. However, 
there exist exceptions to this rule that were found during the last decade, such as 





Figure 2.4 | Electromagnetic enhancement in SERS activated by excitation of a dipolar 
LSPR. 
The SERS EF of a molecule within SERS is controversial and varies drastically 
depending on the considerations taken in account. A general expression of the SERS 
EF for the same Raman reporter concentration in the bulk sample solution is given by 





where ISERS  and INRS  refer to the peak intensities of the SERS and normal 
Raman Spectroscopy (NRS), respectively. NSERS and NNRS correspond to the number 
of probe molecules excited in the SERS and NRS tests given. Basically,  NSERS and 
NNRS  are equal in the concentration of molecules is the same, homogenously 
distributed in the region to excite and to use the same volume of sample to excite. 
However, this measurement might mislead. When comparing intensities, a refinement 
from this measurement includes considering a background signal that will be equally 
excited in both measurements and normalise the signal so that both backgrounds have 
equal intensities. Then the formula (2.1.2) can be considered correct. However, when 
the sample presents hot spots that vary under environmental changes, it will not be. 
Because of this unique Raman signal boost, many applications have been devloped 
to exploit the capabilities of this effect in a wide variety of fields. In medical diagnosis, 
deep Raman spectroscopy has supposed an innovative approach to measure 
molecules through a thick tissue layer. This technique, combined with the SERS 




bacteria and viruses inside of the human body. However, there still is a debate about 
the consequences of introducing nanostructures in the organism in the long term. 
2.1.1.2. Coherent anti-Stokes Raman spectroscopy 
Coherent anti-Stokes Raman spectroscopy (CARS) is a nonlinear four-wave 
mixing Raman spectroscopy technique that typically uses two powerful collinear 
synchronised lasers, pump and Stokes, to irradiate a sample. CARS is particularly 
useful for enhancing the weak (spontaneous) Raman signals. CARS microscopy is 
frequently used to study cancer cell behaviours in vivo and in vitro [74].  
 
Figure 2.5 | Jablonski diagram of the Coherent Anti-Stokes Raman Spectroscopy in 
terms of energy levels following the same terminology used in Figure 2.2. 
In a generic CARS process, three lasers at the pump (ωpump), Stokes (ωstokes), 
and probe ωprobe) frequencies interact with a medium to generate a new field at the 
anti-Stokes frequency [75] obtaining 




In most experiments, the pump field and probe field come from the same laser 
beam, and therefore, ωpump = ωprobe which leads to  
ωanti−stokes = 2 × ωpump −ωstokes (2.1.4) 
The frequency of the pump is usually kept constant, and the Stokes laser is 
tuned to ensure that the frequency difference between the two lasers equals the 
vibrational frequency of the Raman-active mode of interest (see Figure 2.5).  
To obtain a strong Raman signal, the Stokes laser frequency is tuned to the 
difference between the pump and the vibrational frequency of the Raman-active mode 
of interest. Consequently, the scattered light frequency is higher than the excitation 
frequency, which leads to conclude that anti-Stokes scattering is occurring.  
CARS microscopy provides spectroscopically high-resolution confocal mages 
cell and insights of cellular structures. Coherent Raman imaging techniques have 
demonstrated high-speed, high-spatial-resolution imaging, but with contrast limited to 
single or few Raman peaks [11,76–78].  
2.2. Cell Targeting 
Cell targeting is the delivery of a particular agent to a cell, and can also be used 
for its identification. There are primarily two subtypes of targeting modalities: active 
and passive. Both active and passive targeting promotes NPs’ accumulation in the 
location of interest. Targeted cancer delivery of therapeutics or diagnostic agents 
involves systemic administration in passive targeting or localised delivery of the 
nanoscale agents to the diseased tissue active targeting [79]. The main controlling 




of the bare nanoparticles, and pathophysiological characteristics of the tumour 
microenvironment.  
In passive targeting, the success of nanoscale object excretion relies on having 
a prolonged circulation time. This can be achieved by coating the NP with some highly 
biocompatible and non-reactive substance such as polyethylene glycol (PEG)[80]. The 
first clinically approved passively targeted nanocarrier was PEGylated liposomal 
doxorubicin (DOXIL™) in 1996 [81]. Long circulation time also maximises the chances 
of NPs excretion. On the other hand, active targeting is essential for the effective 
delivery of drugs, genes and theranostics to the location of interest, avoiding the 
healthy tissues and minimising side effects. Active delivery maximises the number of 
nanoscale object delivered to the target cell [82]. To achieve this, proteins on the 
surface of the cell are being targeted via antibody-antigen interaction. In this type of 
interaction, the antigen-binding fragment (fab) of the antibody binds to the epitope of 
the antigen. Epitopes or antigenic determinants are outer regions of proteins that can 
trigger an immune response from T or B cells [83]. The antigen can display multiple 
epitopes of which the antibody needs to recognise at least one to achieve the binding. 
By functionalising the surface of the NPs with these antibodies, the NPs can target the 
surface of the desired cell.  
Despite the antibody targeting approach which the main route to delivery 
nanoscale objects to a cell, it is also possible to obtain NPs selectively uptaken by 
cancer cells via anionic surface functionalization [84]. 
There have been reported some highly successful cases of NPs for cancer in 
recent years, most of which are nab type (NP albumin-bound) tested for cancer 




most notable examples are Doxil®, a liposomal system for doxorubicin delivery and 
treatment of ovarian carcinoma; Abraxane®, albumin NP taxol conjugate for the 
treatment of metastatic breast cancer; nanoliposomal irrinotecan, a SPIO Feridex I.V.® 
(ferumoxides injectable solution) to diagnose the pre-operative stage of pancreatic 
cancer with MRI with passive targeting[90]; a transferrin targeted cyclodextrin polymer-
based NP for siRNA delivery CALAA-01 which uses multiple antibodies including anti-
RRM2, anti-GAPDH, anti-hTfR and anti-β-actin [91]; and lyso-thermosensitive 
liposomal doxorubicin (Thermodox®) as a novel activated therapy using 
radiofrequency ablation [92,93]. 
2.3. Cytotoxicity 
Cytotoxicity is the ability of any agent or process to kill cells. The cytotoxicity 
test is one of the most critical biological evaluation tests that use cultured tissue cells 
in vitro to observe the cell growth, reproduction and morphological effects by exposure 
to a certain drug or medical device. Cytotoxicity investigations of engineered NPs are 
particularly relevant in drug and gene delivery, biosensors, cancer treatment and 
diagnostic tools [94]. Recent studies showed varied in vitro cytotoxicity of NPs 
concerning size, shape, material composition, surface charge and cell type [95]. For 
instance, macrophages are highly susceptible to nanomaterial toxicity. At the same 
time, 3T3 fibroblasts are more resistant, the viability of 3T3 cells slightly decreases as 
the concentration of nanomaterials is increased and, in telomerase-immortalised 
bronchiolar epithelial cells, multi-wall carbon nanotubes  <8 nm are substantially more 
toxic than similar materials with bigger diameters (20-30 nm and >50 nm). One reason 
for these effects is the correlation between particle size and surface area. Also, there 




cytotoxicity compared to other mainstream materials and lead to their approval for 
clinical use by drug regulatory agencies. 
Most human cells are actively maintained neutral or slightly positive charge at 
the cell surfaces via the ion pumps and channels on the plasma membrane. Significant 
amounts of surface charge on cells are usually generated by an abnormal movement 
of mobile ions across the plasma membrane [96]. Cancer cells are distinctively 
characterised by having a negatively charged surface as a consequence of their 
unique metabolic processes [97]. The surface charge is measured using the zeta 
potential. Positively charged NPs will rob electrons from cells which can cause 
damage to them. Furthermore, positively charged NPs could easily enter any cell, not 
just diseased cells, in contrast with negatively charged and neutral NPs [97]. This is 
potentially very dangerous for healthy cells because cells contain negatively charged 
DNA that will bind to them. Moreover, positively charged NPs have an enhanced 
capacity to adsorb proteins, including antibodies, albumin and fibrinogen. Proteins 
binding to NPs alters the protein structure, which may lead to various diseases, such 
as amyloidosis [40]. Some studies have shown that there is a tendency to accumulate 
positively charged and neutral NPs by all cell types while negatively charged NPs are 
primarily uptaken by cancer cells [84]. NPs enter the cells by endocytosis, which is 
divided into phagocytosis for larger particles (>500 nm) and pinocytosis for smaller 
NPs [98]. 
Many studies have shown that more advanced in vitro toxicity assays allow 
more accurate representations of the physiological tumour microenvironment. For 
instance, a 3D cancer microfluidic cell culture for studying onco-nanomedicine efficacy 




response of malignant human colon carcinoma cells in a gradient-like fashion, as 
occurs in a physiological concentric tumour microenvironment, for several 
concentrations of GEM-loaded CMCht/PAMAM dendrimer nanoparticles as they 
penetrate the cancer hydrogel in a gradient fashion. Another relevant example is the 
dynamic multi-organ-chip for long-term cultivation developed by Wagner et al. 2013 
[100]which obtained crosstalk between the tissues in 14-day co-cultures exposed to fluid 
flow. 
2.4. Nanotherapy 
The most important idea about therapy is that there is a need to find the 
therapeutic window where the treatment kills the cancer cells without killing too many 
healthy cells and therefore impact on the recovery or survival of the patient. This is the 
pillar on which all the different techniques are based.  
The intrinsic limits of most cancer therapies require a better delivery control, 
total elimination of the selected NPs after therapy and safer treatment. Most of the 
current clinical chemotherapies include chemical agents that have a low molecular 
weight with the high pharmacokinetic volume of distribution that leads to increasing 
their cytotoxicity. Also, the low molecular weight of these chemicals promotes their fast 
excretion; hence more doses are required, which ends up with a higher net 
concentration. This contributes to the notable increase in toxicity. Therefore, the 
current pharmacological approach is being challenged by many other novel 
alternatives that currently present lower known risks. Examples of these are 
nanotechnology structures that can generate lethal effects such as absorbing oxygen 
(hypoxia), invading the inside of cancer cells, heating single cancer cells 





Figure 2.6 | Diagram of the hyperthermia treatment procedure. (1) NPs injection. (2) 
Heating treatment activation by increasing the NPs temperature. (3) The result of the 
hyperthermia treatment. 
Recently, innovative magnetic hyperthermia has been implemented (see Figure 
2.6), where the temperature increment is generated by the action of an alternating 
magnetic field to the magnetic material. The most common example is ferrite NPs, 
with sizes from 10 to 100 nm[101–105]. However, there is some concern about the toxicity 
of this type of NP since the human body cannot efficiently excrete sizes closer to 100 
nm or larger, and most of the IONP used until this decade exceeds 100 nm without 
including any additional coating or aggregation. These giant magnetic NPs produce 
heat via two main mechanisms: hysteresis loss (multimagnetic domain) and 
relaxational losses (single magnetic domain). The combination of these mechanisms 




effective hyperthermia range of 42-48°C under these fast heating processes is hardly 
controllable. When the IONPs are small enough, close to 10 nm, their 
superparamagnetic behaviour becomes dominant and the single domain 
approximation becomes valid. And therefore, the only heat arises from relaxation 
losses that can be either Neel or Brown, which can be monitored and easily controlled 
to remain at 42-48°C to deliver magnetic hyperthermia. For Fe3O4 NPs, the 
dimensional limit for domain walls is in the order of 50 nm [106]. Moreover, most 
composite versions of these NPs bring this size issue. 
Some of the most innovative approaches to combat cancer with NPs are 
hypoxia-activated drug treatment [107] and hyperthermia-induced by some external 
energy sources such as applied magnetic fields or NIR lasers. The hyperthermia 
treatment is described in Figure 2.6. Hence Figure 2.6.(1) shows the first step of this 
procedure, the nanotechnological agent introduced into the blood vessel. This agent 
has been previously functionalized with antibodies specifically selected for the unique 
antigens of the targeted cancer cells.  In Figure 2.6.(2), the two most common external 
sources of heating are shown. The applicability of any of them depends on the type of 
NP selected. In oncology, the term hyperthermia refers to sustained therapeutic 
heating of a region of interest to temperatures above 40°C produced by some external 
source of energy.  These two sources provide the possibility to activate the destructive 
temperature-dependent effect only when required and switch it off after. Finally, once 
the method ends the outcome results in the total or partial thermal damage and 
destruction of the cancer cells. The most important considerations before injecting the 
NPs for this kind of treatments are: right functionalization of the external surface with 
antibodies for the specifically targeted cancer cells, small size to avoid obstructions in 




Some relevant examples of antibody functionalisation for cancer cells surface antigen 
targeting on the external NP surface of NPs similar to ours include the following. In 
2003, Artemov et al. successfully implemented anti-HER2/neu antibody Herceptin 
(Genentech) functionalized SPIO which are MR contrast agents to target MCF-7, 
MDA-MB-231, and AU-565 human breast cancer cells [110]. In 2010, Day et al. 
produced anti-HER2 antibody-conjugated Au-Au2S sulphide nanoparticles as 
multifunctional agents that specifically binds SK-BR-3 human breast carcinoma cells 
that over-express the HER2 receptor, enabling the cells to be imaged via multiphoton 
microscopy with an incident laser power of 1 mW [111]. 
2.5. Nanotheranostics 
 
Figure 2.7 | Venn diagram showing the combination of fields that constitute 
nanotheranostics. 
“Theranostics” is a combination of therapy and diagnostics that focuses on 




of the patient. A theranostic system couples the therapy with diagnostic information 
specific for the intended target [112]. Materials that, by having a multiphase structure, 
can be used for diagnosis and therapy (like our final material) are theranostic materials. 
Particularly, nanotheranostics is the most common type of theranostics and it utilises 
nanomaterials as a single platform to deliver both diagnostics and therapy [113–116]. 
Figure 2.7 shows the main concepts that involve this new field.  
There exist nanoplatforms that can deliver imaging and therapeutic functions 
with higher precision than their bulkier counterparts. Over the last decade, a vast 
development in this area has been undertaken primarily for characterization of 
subtypes of cancer cells, identification of the cancer stage, analysis of the patient 
characteristics through imaging and having a complete solution to find and destroy 
cancer. Therapy personalisation to each specific case while imaging is one of the keys 
to each success. Therapy arising from NPs can be generated more generically, e.g. 
cellular hyperthermia or hypoxia. Then, by functionalising their surface with the right 
antibody, targeting cancer cells unlocks the potential to a cell by cell treatment. 
2.6. Nanoparticles fate 
The fate of the NPs in the body is crucial to minimise toxicity and side effects. 
Hence, NPs clearance is one of the most critical aspects to consider when designing 
NPs, but also can be a burden since optimising safety sometimes is at expenses of 
losing useful properties for either diagnosis or therapy. NP excretion and toxicity are 
highly dependent on many parameters including NP concentration, size, shape, 
density, hydrophobicity, pH stability, surface charge and surface chemistry [117]. The 
overall idea is that NPs that have long circulation time in the blood and low organ 




because the kidney is capable of rapidly removing molecules from the vascular 
compartment such as the injected NPs and starting a renal clearance for final 
elimination through urinary excretion. Different strategies can be combined to 
accomplish prolonged circulation of NPs in blood and target specific clearance 
pathways. 
When the NPs are intravenously administered, they encounter several 
sequential obstacles hindering efficacious, site-specific delivery to tumours [119]. Firstly, 
NPs undergo opsonization and subsequent uptake by resident macrophages of the 
mononuclear phagocyte system, which leads to high NP accumulation in healthy 
organs, such as the spleen and the liver. Secondly, under normal flow conditions in 
blood vessels, NP size and geometry influence margination dynamics to vascular walls. 
Small spherical NPs migrate far from endothelial surfaces in a cell-free layer, which 
limits both active targeting and accumulation through passive targeting mechanisms. 
Additionally, high intratumoural pressure in tumours is an important barrier to NP 
accumulation due to interrupted vasculature, the aggressive nature of cellular growth, 
fibrosis, a dense extracellular matrix, and impaired lymphatics. Moreover, cellular 
internalization and endosomal escape are critical barriers, dependent on size and 
surface functionalisation. Endosomal compartmentalization of internalized NPs is 
detrimental to cargo, especially to genetic material.  
The fate of NP/cell interaction can be divided into particle/cell interaction and 
NP internalization. The interactions between NPs and cells are usually mediated by 
the formation of the protein corona on the NP surface when in biological environments, 
and these interactions are vital to predict the NPs bioactivity [120]. There is experimental 




frustrated phagocytosis, induction of oxidative stress, and inflammation related to the 
interaction of NPs with biological processes [121]. Cellular uptake depends at a large 
extent on the size and shape of the NPs to be internalized. While spherical shape 
seems the optimal shape to maximise cellular uptake, there is no consensus on the 
optimal size [122]. The wrapping of NPs is usually accompanied by the deformation of 
the cell membrane, which is induced by bending and stretching of the membrane [98]. 
It has been shown that positively charged NPs ranging from 50 nm to 100 nm display 
higher toxicity and cell uptake, and lower transport efficiency than its negatively 
charged counterparts [123]. NP hydrophilicity (charge-polarized and capable of 
hydrogen bonding) usually leads to direct renal excretion, while the hydrophobicity 
undergoes biotransformation before NP excretion [124]. 
The NP shape is also an important parameter. Several studies have shown that, 
during renal excretion, spherical NPs were cleared faster than rod NPs [125,126].  Non-
spherical nanostructures can have distinct and unwanted enhanced permeability and 
retention (EPR) effects due to differences in the in vivo hydrodynamic behaviours such 
as circulation, transport in blood flow, and extravasation into the tumour. The EPR 
effect occurs when high–molecular weight nontargeted drugs and prodrugs 
accumulate in tissues which have increased vascular permeability, such as in sites of 
inflammation or cancer [127]. Enhanced vascular permeability via angiogenesis is the 
primary mechanism used by tumours to sustain an adequate supply of nutrients and 
oxygen for rapid tumour growth, which can lead to high NP uptake. At the same time, 
tumours display impaired lymphatic drainage, which leads to retention of the 
permeated NPs. Unfortunately, this effect can also happen non-tumorous 
inflammations, which will also tend to accumulate more nanoparticles than the rest of 




inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus, 
multiple sclerosis and many others that are common in elderly patients. 
In terms of size dependence, NPs smaller than 5 nm are cleared by glomerular 
filtration in the kidneys while bigger than 200 nm are cleared by the spleen [109].  A 
recent study showed that ≤5 nm inhaled Au NPs for 4 h were still present in blood and 
urine of the volunteers three months after exposure, at levels higher than the initial 24-
h period, pointing towards systemic retention and delayed urinary excretion. Lee et al. 
have reported that particles smaller than 20 nm are cleared more rapidly than larger 
100 nm particles [128]. Cho et al. [108] showed that 50 nm dye-labelled nonporous silica 
NPs cleared faster in the urine and bile than its 100 and 200 nm counterparts, and 200 
nm NPs have a lower excretion ratio. Therefore, optimal sizes to maximise NP 
excretion rate and ratio are typically smaller than 50 nm but larger than 5 nm. However, 
it has been have shown that spherical NPs of 50–100 nm in diameter present 
maximized tumour accumulation due to the EPR effect and minimized the subsequent 
clearance [125,126].  
However, Au NPs present long-term retention within many organ systems, most 
notably the liver and spleen. Some studies in mice have found that Au NPs from 20  
to 40 nm showed high liver accumulation after several months from intravenous 
injection [129]. These results raise some concerns about the fate of these NPs used at 
these sizes, mainly because they are not biodegradable. Nevertheless, one of the 
most significant limitations of the research data in NP excretion is that most studies 
are performed in mice and not in humans, which differ on important physiological 




2.7. Gold nanoparticles 
2.7.1. History 
AuNPs are finding uses in a wide range of applications. They are very well 
known in the literature for their excellent biocompatibility, ready bioconjugation and 
optical properties via plasmons[130]. Even before they were fully understood, AuNPs 
were used to exploit their optical properties in coloured glass with historical examples 
such as the Lycurgus Cup. The first person who accidentally found them was Michael 
Faraday. He described them and reported his particular reduction method of 
chloroaurate (AuCl4-) in a water solution by using phosphorus with CS2 to synthesise 
them on his lecture at the Royal Society in London on 1857[131]. Almost one century 
later, in 1951, Turkevich[132] found a robust method to synthesise different sizes of 
AuNPs and the most relevant parameters that characterise their size and colour. 
Hence, this is the method by which our composites are based on this work. For 
colloidal Au (reddish colour), plasmon peaks are observed in the visible region and 
can, therefore, be excited at optical frequencies (1014–1015 Hz). Combining this 
discovery with the theory developed by Pines and Bohm in 1952 of “plasma 
oscillations” so-called plasmons, a full branch of knowledge has been developed and 
made possible to obtain exciting applications in diverse areas such as biomedical 
imaging, hyperthermia, drug delivery, biosensing, nanoelectronics and energy 
harvesting.   
2.7.2. Morphology and dimensions 
Au nanostructures have obtained a remarkable interest in the scientific 
community due to their unique surface plasmon resonance (SPR) properties. By the 




with the electric field to generate collective oscillations at a resonant frequency relative 
to the lattice of positive ions. The frequencies at which the plasmons resonate are 
those when light absorption is produced. Some photons excite optical phonons that 
propagate along the surface. Therefore, the generation of plasmons can be quantified 
with UV-vis spectrophotometer by analysing the absorption. However, not all the 
incident light will be absorbed—a fraction of the incoming photons that are scattered 
in all directions.  
One of the most critical aspects of using different shapes and sizes of Au 
nanostructures is their unique plasmon resonance frequency, i.e. unique maximum 
absorption in the UV-vis spectra. Monodisperse AuNPs (Figure 2.8.a) with spherical-
like shape have their SPR wavelengths from 510 nm to 572 nm for the size from 3 nm 
diameter to 100 nm diameter, respectively[133]. There is a redshift of increasing sizes. 
This is one of the reasons why bigger particles are more useful for getting an excellent 
SERS enhancement, but they become less biocompatible since their toxicity grows. 
One step beyond is the synthesis of Au nanoshells (AuNSs) which coat other materials 
to combine their properties (Figure 2.8.g)[133]. These AuNSs are surface plasmon 
resonant NPs forming a shell that surrounds a nanoscale core. They have many 
previously studied properties [134–136] by using different cores and thicknesses, different 
outcomes can be achieved. Also, including internal sub-shells between the core and 
the external AuNS, exciting new materials can be found with promising functionalities 
such as robust fluorescence. However, these are not the only Au nanostructures that 





Figure 2.8 | Typical shape of Au nanostructures under transmission electron 
microscopy imaging: (a) spherical NPs (b) nanorods (c) nanobipyramids (d) nanostars 
(e) nanocubes (f) nanotruffles (g) nanoshells (h) nanocrescents (i) nanowires (j) 
nanocages. 
For nanorods (Figure 2.8.b), there are 2 modes: transverse mode and 
longitudinal mode. The transverse mode provides a smaller peak in the UV-vis 
absorption and is approximately fixed for one specific nanorod diameter for any length. 
The longitudinal mode displays the strongest peaks, which are lower in energy 
compared to the transverse mode peaks. Its wavelength depends on both diameter 
and length. For example, for a diameter of 10 nm and lengths of 34 nm to 51 nm, the 
transverse mode plasmon resonance is at 508 nm, and the longitudinal mode is from 
750 nm to 850 nm, respectively[133]. There is a redshift of increments in both diameter 
and length. In the case of assembled nanorods, the maximum intensity decreases 
drastically.  
Au nanobipyramids present a similar behaviour to Au nanorods, as shown in 
Figure 2.8.c.  However, in this case, it is not easy to increase the diameter without 
increasing the length at the same time. For nanobipyramid diameters from 20 nm 
diameter to 45 nm, the respective longitudinal and transversal mode wavelengths are 
from 700 nm to 850 nm, and from 506 nm to 517 nm, respectively[133]. There is redshift 




Au nanostars (Figure 2.8.d) have very similar UV-vis spectra compared with 
nanobipyramids with slightly redder shifted peaks for the longitudinal mode. Au 
nanocubes (Figure 2.8.e) show similar shape than AuNPs, but much more limited in 
terms of wavelengths when increasing size. Once again, assembled nanostructures 
end in a lack of intensity for the SPR peak. The Au nanotruffles or popcorn-like (Figure 
2.8.f) have presented a redshift compared form the original seed. However, it is not 
clear how its absorption changes since it is an irregular shape that can grow in different 
ways. In a general approach, the bigger popcorns, the redder shift. For Au nanoshells 
or hollowed nanospheres (Figure 2.8.g), the UV-vis spectra are different compared 
with its counterpart. This structure shows a blue-shifted for thicker shells while keeping 
constant the core diameter. However, if the thickness is fixed and the core grows, then 
the redshift effect appears again. In the case of nanocrescents (Figure 2.8.h), the blue 
shift also occurs by growing the thickness. However, this structure requires 
considering not only the diameter of both hollow and NP but also the distance between 
both centres. Nanowires (Figure 2.8.i) behaves as nanorods with minimal diameter. 
The hollowed Au nanocages (Figure 2.8.j) structure shows a similar UV-vis absorption 
compared to the Au NPs, but much redder shifted for similar sizes. 
When the Au NPs are chemically synthesised in a solution phase, the shape 
tends to be spherical-like that is the configuration in which the smallest surface area 
is achieved. However, as reported by many researchers, the shape is never wholly 
spherical. For the most accurate spherical shape, a pH 7.0 is highly recommended at 
room temperature or temperatures over 80°C depending on the specific method 
applied. Usually, the synthesis is assisted by ultrasonication to ensure a good 
redispersion and final monodispersed AuNPs. To obtain Au nanorods, it is necessary 




unusual shapes such as hollowed microspheres, nanostars, nanowires or 
nanocrescents require more complex procedures, including customised working 
temperatures or customised surfactants rather than deionised water. Moreover, in all 
the previous cases, the introduction of polymers in the surfactant can substantially 
improve the size, stability, and distribution of particles. 
In contrast, AuNPs can also be synthesised by laser ablation. This technique is 
based on extracting material from a surface (generally solid, but also liquid) by 
irradiating it with a laser beam. Through this method, the generation of AuNPs with 
several useful properties such as high purity, easily functionalisable surface and 
complex structure is achieved.  The kind of structures achieved by laser ablation 
includes doped nanocrystals, core−shells nanocomposites, hollow microspheres, 
nanotruffles, and nanocrescents. Also, changes between structures such as from 
nanorods to nanospheres or from nanospheres to nanocrescents are possible, by 
laser ablation. However, obtaining more unusual shapes such as nanostars have yet 
to be found by the laser ablation technique. This sets a limitation on the possibilities 
that this technique offers. 
A third method would be metal deposition on previously shaped surfaces. This 
method has been extensively used to fabricate a wide range of Au nanostructures 
from nanowires to spherical Au NPs. By combining the metal deposition with some UV 
irradiation, it is possible to have high control of the final morphology and atomic 
structure, achieving even single crystallite based AuNPs. This technique is usually 
called UV-induced photochemical synthesis of Au.  Other methods very similar to this 
one are photothermal reduction and lithography through which an easy and fast 




One of the main applications of AuNPs was discovered in 1974. SERS was first 
observed by Fleischmann et al. when measuring the Raman spectra of pyridine 
adsorbed at a silver electrode [137]. The substantial enhancement in the signal was 
firstly estimated but not linked to plasmonic excitations in 1977 [137]. After then, many 
other researchers tried to understand the reason for such signal enhancement. Soon 
Au became a better choice for biomedical applications, due to its better 
biocompatibility than silver. 
2.7.3. Thiol group 
Thiols (R-SH) are compounds which contain a carbon-bonded sulfhydryl (SH) 
group. Its structure is analogous to alcohol by exchanging the oxygen atom with 
sulphur[138]. And therefore, its name is the combination of  "thion", that means sulphur; 
and "alcohol”. The -SH functional group designates both thiol and sulfhydryl groups. 
The term thiol is sometimes substituted by the term mercaptan that was introduced in 
1832 by William C. Zeise.  
The primary applicability of this functional group is their strong electronegativity, 
similarly, as explained by the amine group. Hence, metals such as Au are good 
candidates to act as donors and fulfils the two remaining unfilled orbitals which create 
a very strong covalent bond. Some thiols are more complex than others and can have, 
for instance, a bond with another sulphur that binds with Au. This also allows a better 
transference of vibrational energy across the Au-S-R bond chain[139]. Different organic 
substituents can be included with desirable properties such as benzene (aromatic 
group). This type of organic structure provides a unique Raman signature or fingerprint 
and very strong peaks in the Raman spectra that can be used to identify the sample. 




disconnected, rings with additional carbon bonds and a different number of carbon 
atoms contained in the rings (five or six). 
2.7.4. Toxicity 
One crucial aspect in biomedicine is the toxicity, and therefore, there is a limited 
number of options to form the nanocomposites that are injected inside the human 
body[140]. Some of the most common NPs used for biomedical approaches are noble 
metals such as AuNPs [141] or silver NPs (AgNPs) [142], SiO2, polymers and transition 
metal oxides [33]. There is not enough research to determine the cytotoxicity of AuNPs 
or AgNPs, and to conclude which one is the better candidate in each scenario; both 
are exciting candidates due to their unique antibacterial activities [141–145]. However, 
there are indications of higher induced cell necrosis by AgNPs independently on the 
size and surface charge while AuNPs have only shown specific toxicological effects 
for small or large sizes, high concentration and high surface charge [146]. Cytotoxicity 
is the ability of certain chemicals to kill or destroy healthy living cells, i.e. toxicity for 
cells. One of the most desirable scenarios is that after the injected NPs end their 
function, a renal excretion process occurs without producing cytotoxicity during the 
removal process. This is possible because the kidney is capable of rapidly removing 
molecules from the vascular compartment such as the injected NPs and starting a 
renal clearance for final elimination through urinary excretion. One of the biggest 
limitations of the research results in NP excretion is that most of the tests until now 
have been implemented in mice. Therefore the conclusions of these non-human 
studies do not provide any certainty of useful, practical or translatable to the clinical 
outcome for improving the understanding of human toxicology. Dimensions and blood 
chemical composition in humans are substantially different from mice; hence more 




The recent literature contains conflicting data regarding the cytotoxicity of Au 
NPs for specific sizes and backgrounds. Several studies have shown that spherical 
Au NPs with a large number of surface functionalizations are generally not cytotoxic 
to human cells even when they are incorporated intracellularly in the cells [147,148]; 
although some NP sizes in specific cell types have shown notable cytotoxicity such as 
1.4 nm diameter Au55 clusters [149]. Very small NPs with sizes < 2 nm have caused 
rapid cell death by necrosis in 12 h or forced the programmed cell death (apoptosis) 
while size > 15 nm is not cytotoxic [150]. The limit of the smallest convenient size for Au 
NPs is 5 nm not to produce any toxicity and 30 nm not to be endocytosed by cells, i.e. 
absorbed into the cell. However, different concentrations of particles have been used, 
and non-conclusive results have been found yet. All these considerations depend on 
the type of procedure followed to deliver the AuNPs. For a local injection, sizes bigger 
than 5 nm could be a good candidate while a long delivery anything below 12 nm can 
constitute a significant risk in terms of cytotoxicity. Also, NPs smaller than 5 nm are 
cleared by glomerular filtration in the kidneys while bigger than 200 nm are cleared by 
the spleen [109]. It has been found that smaller sizes tend to be excreted faster (a couple 
of hours for minimal diameters) than bigger sizes (up to a week for extra-large 
diameters). 
2.8. Silica nanoparticles 
2.8.1. History 
Stöber et al. discovered an effective method to synthesise monodispersed SiO2 
particles with a tuneable size in 1968, via hydrolysis of alkyl silicates and subsequent 
condensations of silicic acid in a mixture of alcohol and water using ammonia as a 




nm to 2 μm in diameter. This original work has since been improved by others [152–156], 
performed the synthesis of colloidal spherical SiO2 NPs via polymerization, nucleation, 
and growth. All current sol-gel methods to synthesise highly stable colloidal SiO2 NPs 
are mainly or partially derived from this method as described in Figure 2.9. Further 
advances were made with the discovery of mesoporous SiO2 NPs (MSN), which 
allowed the development of the concept of MSN as drug delivery vehicles in cancer 
therapy [157–159]. MSNs are mesopores of SiO2 with pore sizes from 2 to 50 nm that 
display favourable physicochemical properties for high biocompatibility [160]. The 
extension of the Stöber process to nanoshells [161–163] is almost immediate and was 
previously achieved by following a different route [164]. In the hydrolysis and 
condensation, there are precursor species and the necessary supersaturation for the 
formation of SiO2 particles over the former core to generate the shell. 
 




2.8.2. Morphology and dimensions 
SiO2 NPs are being considered for several biomedical applications due to their 
biocompatibility, low toxicity, and scalable synthetic availability. It is possible to 
precisely control SiO2 particle size, porosity, crystallinity, and shape to tune the 
nanostructure for diverse applications. Furthermore, the many possible surface 
modifications of SiO2 NPs allow precise control of surface chemistry to modulate drug 
or chemical loading, NP dispersion, blood circulation, and site-specific targeting. The 
ability to combine these properties makes SiO2 NPs a desirable platform for 
biomedical imaging, assaying, therapeutic delivery, monitoring, and ablative therapies. 
With the use of various dopants, surface group modifications, and assembly 
techniques, it is possible to create multimodal NPs with theranostic applications, such 
as including an imaging component along with a therapeutic payload or ablative 
component within the particle. 
The most common type of SiO2 NPs are spherical NPs, but there are other 
shapes frequently used in the literature such as SiO2 nanoshells or hollow NPs. The 
mechanism of growing SiO2 shells over iron oxide cores is based on the 
physicochemical mechanism of the silane agent on the surface of the IONP according 
to Arkles [165] and refined by De Palma et al. [166]. MSN nanocarriers are prepared in a 
variety of sizes and shapes, including nanohelices, nanotubes, nanozigzags, and 
nanoribbons aiming for tunable optical, electrical, and mechanical along with pH 
sensitivity [167,168]. Several synthesis techniques have been developed which produce 
particles with a narrow range of sizes and nearly uniform composition. Figure 2.9 
shows the techniques that are commonly used to synthesise SiO2 NPs. Most of the 
synthetic techniques employ sol-gel processing at 25 °C with careful control of the 




2.8.3. Amine surface functionalisation 
Amines are organic compounds (hydrocarbons) and functional groups that are 
made of one or more atoms of nitrogen (N) with a lone electron pair in each. The 
molecular structure resembles ammonia (NH3) where one, two or three alkyl or aryl 
groups replace one, two or three hydrogen atoms, respectively. There are basically 3 
types of functional groups: primary amines (RNH2) which have an alkyl or aromatic 
group (R)  and a N attached to two H; secondary amines (R2NH) that contain a pair of 
alkyl or aromatic groups (R2) and a N attached to a H; and the tertiary amines (R3N) 
have three alkyl or aromatic groups (R3) attached to a N. There are also other so-
called cyclic amine groups that are any of the previous types bonding with some 
aromatic group that contains carbon rings such as benzene. Hence, surface amine 
functionalisation is the addition of amine groups on the surface for a subsequent effect 
related to this functional group. For our specific context, the importance is about the 
strong ligand generated between Au and N. This happens since Au is a noble metal, 
so it can donate electrons, and N has one of the highest electronegativity. Therefore, 
N will incorporate three electrons from Au to be more stable by filling its d orbitals. 
Only if there is some process that transfers higher energy than the one to fill these 
orbitals, then the bond will break. 
In SiO2 platforms, APTES is the most common option for Au seeding. The 
critical aspect of this functionalization is the NH2 ending on top that needs one electron 
to become energetically stable. At the same time, the AuNPs have a tendency to share 
their electrons, forming a covalent bond [169]. These NH2 ligands can also react with Au 
after breaking it in two parts by heating: first releasing H2 when the H atoms absorb 
higher energy than the bond; and, in the other side, a firm bond is generated between 




Au nanoseeds and subsequently grow Au on top stably and homogeneously. 
Immobilization of Au NPs has received interest in biomedical applications during the 
last decades. To ensure the AuNPs are homogeneously distributed on top, a 
redispersion of Au NPs and SiO2 NPs or nanoshells need to be done during the entire 
process. Controlling the immobilization step, especially NPs dispersion and coverage, 
is an essential issue for all of these communities. Moreover, APTES can be attached 
easily to any hydroxyl group (-OH) on top of the surface, some examples of easy 
hydroxyl groups functionalization materials are SiO2 or magnetite (Fe3O4). 
2.8.4. Toxicity and clinical approval 
SiO2 is generally accepted as a safe material by the United States Food and 
Drug Administration (FDA) [170]. Cytotoxicity of SiO2 NPs has been found closely 
related to multiple factors including their size, dose, the cell type in the study, treatment 
time, surface area, and structural discrimination [171]. It was found that SiO2 particles 
at low dose present small retention, which is dependent on the particle size and organ 
[172]. In terms of toxicology, there are many reports for various formulations showing 
that SiO2 NPs are generally well tolerated with a large maximum tolerated dose. 
However, the synthetic method profoundly influences the cytotoxicity. Fumed/pyrolytic 
SiO2 NPs heat-treated between 1,200 and 1,400 °C show much higher cytotoxic 
behaviour than the Stöber counterparts[173]. 
Cornell Dots or C Dots are inorganic SiO2 NPs that were developed at Cornell 
University as a diagnostic and therapeutic tool in cancer treatment [174]. These SiO2 
NPs have undergone FDA-approved trials at the Memorial Sloan Kettering Cancer 




cancer [175]. They have lately been working with antibody functionalization to help to 
target a renal clearance. 
2.9. Iron oxide nanoparticles 
2.9.1. History 
Iron oxides are commonly found in nature as rust and can be easily synthesised 
in the laboratory. This magnetic material has been used for centuries [176]. IONPs as a 
contrast agent for in vitro diagnostics has been produced and used for a wide diverse 
range of applications for nearly half a century [177–179].  
Eight iron oxides are known [180]. In the last decades, increased investigations 
with diverse types of IONPs have been performed, particularly Fe3O4 (magnetite, 
FeIIFeIII2O4, ferrimagnetic, superparamagnetic when the size is less than 15 nm), α-
Fe2O3 (hematite, weakly ferromagnetic or antiferromagnetic), γ-Fe2O3 (maghemite, 
ferrimagnetic), FeO (wüstite, antiferromagnetic), ε-Fe2O3 and β-Fe2O3) [181], among 
which magnetite and maghemite are the most promising and popular candidates due 
to their biocompatibility, strong magnetic magnetization and polymorphism involving 
temperature-induced phase transition [178]. Each of these iron oxides has unique 
biochemical, magnetic, catalytic, and other properties which provide suitability for 
specific technical and biomedical applications. In cancer research, IONPs have been 
used for two main applications: magnetic hyperthermia [103,104,182–186] and MRI [187–195], 
both owing to their magnetic properties. 
The synthesis of IONPs has been extensively studied in the last decades, 
obtaining many different routes for efficient synthesis approaches to produce the 




common methods including co-precipitation, thermal decomposition, hydrothermal 
synthesis, microemulsion and sonochemical synthesis to obtain high quality of IONPs. 
The most conventional method for obtaining Fe3O4 or γ-Fe2O3 is by co-precipitation. 
In 1981, Massart reported the synthesis of magnetic NPs in acid and alkaline media 
[196], which were IONPs. This result triggered different modified versions of the 
procedure that are widely used today.  
2.9.2. Morphology and dimensions 
Different sizes display different magnetic properties. There is a transition from 
the single magnetic moment (one spin) to single magnetic domain (several spins that 
behave like one) to multi magnetic domain (several single magnetic domains). These 
transitions confirm the growth of sizes of the NP, which also leads to a transition from 
superparamagnetic to ferromagnetic or ferrimagnetic behaviour. Multi domains occur 
in highly ferromagnetic or ferrimagnetic samples with large NP diameters. When the 
diameter is small enough, the magnetic behaviour corresponds to a single domain, 
which present superparamagnetism. 
Strongly ferrimagnetic samples usually aggregate, which can have two main 
side effects. On the one hand, the hydrodynamic radius of these NPs is vast and 
therefore not suitable for excretion once injected in the body. On the other hand, 
aggregated ferrimagnetic NPs have shown drastically decreased hyperthermia 
capabilities [197]. These NPs also are not suitable for core-shell structures since a 
potential multicore structure might happen, which would undervalue the potential not 
only in hyperthermia capabilities but also as an MRI contrast agent. These significant 
issues have prompted many efforts in finding suitable substitutes that can be easily 




Moreover, the best Fe3O4 sizes for MRI are the ultra-small magnetic IONPs (3-
4 nm). This has been shown to have longer dwell time, and therefore, can activate 
macrophages. Macrophage phagocytosis leads to non-excretion and therefore, high 
toxicity. For this reason, seeking for a more reliable imaging method than MRI by using 
different composite nanostructures such as SERS in AuNPs is in high demand. 
2.9.3. Toxicity and clinical approval 
Currently, ferumoxytol is the only FDA-approved SPION and is used for the 
treatment of iron-deficiency anaemia in patients with chronic kidney disease. However, 
ferumoxytol is also being used off-label as an MRI angiography agent in patients with 
renal failure who cannot be given gadolinium, and in clinical trials for the 
characterization and mapping of metastatic lymph nodes and hepatic masses. The 
advantages of ferumoxytol include its size relative to other SPION formulations (<40 
nm) and its long circulating half-life (∼15 h).  
MagForce received FDA investigational device exemption approval to conduct 
a clinical trial with NanoTherm® therapy as a focal ablation treatment for intermediate-
risk prostate cancer. 
2.10. Tungsten oxide 
The combination of materials that possess different properties (such as metals, 
semiconductors, magnetic materials, polymers and biomolecules) in specific size, 
morphological and spatial configurations in a single nanoscale object has led to a 
revolution in materials and chemistry, creating an enormous impact in physical, 




Metal oxides are crucial materials for the development of many advanced 
functional materials and smart devices due to their multiple potential functionalizations 
and dopings. Tungsten oxides (WOx) are unique materials that have been rigorously 
studied for their chromism, photocatalysis, and sensing capabilities. However, they 
exhibit further important properties and functionalities that have received relatively little 
attention in the past[198]. 
WOx is a transition metal oxide with a wide range of applications. Interest in 
WOx can be dated back to the 17th century when the properties of LiWO3 and the 
techniques for the synthesis of WO3 and NaWO3 were first studied [199]. More recently, 
renewed research interest in WOx was sparked by the discovery of its electrochromic 
(EC) effect [200,201]. Examples of WO3 based fibre-optic sensors can also be found in a 
report by Ito et al.  [202]. Based on the principles of H2 sensing, WOx was also explored 
in biological sensing [199]. Recently some authors have been working with infrared 
lasers in tungsten oxide nanostructures to the unlock electrochromic mechanism in 
this regime [11,199,203–209]. Therefore, WOx to be a promising candidate for sensing 
applications, such as in cancer imaging.  
2.10.1. Electrochromism 
The first electrochemical reduction of a solid, WO3, that displayed a colour 
change mediated by hydrogen (H) ions was reported by Kobosew and Nekrassow in 
1930 [210]. When WO3 was coated on an electrode, immersed in aqueous acid and 
possibly the electrode substrate was inert (there is no explicit record of this but it 
seems to be the most likely case), colouration occurred. They described the 





+ + 𝑒−) → 𝐻𝑥𝑊𝑂3 (2.10.1) 
where 𝑥 is the insertion coefficient that takes values from 0 to 0.03. This colour change 
from the oxidised form of WO3 in a very pale yellow to its reduced form in an intense 
blue is due to the formation of HxWO3. Instead of introducing H in the Eq., another 
electro-inactive positive ion can be used instead. This ion is usually designated as a 
counter ion (positively charge, cation) and its main function is to preserve or maximise 
electroneutrality within the solid oxide film[201]. 
Electrochromism with arbitrary ion species in thin films of WO3 was found in 
1969 by Deb, and then the crusade for fabricating electrochromic devices started. 
During the following decades, several companies developed commercial products to 
exploit this effect such as Gentex Corporation’s self-darkening rear-view mirrors for 
cars, adjustable opacity windows at the Boeing's 787 Dreamliner, Gyricon 
electrochromic paper developed by Xerox for electronic books, NTera’s coloured 
electrochromic paper-quality displays and Skugga’s electrical sunglasses with 
adjustable tint. Nowadays, the leading industrial interest in these technologies is 
focused on large-scale screens that tolerate living conditions for buildings. The state-
of-the-art in this research field is more focused on novel applications such as self-
powered electrochromic windows for smart management of the optical transmission 
of the visible and near-infrared in solar cells harvesting.  
Electrochromic materials display a reversible and persistent change of visible 
optical properties (colour, transparency) by using a small electric field that causes 
electrochemical redox reactions. This means creating different visible light absorption 
bands by switching to different redox states via different voltages applied. An 




or electron release for oxidation at an electrode. An electroactive material may be an 
atom, ion, molecule or radical, in some cases multi-bonded in a solid film. The 
electroactive material is usually a uniform film on an electrode submerged in a solution 
or a material embedded in a matrix that is in contact with an electrode substrate for an 
effective electron transfer. In case it is a solution, it needs to be close enough to the 
electrode substrate and provide the necessary conditions to achieve the activation 
energy for the electron transfer. Also, the electroactive material can be a solid or being 
dispersed within a solid matrix. In this matrix, the part of the electrochromic component 
that is physically in contact with the electrode substrate undergoes a redox reaction 
much faster than the rest of the component. The electrode is usually defined by the 
oxidised form, the reduced form and the metallic or quasi-metallic conductor. An 
electrode is a metallic conductor that in electrochromism is usually an adequately 
conductive semiconductor usually deposited as a thin film on top of a glass. This 
conductive glass surface is called the optically transparent conductor. In between two 
of these, the reversible change of colour and opacity occurs. This shift in optical 
properties happens when the inflow of charge-balancing electrons enters the 
electrochromic material and changes the valency of its atoms. The ion flow is in many 
cases held by an electrolyte that promotes the charge exchange. An electrolyte is a 
substance that dissolved in a polar solvent, such as water, yields ions, and therefore 
converts the solution into electrically conducting.   
When an atom or molecule causes the colour of a compound, this part is called 
a chromophore. The mixture of all the visible colours results in white light. Only when 
some chromophore absorbs some specific wavelength in the visible region, its 
complementary colour is displayed as the dominant. For instance, when some 




AuNPs; this means that the maximum absorption is actually at the wavelength that 
corresponds approximately to green (532 nm). The absorption of light is produced by 
the electrons in the atoms that comprise the material, whose energy levels are 
quantised. Therefore, the energy absorbed by the atoms is invested in electrons 
jumping to more energetic levels. The original stable distribution is called the ground 
state, and the promoted levels are called excited states. The wavelength of maximum 
light absorption, 𝜆, is governed by the energy gap, 𝐸, between these states and follow 
the Planck’s Law, 




Where ℎ is the Planck's constant, 𝑐 is the speed of the light, and 𝜈 is the frequency. 
The change in the absorption spectra in an electrochromic material after a redox 
reaction is not visible if the optical absorptions of the two redox states are in the UV or 
NIR regions. So the traditional definition of electrochromism only includes changes in 
the absorption for visible spectra, but this has been changing in recent years towards 
exploring infrared light interactions [199,203–209]. 
In contrast to the above definition, there is an alternative approach for the term 
electrochromism. When some polarizable molecules suffer a molecular Stark effect in 
which their UV-vis bands show a spectroscopic shift in the presence of a strong electric 




2.11. Multifunctional nanoparticles 
 
Figure 2.10 | Diagram of the main aspects of multifunctional materials. 
The development of multifunctional nanostructures is a challenging process 
due to the need for chemical and molecular stability from the synthesis until the 
multiphase activation.  The multifunctional NPs have developed a degree of maturity 
in some areas where there was an urgent need of finding new alternatives such as 
bionanotechnology that involves medical imaging, drug delivery and illness therapy.  
In nanooncology, due to the small size, surface functionalizations, variable shape and 
tuneable porosity of these nanostructures, they can stably bind, absorb, and carry 
nanometric and subnanometric biological objects such as molecule drugs, DNA 
(deoxyribonucleic acid), RNA (ribonucleic acid), proteins, and organic dyes which can 
be used for cancer linking and medical imaging techniques. 
There are three main ideas behind the concept of multifunctional nanomaterial: 
design, synthesis and applications (see Figure 2.10). There is no one single and 




nanomaterial are considered first. Then, the fabrication process begins. However, 
multifunctional NPs are used for many different applications, for instance, biomedicine, 
sensors, catalysis, energy harvesting and water treatment. Sometimes, multifunctional 
NPs can find more approaches to their usability than the previously expected and 
targeted. Also, the design is in many cases modified as well to analyse possible 
improvements.  
2.12. Magnetic heating 
Substantial hysteresis losses occur in large magnetic IONPs which possess 
multiple magnetic domains while subjected to external alternating magnetic fields 
(AMFs). Below approximately 128 nm, the number of magnetic domains is 
approximately reduced to one, single magnetic domain [212]. When reached, the NPs 
present a superparamagnetic behaviour. Magnetic field heating of small IONPs is 
typically accomplished by either Néel relaxation, Brownian motion, or perhaps, 
particle-particle interaction in super-paramagnetic NPs at frequencies between 100 
and 300 kHz [213]. The precise mechanism is still controversial at this point, but it is 
understood that pure superparamagnetic NPs (below 30 nm) tend to relax through 
Néel relaxation, ferrimagnetic NPs (close to 100 nm) through Brown relaxation and 
materials presenting a hybrid behaviour may present a combination of these, and 
perhaps other, mechanisms [105,214]. In all cases, the heating field is highly local, and 
effective treatment depends on clustering and the spatial distribution of particles in 





Figure 2.11 | Comparison between Neel and Brownian relaxations for single domain 
magnetic moment networks. The Neel relaxation diagram is based on the Nobel 
lecture of Neel [215].  
Brownian relaxation occurs when the NP and the magnetic moment rotate 
together. This results in a frictional heat generated from the physical rotation of 
particles within a supporting medium when the particles attempt to realign themselves 
with the changing magnetic field [216]. On the other hand, Néel relaxation occurs when 
the magnetic moment rapidly rotates with respect to the crystal when exposed to AMF. 
The rapid realignment is opposed by the particle's crystalline structure, resulting in 
heat generation (see Figure 2.11). The type of behaviour can be extracted from the 
hysteresis loop. When the hysteresis loop has linear transitions, this is indicative of a 
Brown relaxation. Neel relaxation typically leads to curved profiles that intersect with 




dominating the overall magnetic behaviour, but a mixture of them or even other more 
complex behaviours. 
The temperature profile over time will be dependent on the area formed by the 
hysteresis loop. Larger areas will increase the magnetic material temperature faster. 
The loop requires to correctly completed to maximise its heating performance, which 
implies reaching the saturation magnetization of the sample. Of course, to perform 
effective and safe hyperthermia, the most essential feature is the heat transferred to 
the cells. When working with materials that have layers on top of the magnetic 
component, this result is much more complex to understand, particularly at the 
nanoscale. 
2.12.1. Magnetic hyperthermia 
The oldest written record on the use of increased temperatures in cancer 
treatment was found in the Edwin Smith surgical Egyptian papyrus, dated around 
3,000 BC [217]. Hippocrates (460–370 BC) introduced a hyperthermia method in one of 
his aphorisms. In the 19th and 20th centuries, fever therapy has been used as a 
method to increase temperatures, while other investigators in recent times started to 
apply radiofrequency techniques [218]. Worldwide interest in hyperthermia research 
was initiated by the first international congress on hyperthermia oncology in 
Washington in 1975. In the first decade, there was an exponential increase in the 
number of papers and participants at meetings. Later, it slowed down due to 
disappointing clinical results from some of the first randomised trials. Nowadays, there 
is a renewed interest thanks to successful randomised studies that show 




Hyperthermia therapy for cancer treatment seeks to destroy tumours through 
heating alone or combined with other therapies at elevated temperatures in the range 
of 41.8-48 °C. Generally, there is no difference between hyperthermia sensitivity of 
normal and tumour cells, except for haematological malignancies. However, selective 
tumour cell killing effect is achieved at temperatures in the range of 40-44 °C, which 
is related to structural differences between normal and tumour physiology. For 
instance, in solid tumours, the vasculature is chaotic, which leads to hypoxic and low 
pH regions [218,221] that are not found in healthy tissues. These environmental factors 
make cancer cells more sensitive to hyperthermia which means that this method is a 
promising approach to treat cancer at the cellular level.  
Various forms of cell death, including apoptosis and necrosis, occur depending 
on temperature and heating time. At temperatures above 42.5-43 °C, the exposure 
time can be halved with each 1 °C temperature increase to achieve the same number 
of cell deaths [222]. Most normal tissues are undamaged by treatment for 1 h at a 
temperature of up to 44 °C [223]; only nervous tissue appears more sensitive. For the 
central nervous tissue, irreversible damage was found after treatment at 42-42.5 °C 
for longer than 40–60 min [224]. Treatment of peripheral nervous tissue for >30 min at 
44 °C, or an equivalent ‘dose’, results in temporary functional loss, which recovers 
within 4 weeks [225]. The primary mechanism for cell death is probably protein 
denaturation, observed at temperatures >40 °C, which leads to, among other things, 
alterations in multimolecular structures like cytoskeleton and membranes, and 
changes in enzyme complexes for DNA synthesis and repair [226].  
Magnetic fluid hyperthermia has been intensively investigated since Jordan et 




particle suspensions (“magnetic fluids”) subjected to an alternating magnetic for 
hyperthermia. Magnetic NPs have been under experimental investigation in recent 
years to provide a favourable therapeutic ratio for local hyperthermia; however, the 
number of practical numerical models that can be used to study the underlying 
mechanisms is still limited. Magnetite and maghemite NPs have been used 
successfully to localise tumour heating in vitro and in vivo [102,227–234]. 
2.13. Magnetic resonance imaging 
2.13.1. Basics 
MRI is a non-invasive medical diagnostic technique that uses alternating 
magnetic fields to create radiofrequency (RF) pulses that interact with nuclei with 
magnetic nuclear spin such as 1H to obtain multiple cross-sectional 2D RF signals in 
the Fourier domain that can be transformed into a 3D image with high contrast 
between specific tissues and materials. A big part of this technique success lies in the 
avoidance of exposure to potentially harmful ionising radiation as in other medical 
imaging techniques such as CT and PET. 
All atomic nuclei consist of protons and neutrons, with a net positive charge. 
Specific atomic nuclei, such as the hydrogen nucleus (1H), sodium nucleus (23Na) or 
phosphorus nucleus (31P), possess a property known as “spin”, dependent on the 
number of protons and neutrons. This can be conceived as the nucleus spinning 
around its own axis, although this is a mathematical analogy. If the number of neutrons 
and the number of protons are both even, then the nucleus has no net spin. Otherwise, 




Application of a strong, external magnetic field (B0) aligns the nuclear spin 
either in parallel with or perpendicular to the external field. A liquid solution containing 
many nuclear spins, placed within the B0 field, will contain nuclear spins in one of two 
energy states: a low-energy state (oriented parallel to the magnetic field) or a high-
energy state (orientated perpendicular to the magnetic field direction). The nucleus 
has an angular momentum similar to a tiny magnet due to its rotation, so it will precess 
around the B0 trying to align with or against the field. The nucleus is then bombarded 
with a perpendicular radiofrequency (RF) field usually at 10-5B0 intensity and at certain 
resonant frequencies, the proton spins flip to the high energy state. When the RF 
energy is turned off, the new high energy excited nucleus may revert to its low energy 
spin state, producing an RF signal in the process called relaxation. The resonant 
frequency at which this happens is called the Larmor frequency (ξ) and is proportional 
to the field strength: 
ξ = B0 × γ (2.13.1) 
where 𝛾 is the “gyromagnetic constant” of the material. A typical field strength 
B0 used in MRI is 1.5 Tesla. At this field strength, the Larmor frequencies ξ  for 
Hydrogen and Carbon 13 (the atoms most relevant in medical imaging) are 63.9 MHz 
and 16.1 MHz, respectively. Probing with different frequencies of RF energy enables 
us to build a spectrum of what is in the sample. 
There are two major relaxation processes: proton spin-lattice or longitudinal 
(T1) relaxation and proton spin-spin or transverse (T2) relaxation [235]. Shortening T1 
and T2 increases the corresponding relaxation rates, 1/T1 and 1/T2, producing 
hyperintense and hypointense signals respectively in shorter times. Moreover, the 




T1, called the spin-lattice relaxation time, relates to how fast the magnetization parallel 
to the static magnetic field recovers after a perturbation is applied to the system. 
Protons that relax rapidly (short T1) recover full magnetization along the longitudinal 
axis quickly and produce high signal intensities. For protons that relax more slowly 
(long T1), full magnetization along the longitudinal axis is not recovered before 
subsequent RF pulses, and so they inherently produce a lower intensity signal. 
The usual inversion recovery sequence begins with a 180°-inverting pulse, which 
reverses the longitudinal magnetization (Mz) for all tissues. The repetition time (TR) is 
the amount of time between successive pulse sequences applied to the same slice, 
from the start of one RF sequence at 180° until the next sequence. The inversion time 
is period from the start of one RF sequence at 180° inverting pulse until the 90° pulse. 
During the inversion time (TI) interval, Mz increases via T1-relaxation seeking to 
restore its equilibrium alignment in the z-axis. A spin-echo (or more commonly a fast 
spin-echo) sequence then generates a signal based on the longitudinal magnetization 
of each tissue at time TI.  Time to echo (TE) is the time between the delivery of the RF 
pulse and the receipt of the echo signal. 
T1 is calculated by using the following well-known formula for the longitudinal signal 
amplitude is proportional to the longitudinal magnetization derived in the literature [237]: 






where S is the MRI signal amplitude, and S0 is the the MRI gnal amplitude at t=0. 
Where This formula is proportional to the longitudinal magnetization. 
On the other hand, T2 relates to how rapidly the magnetization in the plane 




nuclei spin in phase with each other, whereas after the pulse, the magnetic fields of 
all the nuclei interact with each other, and energy is exchanged between them. 
Consequently, the nuclei lose their phase coherence and tend to spin in a random 
fashion. Because T2 decay is the result of the exchange of energy between spinning 
protons, it is referred to as spin–spin relaxation. A long T2 happens when the signal 
decay slowly. Therefore, substances with long T2 have stronger signals and appear 
brighter than substances with short T2. 






Longitudinal and transverse relaxation processes are executed independently and 
simultaneously, although T2 is usually much shorter than T1, and this difference allows 
tissues to be differentiated.  
The stronger the magnetic field, the higher the signal-to-noise ratio, which 
means the body can be imaged either at higher resolution, or at the same resolution, 
but faster. At 3 T, MRI machines can resolve details of the brain as small as 1 mm. 
That resolution can be as subtle as 0.5 mm in a 7-T machine. The nature of the image 
contrast is based on relative contributions from different tissues. 
Specific Absorption Rate (SAR) is a measure of the rate at which energy is 
absorbed by the human body when exposed to a radio frequency (RF) electromagnetic 
field. Unit of SAR: watts per kilogram (W/kg). It can also refer to absorption of other 
forms of energy by tissue, including ultrasound. Radiofrequency pulses used in MR 









with the tissue conductivity σ, the root mean square of the electric field and the 
tissue density ρ. However, this formula is valid for materials that are monophasic and 
would not represent more complex materials such as composite NPs. Hence, SAR 
needs to be calculated experimentally by using the magnetic heating profile during the 
initial linear slope. Excessive SAR levels might lead to elevated temperature levels, 
making a careful SAR evaluation mandatory to confirm compliance with the RF power 
deposition limits given by the International Electrotechnical Commission (IEC) 
standard 60601-2-33:2010 Ed.3 for the safe operation of transmitting RF coils tailored 
for UHF-CMR. The IEC 60601-2-33:2010 Ed.3 technical standard defines limits for 
whole-body averaged SAR (normal mode: 2 W/kg, first-level controlled mode: 4 W/kg), 
which is used for large-volume body RF coils commonly used for transmission at 1.5 T 
and 3 T. RF power deposition of local transceiver RF coil arrays used for UHF-CMR is 
limited by a more restrictive local SAR of 20 W/kg for the trunk in first-level controlled 
mode. 
2.13.2. Contrast-enhanced magnetic resonance imaging 
Image contrast is the difference in brightness between an area of interest and 
the surroundings. The more significant the difference in brightness between different 
tissue types, the easier it usually is to differentiate them from each other. In MRI, this 
difference is critical since the spatial resolution of standard MRI images is quite low, 
in the range of 1.5 to 2.0 mm. Therefore, magnetic resonance imaging (MRI) contrast 
agents are an integral component of modern radiology. An additional reason to use 
contrast agents is that it reduces the need for more powerful machines to achieve 




magnetic field intensities. The primary type of MRI contrast agents is gadolinium-
based. Gadolinium is one of the metals in the Lanthanide series, the metal of the 
chelate complexes, has a 4f7 sub-orbital configuration and a spin quantum number of 
7/2. This implies a coordination number of 8 and seven unpaired electrons. 
Gadolinium-based contrast agents are paramagnetic; that is, these atoms act like 
ferrimagnetic and superparamagnetic substances, and have a positive magnetic 
susceptibility. The effect of paramagnetic substances is several orders of magnitude 
weaker than that of other substances with much higher positive susceptibility. The first 
patented MRI contrast agent was made of gadolinium diethylenetriaminepentaacetate 
(Gd-DTPA or Magnevist) and was filed in 1981. Until today, this remains as the most 
widely used contrast agent [239,240]. Although, since then, contrast-enhanced MRI has 
played an increasingly important role in diagnostic medicine and other alternatives 
have been heavily investigated, and a dozen contrast agents have been approved by 
the US Food and Drug Administration (FDA) for intravenous use [241].  
Alternatives to gadolinium-based contrast agents are crucial since elevated 
toxicity was identified from gadolinium-based contrast agents in the past few decades.  
However, contrast agents made of non-gadolinium-based materials are not 
widespread yet. Among the most promising options, SPION covered in dextran or 
carboxydextran has gained substantial recognition for their biocompatibility and strong 
magnetic properties. However, most of them have not been approved for clinical use 
yet. There currently exists a scientific quest to find the best candidate to substitute 
gadolinium-based MRI contrast agents. Some of the most notable examples for T2 
contrast clinically approved are ferumoxides with a particle size of 120 to 180 nm with 
SPION cores of 5 nm approximately dextran coated; ferucarbotran with a particle size 




coated; and ferucarbotran with a particle size of about 17-31 nm with SPION (Fe3O4) 
cores of 6.8 nm carboxydextran coated [242,243]. Ferumoxides have displayed contrast 
30 minutes after administration.  A significant challenge today is to design all-in-one 
contrast agents that can be detected by multimodal techniques, as many as possible. 
The optimal MRI contrast agents would need to display a long T2 and short T1 to be 
high contrast in both modes. 
2.14. Microcomputed Tomography 
X-ray microcomputed tomography or computerised microtomography (microCT 
or µCT) is a non-destructive 3D imaging technique that uses X-rays record 
tomographic cross-sections of a physical object to recreate it virtually without 
destroying the original object. The non-destructive nature of microCT, combined with 
three-dimensional visualization and analysis, allows for a complete internal and 
external view of material geometry and composition at both macro and microscale. 
The nanoscale, however, is not accessible with conventional microCT scanners and 
requires the recently developed high-resolution X-ray micro-computed tomography 
(HRmicroCT or HRµCT) [244]. Applications include product quality checking, damage 
or defect analysis, porosity analysis, composite and laminate materials. 
2.14.1. CT contrast agents 
Contrast agents are pharmaceuticals that increase the sensitivity and specificity 
of diagnostic images. Among the most clinically used CT contrast agents, water-
soluble barium- and iodine-based are the most common [245].However, the gold 
standard in X-rays CT contrast and safety is Au [246], AuNPs have the most promising 
candidate as an x-ray contrast agent due to their high x-ray opacity (attenuation), non-




targeted delivery. Beyond these properties, other essential parameters are vascular 
retention time and biodistribution [247]. All these physical, colloidal, and biological 
properties are consequences of the structural characteristics, including the NP 
composition, mass concentration, size, morphology and molecular functional groups. 
2.15. Heat treatment for nanopowders 
The conversion of certain materials to different materials using high 
temperatures has existed for centuries. Working at very high temperatures in a highly 
controlled environment, however, is a new experimental set up that has been only 
possible over the last century. Nanomaterials have also gained momentum over the 
last 50 years thanks to improved synthesis techniques. In this regard, during the last 
20 years, researchers have made significant progress in combining both high 
temperatures in specific environments using nanomaterials. Most of these materials 
were treated in the form of thin-film but not nanopowders due to technical difficulties 
in preventing large samples lose. In the last decade, heavy NPs have been thermally 
treated in gaseous environments thanks to a better understanding of the 
characteristics that NPs need to meet to efficiently be treated without sample loss. 
Conversion of NPs is essential to unlocking novel properties and functionalities for 
diverse applications. Even though, today, most powder samples are up to the 
microscale [248,249].  
2.16. Microfluidics 
The history of microfluidics dates to the 1950s, in inkjet printer manufacturing. 
The mechanism behind these printers is based on microfluidics; it involves the use of 
tiny tubes carrying the ink for printing. First true micropumps were reported in 1976 




designs based on actuation of both, the pump diaphragm and the valves [251]. Jan 
Smits developed MEMS micropumps in 1990 to control insulin delivery systems for 
maintaining diabetics' blood sugar levels without frequent needle injections [252]. All 
these examples represent microfluidic systems since they enable the precise control 
of the decreasing fluid volumes on the one hand and the miniaturization of the size of 
a fluid handling system on the other. Today, much more advanced tests are performed, 
such as organ-on-a-chip developments for drug testing and NPs membrane filtration 
for enhancing nanoscale samples purity. 
2.16.1. Microfluidic pump 
Microfluidics exploits the small size of channels and laminar flow of fluids inside 
them, due to the low Reynolds number. Microfluidic pumps or micropumps are devices 
that supply fluid from syringes in small doses continuously, for a defined period or in 
pre-set intervals. These pumps usually operate fluids in the range of 500 µms−1 in 20 
µm deep and 100 µm wide. Microfluidics µL (10-6 L) to pL (10-12 L). The first 
applications of microfluidic technologies have been in the areas of biological and 
chemical analysis. Most micropumps found today can roughly be divided into two 
groups: The so-called “reciprocating micropumps” use the oscillatory or rotational 
movement of mechanical parts to displace fluid. Micropump development has started 
with “piston type” reciprocating micropumps like micro diaphragm pumps and 
peristaltic micropumps that do still form the main representatives of this class in the 
MEMS world. 
2.16.2. Nanoparticles membrane filtration 
Nanomaterials membrane filtration is the process of filtering nanoscale solid 




can be two-dimensional (2D) with nanoporous membranes or three-dimensional (3D) 
with nanoporous scaffolds. For tangential flow filtration (TFF) mode, depending on the 
molecular weights, particle size and pressure during the filtration can be subdivided in 
ultrafiltration (UF) and nanofiltration (NF). Both UF and NF are heavily used for water 
purification and waste management, and over the last decades have been used for 
many more applications, including pharmaceutical applications and biotechnology [254–
256]. Traditionally, synthetic nanoporous membranes have found biological and medical 
applications that involve sorting, sensing, isolating, and releasing biological molecules 
[257]; but just lately for NPs separation [258–262]. Normal flow filtration (NFF), also known 
as dead-end filtration, is the other filtration mode available using nanoporous 
membranes and has been primarily used for laboratory and medical filtration [263]. 
Unlike TFF membrane processes, the fluid to be filtered in NFF is fed perpendicularly 
to the filter element, and all the fluid passes through the filter element with retained 
solids forming a cake layer on the element surface.  
High control of thickness, porosity, and pore size in nanoporous membranes 
production is essential to achieve excellent performance during the nanofiltration. 
Striemer et al. in 2007 published the first ultrathin porous nanocrystalline silicon (pnc-
Si) membranes fabricated via crystallization of amorphous silicon thin films deposited 
by radio frequency sputtering [264]. Achieving a genuinely thin membrane is essential 
to reduce the effect of the membrane in the flow and maximise control during filtration 
and capture of nanomaterials during the filtration process. After this scientific 
breakthrough, many others used similar kinds of technology to achieve ultrahigh 
performance desalination by filtering reactive NPs [265], pH stimuli-responsive devices 
based on ionic current rectification [266] and removal of insoluble and soluble organic 



















3.1. High-temperature gas treatment 
This chapter showcases performed heat treatment using an Elite single-zone 
horizontal tube furnace to change the oxidation state of WO3 and γ-
Fe2O3 nanopowders. This furnace has a theoretical accuracy of 0.1 °C and can 
operate up to 1200 °C. The heat-treating processes require the precise control of 
temperature over the heating cycle. The heating rate is 5 °C per minute, and dwell 
time is 60 minutes, with variable target temperatures from 200 °C to 400 °C. The 
addition of a mixture of H2 and argon (Ar) gas was used to perform redox reactions in 
metal oxides which could not usually happen in nature at these heating rates and 
target temperatures due to being highly endothermic. To achieve this purpose, our 
Elite gas furnace oven brings the capabilities to control with high precision the 
reaction’s environmental parameters. The main drawback of this method is that it 
requires a dry sample and in the case of NPs, this leads to aggregation, which in some 
cases might be irreversible. 
The sample is placed in alumina boats of 70 mm x 20 mm x 20 mm to hold it 
while interacting with the gas and to prevent damage to the quartz glass of 50 mm of 
diameter. Alumina boats are commonly used due to their strong heat resistance to 
very high temperatures and smooth surface that allows easy cleaning for long-lasting 
reusability. The external calibration thermometer is not necessary if the furnace is very 
well-calibrated, but it is recommended to use it every time to verify the calibration is 
correct. Once tightly closed, the gas continuously enters the quartz glass tube through 
the inlet, interacts give the sample exposed local atmosphere and leaves the tube 




the gas, no air remaining. Once the atmosphere is homogenised, the furnace is turned 
on pointing to the target temperature at a certain speed and dwell time. The speed is 
how fast the temperature will rise, and the dwell time is how long the furnace will 
remain at the target temperature once reached.  
3.2. Massart procedure 
Coprecipitation from aqueous solutions is one of the most frequently used 
methods. The first controlled preparation using an alkaline coprecipitation of FeCl3 and 
FeCl2 of superparamagnetic magnetite NPs was performed by Massart [196]. This is 
the method user the Massart method to obtain Fe2O3 NPs presented in this report. 
Most synthetic routes on the literature to obtain IONPs are based on the 
Massart procedure. In this procedure, an aqueous solution of ferrous (Fe2+) and ferric 
(Fe3+) ions in a 2 :1 stoichiometry is mixed with ammonia solution giving gelatinous 
precipitate. Since that time, many other modifications have been examined. The 
coprecipitation of very fine maghemite NPs using citrate stabilising ions was described 
by Bee et al.[268] The size and shape of the IONPs depend on the type of salt used 
(such as chlorides, sulfates, nitrates and perchlorates), the ferric and ferrous ions ratio, 
the reaction temperature, the pH value, ionic strength of the media, and the other 
reaction parameters (e.g. stirring rate, dropping speed of basic solution) [269]. 
The average size of the resulting NPs in this thesis is 11 nm approximately. To 
achieve, this size, 0.09 mol of iron (III) chloride hexahydrate and 0.054 mol of iron (II) 
chloride tetrahydrate were mixed in a total volume of 488 mL of distilled water. This 
mixed was added at rate of 0.2 mL/s into 75 mL of NH4OH 25% while heating at 90ºC 





3.3. Stöber process 
In this thesis, the Stöber process is used to create silica nanoshells that cover 
the NP cores in a core-shell structure. The Stöber process is a sol-gel method that 
involves consecutive hydrolysis and condensation of alkoxysilanes in an aqueous-
alcoholic solution in the presence of a base catalyst, whose most popular version uses 
tetraethyl orthosilicate (TEOS) as alkoxysilane and ammonia as a base catalyst. In the 
course of the hydrolysis reaction, the ethoxy group of TEOS reacts with the water 
molecule to form the intermediate [Si(OC2H5)4-x(OH)x] where the hydroxyl group is 
replacing ethoxy groups. Ammonia serves as a fundamental catalyst for the hydrolysis 
and condensation, so the hydroxyl anions break the silicon bonding on TEOS 
molecules [270]. Nevertheless, the role of ammonia is also to protect the newly formed 
SiO2 from undesired aggregation; in other words, it helps to obtain monodisperse SiO2 
core-shell composite NPs. Immediately after the hydrolysis reaction, the condensation 
process occurs, and the hydroxyl group of intermediate [Si(OC2H5)4-x(OH)x] reacts with 
the ethoxy group of other TEOS and the hydroxyl group of another hydrolysis 
intermediate steps where temporary Si-O-Si bridges are formed. K. S. Kim et al. stated 
that the rate of water condensation is thousands of times faster than the alcohol 





Figure 3.1 | Illustration of the Stöber process overall reaction and formation of SiO2 
structures. 
The hydrolysis can be expressed as the following: 
Si(OC2H5)4 + xH2O     →      Si(OC2H5)4−x(OH)x + xC2H5OH (3.3.1) 
The sol-gel process can be described more in detail as water condensation in 
Eq. (3.3.1) and alcohol condensation in Eq.  
≡ Si − O − H+ H − O − Si ≡       →       ≡ Si − O − Si ≡   +  H2O (3.3.2) 
≡ Si − OC2H5 +H − O − Si ≡        →       ≡ Si − O − Si ≡   +  C2H5OH (3.3.3) 
During this process, TEOS molecules form silanol groups, and the 
polymerization/nucleation between silanol groups and ethoxy groups creates the 
siloxane bridges (Si-O-Si) that integrate the SiO2 structure as described in Figure 3.1. 
SiO2 reacted with hexamethyldisilazane (HMDS) to form non-stable trimethylsilyl 
groups which have high reactivity with the SiO2 surface silanols; therefore, the product 
is hydrophobic as shown in Eq.: 
2(≡ Si − OH) + 2((CH3)3 − Si)  − NH → 2(≡ Si − O − Si − (CH3)3) + NH3 
(3.3.4) 
TEOS concentration is the main parameter on the SiO2 particle size[276]. The 
more TEOS in the reaction, the thicker the SiO2 shell in the product. For each core, 
the main differences rely on the stirring method. For WO3[277], a robust ultrasonic 






3.4. Turkevich Method 
Colloidal AuNPs can be obtained following different methods[278]. In our 
research, colloidal Au NPs were obtained by using the reduction of Au salts in the 
presence of surfactants, reduction of chloroauric acid with 
tetrakis(hydroxymethyl)phosphonium chloride (THPC, C4H12ClO4P). There exist other 
very famous methods such as the trisodium citrate (NaCtr, Na3C6H5O7) and sodium 
borohydride (NaBH4).  
The THPC starts by dissolving chloroauric acid hydrate or Au (III) chloride 
trihydrate (HAuCl4) in water described by the overall reaction 
 HAuCl4 +H2O → AuCl4
− + OH− + H2
+ (3.4.1) 
HAuCl4 can be dissolved in water or another polar organic solvent. Using the 
citrate reduction method, reduction reaction between HAuCl4 with sodium citrate 
(Na3C6H5O7) the reaction (3.4.2) or the reaction (3.4.3) in case of using different 




    100°C    
→      2Au + 3CH2O + 3CO2 + 8Cl





    100°C    
→      6Au + 6CO2 + 24Cl
− + 18H+ 
(3.4.3) 
The Eq. (3.4.3) is the previously mentioned sodium citrate method developed 
by Turkevich. Here, 1 mM HAuCl4 is dissolved in deionised (DI) water in which Au3+ 
cations are reduced. The colour change to dark blue/purple happens because the 
sodium citrate is reducing the HAuCl4 and produces very small AuNPs that are 
dispersed in the solution rather than precipitate out. This is why they are called 




heating during the whole procedure, and the sizes are over 20 nm on average which 
is inconvenient for coating. 
Another common alternative for the AuNPs formation is the sodium borohydride 
reduction[279] expressed as given in (3.4.4) and the scheme for the reduction reactions 
of Au ions can be written by the equation (3.4.5): 
4[HAuCl4] + 3NaBH4 + 9H2O →
4
n[Au0]n
+ 3NaCl + 3H3BO3 + 13HCl + 6H2 
(3.4.4) 
2Au2+ + BH4− + 4H2O → 2Au
0 + B(OH)4− + 2H2 + 4H
+ (3.4.5) 
This method is highly stable and has been previously performed, obtaining 
good results[280]. The main disadvantage is the high average deviation in size, which 
is inconvenient for a subsequent Au coating. 
Finally, a version of Turkevich method with THPC by Baiker et al.[281] was also 
reproduced. The first reaction is  
[P(CH2OH)4]Cl + NaOH → P(CH2OH)3 +H2O + H2C = O+ NaCl (3.4.6) 
The product, tris(hydroxymethyl)phosphine (P(CH2OH)3), is used to 
synthesise AuNPs by treating it with aqueous sodium hydroxide (NaOH.xH2O) what 
is necessary to generate the reduction reaction given by equation  
3P(CH2OH)3 + 2AuCl4
− + 6OH− → 3O = P(CH2OH)3 + 2Au + 8Cl
− + 3H2O (3.4.7) 
This method allows the generation of ultra-small diameter Au NPs and high 
stability in aqueous solution for long periods [282]. If the solution were stored in the 
presence of NaOH, THPC could progressively decompose, thus reducing its ability to 





During the formation of the metallic sol and the storage time, a considerable excess 
of NaOH is present. The reactions of THPC with NaOH performs the role of the 
reducing agent via the formation of formaldehyde, a well-known reducing agent for Au 
under standard conditions, following the mechanism. The modification of the Turkevich 
method via THPC resulted in the most appropriate one for the NPs and nanoshell 
synthesis because a bigger tunability in terms of the particle size and also very high 
reproducibility was obtained. However, some authors previously reported some 
limitations in the tunability of small-diameter Au nanoshells[283,284]. 
 
Figure 3.2 | Illustration of the Turkevich method steps using THPC.  
Finally, the growth of Au on top of the SiO2 is a pivotal element to improve the 




tune the LSPR peak position to match the excitation wavelengths from the incident 
laser, which optimise the SERS enhancement.  This method can be the approach in 
different ways but in the end, follows the same fundamentals than the original Au NP 
formation. One of the most reliable and easily reproducible approaches is the 
reduction of the Au stock solution with potassium carbonate dissolved in an alkaline 
solution. This method leads to a smooth Au nanoshell growth. 
3.5. Surface functionalization 
3.5.1. Amine group 
There are significant optical and chemical properties of AuNPs that depend 
strictly on the type of ligand and ligand-metal bond. 3-aminopropyltrimethoxysilane 
(NH2(CH2)3-Si-(OCH3)3), APTS or APTES) is one of the most common chemicals used 
to amine functionalised surfaces for successive Au attachment due to its stable 
bonding with Au, fast attachment and low price. The amine functionalisation technique 
is applie din this thesis following the standard heating while stirring procedure to the 
surface of our SiO2 nanoshell for the attachment of gold nanoparticles on top as 
described in Figure 3.3. 
SiO2 is formed by strong covalent bonds where one atom of SiO2 is connected 
to 4 atoms of oxygen, and each oxygen is connected to 2 Si atoms. The amine 
functionalisation provides the same type of periodic molecular structure which make it 
very stable. However, due to potential defects and a higher degree of disorder, small 
variations from the formulas presented in Figure 3.3 may appear as described by 
Pasternack et al. [285]. The defects can be minimised by controlling specific parameters 






Figure 3.3 | Illustration of the amine groups interactions with nanostructures. (a) Amine 
surface functionalization of SiO2 dispersed in ethanol by using APTES. (b) Amine 
functionalised surface of SiO2 bonding with Au NPs. 
3.5.2. Thiol group 
Self-assembled monolayers (SAMs) of organic molecules provide an 
inexpensive and adaptable surface coating for a wide range of applications; and, in 
the case of noble metal substrates such as Au, thiol moieties are commonly used as 
end groups because of the strong affinity of sulphur with these metals. There is a 
profound debate in the field regarding the fate of the hydrogen from thiol molecules 




predict their physical, spectroscopic, and chemical-structural formation properties. 
Traditionally, it was understood that thiol moieties are chemisorbed to planar Au 
surfaces, with the loss of hydrogen during the formation of the bond. Ipken et al. 
probed recently that the Au-thiol SAMS bond does unexpectedly not have 
chemisorbed character, which means the hydrogen atom is probably retained [286]. 
This comparison is portrayed in Figure 3.4, where R refers to any functional group. 
This new model indicates that the Au-thiol bond is maybe not as strong as initially 
thought. 
 
Figure 3.4 | Illustration of a SAM on an Au(111) monolayer. (a) Traditional model. (b) 
New model. 
The -SH  binds to Au at temperatures in the range of 20-70°C. In this thesis, 
the binding was performed at room temperature (approx. 24°C). Combining this with 
a structure that includes at least an aromatic ring which has vibrational modes, the -





ring peaks. Price and biocompatibility are the most important factors taken into 
consideration when choosing the thiol molecule.  
4-MBA (HSC6H4CO2H) is one of the best options as a Raman reporter for 
biomedical applications. This molecule contains one benzene ring, a thiol and a 
carboxylic group. The main reason to choose 4-MBA is its extensively proven 
performance in the literature for SERS and being cost-effective. Raman scattering 
shows that the two most important peaks that should be used as a reference for this 
molecule are at 1078 cm-1 and 1590 cm-1. However, once a good SERS effect is 
proven with the coupling between the 𝐴𝑢 surface plasmons and this thiol molecule, 
many other thiolated molecules with alternate marker peaks can be subsequently 
tested if required for biomedical imaging purposes.  
3.6. Electron microscopy  
3.6.1. Scanning electron microscopy 
An SEM scans a focused electron beam over the surface of a micro- and/or 
nano- structured solid material to create an image such as micro and NPs. The 
resolution of SEM is approximately 10 nm in standard machines and 2.5 nm in 
advanced versions [287]. In this thesis the SEM models used were TESCAN VEGA3 
SEM with the best resolution of 2 nm at 30 kV in high-vacuum mode and 2.5 nm at 30 
kV in low-vacuum mode; and Zeiss Auriga FIB-SEM capable of resolutions of 1.0 nm 
at 15 kV and 1.9 nm at 1 kV. 
SEM can also be used to obtain information about the surface composition by 




microanalysis (EDX, EDS, EDAX), for the determination of the composition or 
orientation of individual crystals or features [288]. 
One of the significant advantages of SEM against other electron microscopy 
techniques is the simplicity of the specimen preparation techniques. In the same line 
as the rest of electron microscopy techniques, it is necessary to have a conductive 
material or partially conductive material. When working with non-conducting or poorly 
conducting materials, and additional nanocoating is added on top of the material 
surface to enhance the SEM imaging. However, this coating will interfere with the 
composition analysis when using EDX. 
3.6.2. Transmission electron microscopy 
Transmission electron microscopy (TEM) is a microscopy technique in which a 
beam of electrons is transmitted through a specimen to form an image [289]. This 
specimen is a TEM grid that contains the sample scattered over the grid holes 
frequently suspended on a holey carbon film. The TEM specimen usually range the 2-
3 mm and contains a mesh of copper (Cu) covered in a thin film of carbon (C) 
sometimes holey. The mesh usually has from 200 to 400 sub-regions or wholes where 
NPs or other nanomaterials can be seen and analysed. In this thesis, most images are 
obtained using the JEOL 2100 TEM which operates at 200 kV, providing point 
resolution of 0.25 nm and ideal lattice resolution of 0.14 nm, generating atomic 
resolution images of nanomaterials. It can operate in bright field (BF) and dark field 
(DF) modes and in both TEM and scanning transmission electron microscopy (STEM) 
modes. Moreover, the nanofiltration studies of this thesis are performed using an FEI 
Tecnai G2 TEM which has 0.24 nm resolution (Twin lens) with ±70˚ sample tilt (±30˚ 





TEM achieve higher resolution than other electron microscopy modalities such 
as STEM or SEM. When the atomic structure of the sample is visible and can be 
imaged via TEM imaging, it is called HRTEM. HRTEM is a powerful tool to study the 
atomic scale of NPs or 2D nanomaterials such as graphene.  
3.6.3. Scanning transmission electron microscopy 
STEM is a type of TEM that includes SEM functionalities that which permits a 
fine electron probe to be scanned across the specimen. In many ways, STEM is like 
SEM. Scattered electrons are detected, and their intensity plotted as a function of 
probe position to form an image. In contrast to an SEM, where a bulk sample is 
typically used, the STEM requires a thinned, electron-transparent specimen usually 
less than 100 nm in thickness [290]. The most used STEM detectors are therefore 
placed after the sample and detect transmitted electron. 
STEM can also perform atomic spectra analysis using EDX. The critical 
difference between performing EDX analysis in the STEM as opposed to the SEM is 
the improvement in spatial resolution. The increased accelerating voltage and thinner 
sample used in STEM leads to an interaction volume that is some 108 times smaller 
than for an SEM. 
3.7. X-rays powder diffraction 
Atoms in solid materials are arranged into crystalline and amorphous structures 
[291]. Amorphous materials are isotropic, i.e., present irregular atomic arrangements 
and possess the same properties in all directions. In contrast, the crystalline materials 
are anisotropic because their atoms are arranged in a regular and repeated pattern, 
and their properties vary with direction. There are many types of crystalline structures 




XRD is a rapid and powerful non-destructive analytical technique for phase 
identification of crystalline material. The X-ray diffraction pattern is distinct for each 
different phase, and it can provide information on unit cell dimensions. Amorphous 
materials, like glass, do not produce sharp diffraction peaks but broad peaks. The 
material to analyse needs to be flatly homogenised typically in a glass slide, and then 
an average bulk composition is determined. X-ray diffraction peaks are produced by 
constructive interference of an incident monochromatic beam of X-rays scattered at 
specific angles from each set of lattice planes in a sample. The peak intensities are 
determined by the distribution of atoms within the lattice. Consequently, the X-ray 
diffraction pattern is the fingerprint of periodic atomic arrangements in each material. 
The diffraction pattern of a mixture is a simple sum of the diffraction patterns of each 
individual phase.  
In this thesis, the XRD spectra are obtained using a Bruker D8 that can analyse 
powders, bulk and thin-film materials for phase composition, quantitative phase 
analysis, unit lattice parameters, crystal structure, and average crystallite size of 
nanocrystallites. The spectra were obtained working at 0.03° step per second of 2θ 
from 10° to 80° at room temperature. 
3.8. Ultraviolet-visible-near infrared spectrophotometry 
Ultraviolet-visible-near infrared (UV-vis-NIR) or ultraviolet-visible (UV-VIS) 
spectrophotometry is a device developed to analyse the light scattering or absorbance 
characteristics of matter. For this purpose, the wavelength of collected light dispersed 
into its constituent wavelengths with a diffraction grating. To calibrate these 





the sample in redispersed to subtract the effects of the liquid medium and the cuvette 
absorption properties. 
The nanoparticles were characterised by using the Thermo Scientific Evolution 
Array UV–vis spectrophotometer to obtain the light absorption spectra of the colloidal 
composite nanoparticles suspended in ethanol at mild conditions using plastic 
cuvettes. This UV-vis system uses light sources of pre-aligned Deuterium and pre-
aligned Tungsten which can measure a full spectrum every 20 milliseconds, have a 
wavelength reproducibility < 0.02 nm (ten consecutive scans) and can scan in the 
range of 190 to 1100 nm.  
3.9. Dynamic light scattering 
Dynamic light scattering (DLS), also known as quasi-elastic light scattering or 
photon correlation spectroscopy (PCS), is a technique that determines the size of 
spherical particles from the nanoscale to the microscale [292]. DLS measures the 
Brownian motion of particles suspended within a liquid and correlates this to the 
particles’ size. The Brownian motion of particles in solution arises due to collisions with 
solvent molecules and depends on the particle’s size, temperature, and solvent 
viscosity [293]. If the particles are large, their Brownian motion will be slow. The 
molecules from the solvent push the smaller and lighter particles, which increase their 
speed. The translational diffusion coefficient (D), which is concentration-dependent is 
the property that defines the velocity of the Brownian motion. Additionally, temperature 
must be stable to prevent convection currents which induce non-random movements 
that will lead to wrong results. Moreover, the viscosity of the solvent is required for the 




The hydrodynamic diameter is measured by applying the Stokes-Einstein 






where d(H) is the hydrodynamic diameter of the particles, k is the Boltzmann’s 
constant, T is the absolute temperature of the liquid, η is the liquid’s viscosity and D is 
the translational diffusion coefficient. 
This calculation is useful but might mislead for particles that has forces that 
drive aggregation such as in the case of magnetic NPs. The actual measured 
hydrodynamic diameter is not the value of the single magnetic NPs but the aggregates. 
The electric surface charge can also lead to aggregation and modified diffusion speed 
which will lead to a change on the apparent size of the particle. When clusters occur, 
they sometimes do not form spherical shapes which will also contribute to 
misidentification of the hydrodynamic diameter. Also, heavy particles might eventually 
precipitate, which will drastically modify the number of NPs dispersed in the medium 
and the concentration of them. Therefore, multiple readings at different densities are 
usually recommended to find the region in which the results are consistently 
reproducible for prolonged periods of time. 
The colloidal NP size and hydrodynamic radius were analysed using the 
NanoSight NS300 and Zetasizer Nano ZS for DLS from Malvern to measure the 
colloidal NP hydrodynamic radius. All samples where measured at concentrations 
between 10 to 400 ug/mL to obtain reproducible readings. The specific concentration 





concentrations until it goes from too concentrated to too diluted, in a range of 
consistent DLS results.  
The scattered light in both systems is detected at 173-175o, it is called 
backscattered detection. Light is also detected at 90 and correlated with the 
backscattered detection to discard incorrect measurements by using the Mie theory of 
NPs size scattering at 90o and 173-175o degrees [292,295]. Also, when the optics are not 
in contact with the sample, the detection optics are called non-invasive. Measuring in 
these conditions is very important to measure without needing the light to travel across 
the entire sample. Otherwise, some issues may arise, such as multiple scattering, 
where light from one particle is itself scattered by other particles. This configuration 
also allows measuring the hydrodynamic radius of higher concentrations. Other 
problems such as contamination are avoided by measuring backscattered light since 
most of these contaminants scatter in the forward directions only. Using the correlator 
is essential to discard this kind of measurements discrepancies. 
3.10. Nanoparticle tracking analysis 
Nanoparticle tracking analysis (NTA) is a new technology commercialised in 
2006 that visualises and analyses particles in liquids by relating the rate of Brownian 
motion to particle size. NTA combines laser light scattering microscopy with a charge-
coupled device (CCD) camera to obtain visualization and recording of NPs in solution. 
In this thesis, NTA is performed using a NanoSight NS300 from Malvern Panalytical 
which can rapidly record particle sizes and concentration of samples ranging 
approximately from 10 to 1,000 nm in particle diameter and 106 – 109 particles/mL in 
concentration, with the lower detection limit being dependent on the refractive index 




experiments, 500 µL were used. The NanoSight NTA software identifies and tracks 
individual NPs moving under Brownian motion and relates the movement to a particle 
size according to the Stokes-Einstein equation given by equation (3.9.1) [296]. 
3.11. Vibrating sample magnetometer 
A vibrating sample magnetometer (VSM) is a magnetometer that measures the 
magnetic properties of liquid and solid samples including powder by vibrating the 
sample while applying a constant uniform external magnetic field which induces 
sample magnetization. The vibrations create perturbations in the external magnetic 
field, which can be detected using a magnetic field sensor such as a gaussmeter. To 
achieve a good reading, it needs to be calibrated first the saturation magnetization so 
that the sample indeed undergoes a hysteresis loop [297]. The intensity of the field must 
be tuned by knowing this parameter.  
In this thesis, the VSM model is MicroSense EZ7 VSM which can reach fields 
up to 21.5 kOe at a sample space of 4 mm and fields above 17.5 kOe with the 
temperature chamber in place; can operate at temperatures from 4.2 K to 450 K; has 
a field resolution of 0.001 Oe in the lowest field range; a 1% moment accuracy when 
calibrated with calibration sample identical in shape and size to the measurement 
sample; and repeatability better than 0.5% at constant temperature and if sample 
position is not changed. Its highest sensitivity (lowest noise) without signal averaging: 
125 nemu (125 nOe·mL) at a 3.5 mm sample space and 500 nemu (500 nOe·mL) with 
the single-stage temperature option in place. This VSM model can measure liquid, 
powder, solid, bulk, and thin-film samples. Approximately, 1 mL of powder sample was 





3.12. Superconducting Quantum Interference Device 
Superconducting quantum interference device (SQUID) is a very sensitive type 
of magnetometer used to measure extremely subtle magnetic fields, based on 
superconducting loops or rings containing Josephson junctions. In this thesis, a 
SQUID direct current (DC)  was used. This device is based on using two Josephson 
(superconducting-insulating-superconducting) junctions instead of one that is used in 
the RF type. This device operates at cryogenic temperatures with quantum-limited 
sensitivity, and it has demonstrated field resolution at the 10−17 T (10−13 Oe) level [298].  
For SQUID measurements, 1 mL of the colloidal sample was pipetted into a 
transparent glass vial with 12 mm diameter x 32 mm height. The increment of 
temperature was measured by using optical fibres. For powder samples, a known 
mass of sample is added to a flat surface like a petri dish and the increment of 
temperature is measured by using and infrared (IR) camera, FLIR E53 
To measure the hysteresis loop of a sample, the sample was placed in the 
centre of the ring, which is the location where the field is the most intense and 
homogeneous. The SQUID performs as a flux-to-voltage transducer that converts 
small changes of magnetic flux into a voltage. These changes are due to magnetic 
properties of the materials such as ferrimagnetism or superparamagnetism and can 
be translated to hysteresis loops which present the magnetization of the sample when 
exposing it to a magnetic an alternating magnetic field. Additionally, a SQUID can 
detect the magnetization of the sample while cooling it while applying or not non-
alternating magnetic field.  
Zero-field-cooled (ZFC) were also obtained by cooling the samples without any 




at the transition temperature. This process is generally reversible for ordered magnetic 
materials such as ferromagnets and antiferromagnets. In contraposition, field-cooled 
(FC) is obtained by cooling the samples with an applied magnetic field. The two 
susceptibilities are related to each other through the coercivity, which is a measure of 
the anisotropy. The ZFC susceptibility can be calculated from the FC susceptibility (or 
vice versa) and the coercivity [299].  
3.13. Spontaneous Raman spectroscopy 
In this thesis, the 2D Ramana maps were obtained using a inVia™ Reflex 
confocal Raman microscope from Renishaw. This system can obtain micro-Raman 
mappings and uses 785 and 830 nm NIR laser sources, reaching 140 mW power at 
sample illumination. A Leica microscope was used with the following parameters: 
5×/0.12 NA (numerical aperture) for large area surfaces which has spot sizes of 7.98 
µm (785 nm) and 8.44 µm (830 nm); and 50×/0.75 for small areas which has spot 
sizes of 1.28 µm (785 nm) and 1.35 µm (830 nm), assuming uniform illumination. The 
spatial resolution of the system is approximately 1 μm. Samples are pipetted directly 
to a silicon wafer and dried at 70 °C for 8 h. Spontaneous Raman signals from liquid 
samples were also measured in a plastic cuvette with a 785 nm class-4 laser source. 
3.14. Coherent anti-Stokes Raman spectroscopy 
In this thesis, all CARS measurements were obtained using a broadband CARS 
custom-built microspectrometer from the CONTRAST facility at the University of 
Exeter that provides 2D and 3D mapping of Raman fingerprints of biomolecules. 
Based on broadband CARS, this system utilises a configuration of laser sources that 
probes the entire biologically relevant Raman window (500–3500 cm–1). At the centre, 





specifically for broadband CARS. The system provides synchronization of narrowband 
(∼3.4 ps) flat-top laser pulses at 770 nm synchronised with supercontinuum pulses 
(∼16 fs) spanning ∼900–1400 nm (NIR). By utilising intrapulse three-colour excitation 
and non-resonant background, CARS heterodyne-amplifies weak Raman signals. The 
beams are temporally and spatially overlapped and delivered onto the sample via a 
1.2 NA objective and the CARS signal collected in the forward's direction by an 
inverted microscope (Olympus IX73) with a 0.7NA objective. The anti-Stokes signal is 
spectrally isolated from the excitation wavelengths using band-pass filters and focused 
onto the entrance slits of a spectrograph (Princeton Instruments Isoplane 160) 
equipped with a fast CCD camera (Princeton Instruments Pixis). 
3.15. Microcomputed Tomography 
 
Figure 3.5 | (a) Picture of a X-TEK Benchtop CT 160 Xi and (b) zoomed image from 
the inside. (c) Diagram of the MicroCT imaging platform and basic operating principle 
to obtain the X-ray based tomographic image using aggregated nanoparticles 
precipitated at the bottom of a microcentrifuge tube. 
In this thesis, all microCT measurements were obtained using the X-Tek Bench 




2D and 3D maps/structures of materials with a theoretical resolution of 3 micron in 
theory without damaging the samples. The re-constructed data/structure can be 
viewed from any 3D angle, sliced in any direction, accurately measured and even 
animated.  
Aggregated or colloidal NPs are susceptible to absorbing X-rays and therefore 
being potential X-rays contrast agents depending on their size, volume, concentration, 
and material. Our samples were intentionally aggregated in the water at the bottom of 
microcentrifugation tubes to obtain aggregates more extensive than the resolution limit. 
3.16. Magnetic heating 
For our magnetic heating measurements, both NanoHeat from NanoScience 
Laboratories and MagneThermTM from nanoTherics were used. The NanoHeat AC 
Magnetic Field Nanoparticle Heater can perform frequency response profiles readings 
in the frequency range 50 kHz to 1,000 kHz and offers 69 frequency points and field 
strengths up to 56 mT rms (79 mT peak). The NanoHeat employs continuous linear 
power control and provides an extremely homogenous (±5% homogenous field over 
7ml volume) and well-defined AC field. On the other hand, the MagneThermTM system 
can perform frequency response profiles experiments in the frequency range 110 kHz 
to 990 kHz and offers 10 frequency points and field strengths up to 25 mT. In this 
thesis, 1 mL of sample for both systems was used. 
3.17. Micromagnetic simulations of magnetic nanoparticles 
The numerical simulations were carried out by Conor McKeever using the 
stochastic Landau-Lifshitz (sLL) equation [300–304]. The LL equation describes the 







= −γ1α⃗ i × (H⃗⃗ ef,i + H⃗⃗ th,i) − ҡiγ1α⃗ i × (α⃗ i × (H⃗⃗ ef,i + H⃗⃗ th,i)) (3.17.1) 
where γ  is the gyromagnetic ratio, ҡ𝑖 is the phenomenological damping 
parameter, γ1 = γ/1 + ҡ
2,  H⃗⃗ ef,i is the effective magnetic field and H⃗⃗ th,i is a thermal 
field. The local effective magnetic field acting on the magnetization vector ?⃗⃗?  can be 
calculated as shown in equation (3.17.2), 






where W is the magnetic energy density. The total magnetic energy density of 
the interacting NP system is a sum of the Zeeman energy, nearest-neighbour 
exchange interaction, mutual magneto-dipole interaction, and the thermal energy. 
For NPs with uniaxial anisotropy, the first-order magnetocrystalline energy 
density is given by equation (3.17.3), 
Wanis = −Ku1(u⃗ ∙ m⃗⃗⃗ )
2 (3.17.3) 
where 𝐾𝑢1 is the first order uniaxial magnetocrystalline anisotropy constant.  
The energy density due to the Heisenberg exchange interaction is evaluated as 
a six nearest neighbour small-angle approximation with energy density given by 
equation (3.17.4), 
Wexch = −A(∇m⃗⃗⃗ )
2 (3.17.4) 





The long-range magnetostatic field given in equation (3.17.5) is evaluated as a 
discrete convolution of the magnetization with a demagnetising field kernel K̂ 
H⃗⃗ ef,i = K̂i,j ∗ m⃗⃗⃗ j (3.17.5) 
The strong magneto–dipole interaction is known to significantly decrease the 
SAR of fractal clusters of interacting uniaxial NPs [305]. Finally, finite temperature is 
incorporated into the numerical simulations by means of a fluctuating thermal field H⃗⃗ th,i 
given by Brown [301], 




where kb  is the Boltzmann constant, 𝛼 the damping parameter, 𝑇 the 
temperature, 𝑚𝑠𝑎𝑡 the saturation magnetisation, 𝛾 the gyromagnetic ratio, Δ𝑉 the cell 
volume, Δ𝑡 the timestep and ?⃗?  a random vector computed from a normal distribution 
which varies after each timestep. 
3.18. Magnetic resonance imaging 
MRI measurements were taken by using nanoparticles redispersed in water 
inside of microcentifugation tubes of 2 mL. These tubes were placed inside of a silicon 
holder and then placed into a polystyrene box. The box was placed horizontally with 
the tubes oriented vertically, in the MRI Philips Gyroscan Intera 1.5T MRI.  
3.19. Atomic Force Microscopy 
Atomic force microscopy (AFM) can image almost any type of surface, including 
polymers, ceramics, composites, glass, and biological samples [306]. There are AFM 





magnetic, thermal. For some of the more specialised techniques, modified tips and 
software adjustments are needed. Typically, these micro-cantilever systems are 
operated in three open-loop modes; non-contact mode, contact mode, and tapping 
mode [307]. AFM works by raster-scanning a sharp tip over the sample surface using a 
feedback loop to adjust parameters needed to image a surface, and atomic forces are 
used to map the tip-sample interaction. 
The AFM model used in this thesis is the Innova® AFM from Bruker which 
delivers accurate, high-resolution imaging and a wide range of functionality but is 
limited by the operation mode, type of probe and sample characteristics. The sample 
needs to be flat with rugosity not thicker than the maximum amplitude that the tip can 
undergo. In this thesis, an AFM was used to scan over the surface of the nanoporous 
silicon nitride (NPN) membranes that are approximately 50 nm thick, using average 
nanopore sizes of 37 nm and 60 nm. The full possible sample volume is 45 mm x 45 
mm x 18 mm with a motorised Z-axis travel of 18 mm, with pitch and tilt capability. The 
resolution is not due to the system but to the tip and scanning mode. 
3.20. Microfluidics 
Materials: Polydimethylsiloxane (PDMS) sheets were obtained from Trelleborg 
Sealing Solutions Americas, Fort Wayne, IN. The following reagents were purchased 
from Sigma Aldrich: Iron (III) oxide (γ-Fe2O3) nanopowder, <50 nm particle size (BET) 
and pure ethyl alcohol (ethanol, EtOH) 200 proof, anhydrous. Deionised water was 
obtained at 18.2 MΩ and 24.1 °C from Q-POD® Ultrapure Water Remote Dispenser 
connected to a Milli-Q® Advantage A10. 
Equipment: Silhouette Cameo digital craft cutter was purchased from Silhouette 




Separation from SiMPore Inc. VWR High-Speed Microcentrifuge was used at ×500g 
centripetal force. Chemyx Fusion 100 Infusion Pumps were used in TFF to pump the 
solution at a rate of 25 µl/min as a supply and 12.5 µl/min during the ultrafiltration. 
These microfluidic pumps must be synchronised; otherwise, the vacuum pressure will 
break the membrane. For the electron microscopy images, the JEOL 2100 TEM/STEM, 
TESCAN VEGA3 SEM and Zeiss Auriga FIB-SEM systems were used. The colloidal 
NP size and concentration data were obtained using NanoSight NS300 and Zetasizer 
Nano ZS for DLS from Malvern. The XRD patterns were obtained with the Bruker D8 
advanced XRD machine working at 0.03° step per second of 2θ from 10° to 90° at 
room temperature (300 K). Innova Atomic Force Microscope (AFM) from Bruker was 
used at 2 V setpoint, with a scanning mode RESP-20 tip of ~8 nm radius, 10-15 µm 
height and 17.5 º side angle to obtain the AFM profile of the membrane. The 
proportional (P), integral (I) and differential (D) gains for our system were of P=1, I=0.5 
and D=0 
3.20.1. Microfluidic pump 
Two Chemyx Fusion 100 Infusion Pumps were used in TFF to pump the 
solution at a rate of 25 µl/min as a supply and 12.5 µl/min during the ultrafiltration. 
These microfluidic pumps must be synchronised; otherwise, the vacuum pressure will 
break the membrane. They can hold syringes from 0.5µL to 60 mL and operate at 
rates from 0.0001 µL/min to 140 mL/min which display a very high precision for our 
experiments.  
Much attention has been focused over the last decades on miniature systems 
for chemical and biological analysis [308–311]. Miniaturization can reduce costs and 





is necessary if micropumps are to become more widely used in micro total analysis 
systems (μTAS).  Monitoring single cells may require manipulation of fluid volumes on 
the order of 1 pL — the volume contained in a cube 10 µm on a side [312–314]. It is 
possible to work with even smaller objects such as NPs and molecules disperse in the 
microfluidic media for many applications such as cytotoxicity assays, ELISA tests and 
size filtration. 
3.20.2. Microfluidic filtration device 
The fabrication of NPN Membrane performed by  SiMPore Inc. following the 
fabrication steps for NPN membranes has been published previously by J.P. 
DesOrmeaux et al. 2014 [315]. Summarising the main steps, a double-side polished 
silicon wafer is coated with a three‐layer stack made of 50 nm-thick silicon nitride (SiN), 
40 nm-thick amorphous silicon, and 20 nm-thick silicon dioxide. Then, the wafers are 
then annealed using a rapid thermal process to transform the amorphous silicon into 
porous nanocrystalline silicon (pnc‐Si) layer on top of SiN. The backside SiN is 
patterned using reactive ion etching while the SiO2 layer acts as a protection for the 
pnc-Si and SiN films during the backside processing. The nanopores generated in the 
pnc‐Si are transferred into the SiN layer by reactive ion etching after removing the 
SiO2. Finally, to create the free‐standing membranes, the backside of the silicon wafer 
was etched to the silicon nitride layer using ethylene diamine pyrocatechol. The final 
membranes developed following this method have 37 and 60 nm pore size each. 
SepConTM NFF device assembling was obtained as described in the following. 
The assembling process of the SepConTM device follows the steps described below. 
In the first step, a flat and sticky PDMS piece U shaped gasket is added to the bottom 




it in the square hollow and pressing in the edges against the sandwiched PDMS for 
adherence. Finally, this lower part of the SepConTM is inserted in the top cylindrical 
part to finish the assembling. To collect the filtered sample, the SepConTM is placed in 
a microtube before adding the sample and starting the centrifugation. 
The TFF device fabrication was achieved by applying the following steps. 
Custom ordered 100 µm and 300 µm thick PDMS sheets are patterned using a 
Silhouette Cameo digital craft cutter. The patterned silicone sheets are assembled into 
layer stack devices by aligning the patterned layers as previously reported by M. 
Dehghani et al in 2019 [316]. Then, NPN membrane chips (300 µm thick) are 
sandwiched between the stacked layers. The final device is clamped to seal it and be 
ready for flow processes. 
3.20.3. Tangential filtration 
Tangential flow filtration (TFF) or cross-flow filtration is a type of filtration in 
which the solution to be filtered is pumped in parallel to the filtering membrane surface. 
In this configuration, part of the solution remains unfiltered and keeps flowing 
perpendicular to the membrane, and this is called retentate. It is possible to improve 
the quality of filtration by refeeding the retentate into the system as a sole feed or 
mixed with the original feed. Some of the most relevant parameters to achieve better 
filtration are the type of membrane used, the pressure in the upper side of the 
membrane versus the lower part of the membrane, the type of flow present in each 
region and the particles or molecules to be filtered. When working with nanoscale 
objects, this membrane must present permeability for the scale only, and it needs to 






TFF NP filtration was applied following these steps: The two microfluidic pumps 
were connected to the TFF device. The pumps at a rate of 25 µl/min to supply the 
initial media background and avoid creating pressure differences that could damage 
the membranes. The flow rate was the same in both pumps – one pulling below the 
membrane and one pushing above. Then, a rate of 12.5 µl/min was used in both 
pumps during the ultrafiltration while adding 500 µl of the NPs solution at a 
concentration of 4 µg/ml (1:50,000 from stock). Once the entire volume is pulled 


















4. Core material refinement  
4.1. Introduction 
In this chapter, two methods to refine and purify nanoparticles are being 
presented. The first method is a high-temperature gas treatment that uses a mixture 
of H2+Ar gas to hydrogenate dry WOx NPs which has been previously reported [317] 
and to reduce dry γ-Fe2O3 NPs. This method provides a simple and reproducible way 
to obtain alternative materials that be used for medical applications. A second method 
is a novel approach used later in the chapter to size filter colloidal γ-Fe2O3 NPs using 
nanomembranes in microfluidic devices that can be used to improve dispersity, purity 
and automate the synthesis of composite NPs. 
4.2. Heat treatment of WO3 and Fe2O3 nanoparticles under H2 gas 
4.2.1. Experimental setup 
 
Figure 4.1 | Illustration of the high-temperature gas treatment using an electric furnace. 
Figure 4.1 presents a diagram of the heat treatment set-up under controlled gas 
environment using an alumina boat to hold the powder sample. This configuration is a 
standard configuration for heat treatment with powders. Alumina is thermally stable up 
to 1750 °C. The speed of the gas flow cannot be high, or all the powder will be gone 
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quickly. Also, additional external thermometers are regularly used to calibrate the 
temperatures recorded in the internal thermometer using a thermal probe made of 
thermally conductive material with high plasticity to adopt different conditions. 
4.2.2. WO3 colouration 
Materials: WO3 NPs purchased from China, Chang Sha Na Ro Mei 
Nanomaterials Ltd, with a purity of 99.9% and an average size of 40 nm, Ar gas and 
H2 gas. 
The colouration of WO3 via hydrogenation: WO3 was thermally treated under a 
mixture of argon (Ar) and hydrogen (H2) gas environment. Ar gas was pumped at 0.11 
L/min and H2 gas at 100 mL/min, using Aalborg gas mass flow controller for each gas. 
The temperature in the furnace was increased up to 400 °C displayed in the furnace 
(this temperature was additionally monitored using external thermometer) with a 
heating speed of 10 °C/min and a dwell time of 60 min. Then the procedure was 
repeated for different temperatures: 300 °C, 325 °C, 340 °C, 350 °C and 400 °C. By 
following these temperatures, a gradual colour change was observed, ranging from 
yellowish green to dark blue as displays in Figure 4.2. 
 
Figure 4.2 | Colouration process under different target temperatures for H2 + Ar gas 
mixtu treatment. In yellow, the temperature from the external thermometer; in white, 
the temperature from the internal thermometer. 




This thermochemical colouration process has been previously reported in the 
literature, and it is understood that it is due to tungsten oxide bronzes formation, i.e. 
hydrogenation of the WOx structure. It has been recently proven as hydrogen gas 
detector in thin films [318]. In Figure 4.2, the numbers in yellow are the temperatures 
measured with the external thermometer and in white the temperatures displayed by 
the furnace. There are minor discrepancies, but not the same temperature is recorded.  
The samples displayed in Figure 4.2 were evaluated under XRD to understand their 
crystallographic structure, as seen in Figure 4.3. The main WO3 characteristics 2θ 
diffraction peaks from Figure 4.3. appear at approximately 23.1°, 23.6°, 24.3°, 26.6°, 
28.7°, 33.3°, 33.8° and 34.1° which are indexed as the (002), (200), (020), (210), (112), 
(202), (022) and (220) planes, respectively. These peaks are characteristic of 
monoclinic WO3. 

























































Figure 4.3 | XRD spectra of the sets of temperatures under which WO3 has been 
hydrogenised. 
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There are very small fluctuations for most peaks compared to the original WO3 sample.  
However, there is a peak at 31.6 ° in the raw WO3 that is gone already at 200 °C and 
does not reappear at different temperatures. It can be assigned to either (031) or (051) 
of monoclinic WO3 structures. Figure 4.3 shows that once the Hydrogen starts to be 
absorbed by the WO3, there is a peak that is missing. Even the darkest blue at 400 °C 
does not show any other distinguishable difference or pattern compared with the other 
XRD spectra. This peak has been multiple times dismissed in the literature due to its 
weak intensity, but it is present in many WO3 profiles in the literature. Therefore, this 
might reflect a crystalline lattice orientation that is not trivially understood when looking 
at the WO3 structure, and that is altered in the presence of hydrogen atoms. In 2018, 
Rinaldi et al. [317] reported an in-depth study following an almost identical experimental 
approach using variations of temperature of 100 °C. However, here there is a particular 
emphasis in seen changes at much smaller temperature increments. Therefore, the 
XRD results were measured at smaller angle increments to achieve higher precision 
at comparing the XRD patterns of each sample. Hence, the effect of small temperature 
changes is included in a small peak at 31 ° that Rinaldi missed probably due to lower 
spectral resolution. This peak could be the preeminent modification in the structure of 
WO3 to induce a transition to other oxidation states. Controlling the colouration is 
essential to obtain also different material properties of WO3 such as light absorbance 
and electrochromism.  
Although this method seems very powerful for systematic oxidation state transition by 
oxygen reduction, there are some issues to obtain a homogeneous sample for 
intermediate states, as shown in Figure 4.4. There is a gradient of colouration in the 
final sample; therefore, only a particular region can be taken from the sample and 
variations in this region can limit the reproducibility of this technique. 





Figure 4.4 | Colouration gradient after hydrogen treatment at 340 °C. 
4.2.3. γ-Fe2O3 transition to pure Fe 
Materials: Iron(III) oxide nanopowder, <50 nm particle size (BET) from Sigma 
Aldrich (polydisperse commercial γ-Fe2O3 NPs), iron (III) chloride hexahydrate (ACS 
reagent 97% Sigma Aldrich), 0.054 mol of iron (II) chloride tetrahydrate (Alfa Aesar), 
iron (II) nitrate 9-hydrate (Sigma Aldrich), NH4OH 25% (PanReac AppliChem), Ar gas, 
H2 gas, Acetone (PanReac) and deionised (DI) water. 
Synthesis of monodisperse γ-Fe2O3 NPs witn 11 nm in diameter: The synthesis 
method is the modified Massart coprecipitation method [196,214]. Briefly, magnetite NPs 
are prepared by mixing 0.09 mol of iron (III) chloride hexahydrate and 0.054 mol of 
iron (II) chloride tetrahydrate in a total volume of 488 ml of distilled water and adding 
all of it to 75 ml of alkaline medium. In particular, to obtain NPs around 11 nm it is 
necessary a slow addition (0.2 mL/s) of the aqueous solution into the base NH4OH 
25% and 1h of heating at 90ºC. After all, the black product is washed three times with 
distilled water using a permanent magnet to remove the supernatant. Maghemite (γ-
Fe2O3) NPs are obtained by oxidising magnetite (Fe3O4) NPs previously synthesised. 
Fe3O4 NPs were synthesised by coprecipitation of 425 ml of a mixture of FeCl3·6H2O 
(0.09 mol) and FeCl2·4H2O (0.054 mol) in 75 ml of an alkaline medium. Slow addition 
rates (0.2 ml/s) and NH4OH solutions were used to synthesise 11nm diameter NPs. 
After every synthesis, the particles were washed three times with distilled water and 
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the help of a permanent magnet. To oxidise the Fe3O4 to Fe2O3, 300 ml of HNO3 (2 
M) is added to the washed product and magnetically stirred for 15 min. After that, the 
supernatant is removed and 75 ml aqueous solution of iron (II) nitrate 9-hydrate 
(Fe(NO3)3, 1M) and 130 ml of distilled water are added. The mixture is heated until 
reaching the boiling temperature while magnetically stirring, and kept in these 
conditions after, for 30 min. When it cools down, the supernatant is removed by 
magnetic decantation again and 300 ml of HNO3 2 M is added. After 15 min of 
magnetic stirring, the supernatant is removed and the brown product is washed three 
times with acetone. Finally, the acetone is evaporated and the sample is concentrated 
in distilled water. 
 
Figure 4.5 | (a-c) Pictures of raw polydisperse γ-Fe2O3 NPs (left) (commercially 
available) and treated samples under H2 gas heat treatment; γ-Fe2O3 NPs treated at 
240 °C (centre) and γ-Fe2O3 NPs treated at 380 °C (right). (d) TEM image of 
monodisperse γ-Fe2O3 NPs. (e) TEM image of polydisperse γ-Fe2O3 NPs. 
Oxidation state change of iron oxide: γ-Fe2O3 was thermally treated following 
the same procedure described in section 4.1.2. Both polydisperse and monodisperse 




NPs were used to compare their different magnetic properties, further details including 
TEM images are presented in Chapter 6. The so-called “monodisperse” samples are 
not entirely monodisperse but present a minimal degree of dispersity while the so-
called “polydisperse” samples are heavily polydisperse commercial γ-Fe2O3 NPs. The 
temperature was raised at a heating speed of 10 °C/min and a dwell time of 60 min 
targeting 240 °C to create magnetite and 380 °C to obtain pure iron. By following these 
temperatures, a gradual colour change was observed ranging from brown to black to 
shiny grey as displayed in Figure 4.5. 





















































Figure 4.6 | XRD profiles of treated of γ-Fe2O3 and treated samples under H2 gas 
heat treatment at 240 °C, 290 °C and 320 °C.  
The main γ-Fe2O3 characteristics 2θ diffraction peaks from Figure 4.6. appear 
at approximately 30.3°, 36.7°, 43.3°, 53.8°, 57.3° and 63.0° which are indexed as the 
(220), (311), (400), (422), (511) and (440) planes, respectively. All of these peaks were 
the only peaks present in the raw nanoparticles before heat treatment under a 
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hydrogen environment. For pure body-centred cubic α-Fe, main characteristics appear 
at approximately 44.7°, 65.1° and 82.3°, which are indexed as the (110), (200) and 
(211) planes, respectively. Although, most Fe atoms would not be stable at room 
temperature, the samples that contained no oxygen atoms based on the XRD pattern 
were stable indefinitely at room temperature in dry powder and redispersed in DI water. 
This stability is possibly related to the fact that α-Fe, also known as ferrite, on bulk 
below 912 °C is a thermodynamically stable and relatively soft metal. α-Fe can be 
subjected to pressures up to 15 GPa, the pressure at which it transforms into a high-
pressure hexagonal ε-Fe. During the reduction process under hydrogen, there is a 
transition from pure γ-Fe2O3 to pure α-Fe at 320 °C. The transition must be due to a 
partial reduction, which means part of the core has not undergone reduction and 
remains pure γ-Fe2O3. At the same time, there is a shell made of pure α-Fe that grows 
its ratio proportionally to the temperature at which the sample is exposed. 
Magnetic properties measurements: IONPs magnetic properties were obtained 
from γ-Fe2O3 along with its treated counterpart at 240 °C (mixture of γ-Fe2O3 and α-
Fe) for polydisperse samples and at 320 °C (pure α-Fe) for monodisperse samples. 





Figure 4.7 | Hysteresis loops of raw magnetic NPs and NPs under H2+Ar gas heat 
treatment. (a,b) Monodisperse γ-Fe2O3 NPs in water solution and the treated version 
until reaching the Fe oxidation phase using Quantum Design MPMS-XL. (c,d) 
Polydisperse γ-Fe2O3 NPs in powder and the treated version until reaching the Fe3O4 
oxidation phase using MicroSense EZ7 VSM. 
For SQUID measurements, 1 mL of the colloidal sample was pipetted into a 
transparent glass vial with 12 mm diameter x 32 mm height. The increment of 
temperature was measured by using optical fibres. For powder samples, a known 
mass of the sample is added to a flat surface like a petri dish, and the increment of 
temperature is measured by using an IR camera, FLIR E53. Both SQUID and AFM 
magnetization results are displayed in Figure 4.7. 
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These results show that the monodisperse NPs increase the magnetization 
power when reducing the oxidation state, while the polydisperse sample follows the 
opposite trend. The original loops of both polydisperse and monodisperse are very 
similar. However, the monodisperse sample presents a larger hysteresis loop area, 
and therefore better magnetic heating prospects. Moreover, the monodisperse sample 
presented almost no visible aggregation while kept in solution under room conditions. 
However, the polydisperse sample visibly aggregated at concentrations from 500 
µg/mL to 30 mg/mL after short periods (from 10 min to 2 hours) which is not a desirable 
feature for in vivo biomedical applications. 
 
Figure 4.8 | SQUID at 100 Oe of sample curves (a) zero-field-cooled and (b) field-
cooled. 
Figure 4.8 shows how there is an anomalous region for pure Fe NPs at low 
temperatures. Also, Figure 4.8 shows how magnetization of the samples converges 
much faster in the γ-Fe2O3 sample than in the treated Fe sample. This might happen 
due to anisotropies generated during the conversion. Since the heat treatment is a 
surface-mediated technique, it is possible that some NPs were slightly less exposed 
to the gas and therefore are not fully converted to pure Fe but only a shell. 





Figure 4.9 | Magnetic heat profiles using Magnetherm 1.5 from nanoTherics. (a) 525 
kHz, 93 Oe. (b) 111.7 kHz, 170 Oe. 
Figure 4.9 shows a rapid heat arising from the NPs which is highly dependent 
on the applied frequency and field intensity. For 111.7 kHz, 170 Oe if the external 
magnetic field increases slowly, after reaching a critical point close to the coercitive 
field, the heat increases very quickly until reaching the IR camera saturation. 
Figure 4.9 shows that the sample containing pure Fe presents an apparent 
ferrimagnetic behaviour at 111.7 kHz and 170 Oe; a very high saturation 
magnetization around 200 emu/g (off charts) and a coercitive field of 100 Oe, which 
means it can be useful to reach very high temperatures in short periods. When 
applying fields below 100 Oe and 525 kHz, there is no intense heat for pure Fe while 
γ-Fe2O3 presents a reasonable heating rate. On the contrary, when applying fields 
over 100 Oe and 111 kHz, the pure Fe has a massive heat rate reaching 120 ºC in 
less than 10 seconds. There is a critical transition region at which the behaviour which 
initially would follow the single magnetic domain approximation is drastically modified 





4.3. Filtering nanoparticles 
4.3.1. Context 
 
Figure 4.10 | a) Schematic of the assembly steps of the NFF separation container 
(SepConTM) for dead-end ultrafiltration. b) Diagram of the perpendicular flow 
nanosized particle separation in a SepConTM under high-speed centrifugation. c) 
Schematic of the size-dependent filtration process in which the sample is passed 
across the surface of the nanoporous membrane. d) Schematic of the TFF microfluidic 
device. e) Diagram of the tangential flow filtration process in which the sample is 
passed across the surface of the nanoporous membrane. A transmembrane pressure 
(TMP) generated by syringe pumps drives the particle motion through the membrane 
while keeping large NPs and contaminating particles retained on the membrane 





features are patterned into PDMS sheets. g) Schematic of the stack of layers that form 
the TFF process, following the order in which they are assembled. These PDMS layers 
are assembled by stacking and clamping them. 
In this chapter, the tangential and normal flows of colloidal NP solutions are 
studied by incorporating these nanoporous membranes in microfluidic platforms. This 
very high porosity is significantly better than the results reported by others in the 
literature [319–321]. For NFF, a fluid solution inlet containing polydisperse IONPs 
dispersed in water or ethanol flows perpendicularly through a selective nanoporous 
membrane designed to allow all the flow passing through the membrane while leaving 
large NPs and aggregates behind, as shown in Figure 4.10.a-c. Similarly, for the TFF 
design, a fluid solution inlet containing polydisperse IONPs dispersed in water flows 
tangentially over a selective nanoporous membrane with some fraction of the flow also 
passing through the membrane, as shown in Figure 4.10.d-g. These two filtration 
modes are designed to obtain partially purified and size-dependent filtered NPs. In this 
study, NPN based on pnc-Si (previously introduced in 2.16.2) were used because of 
the more than three times higher hydraulic permeability and its larger robustness 
compared to the original pnc-Si [258,322,323]. This membrane has robust chemical and 
mechanical properties that are inherited from the SiN, while keeping pores small 
enough for ultrafiltration (<100 nm) with a porosity reaching 40%. 
UF has been widely used in the preparation and purification of NPs after 
synthesis, particularly for iron oxide and metallic NPs [324–326]. However, the primary 
purpose of this nanomaterial filtration was to separate the NPs from smaller molecules. 
Here this filtration is proposed for size selectivity of polydisperse maghemite (γ-Fe2O3) 
NPs to obtain monodisperse colloidal NPs in different ranges of sizes depending on 





high stability and intense magnetic moment, which makes it a great candidate for both 
magnetic resonance imaging (MRI) and magnetic hyperthermia [43,327]. The size control 
using ultrathin nanoporous membranes can lead to physical nanosizing 
automatization, which can fundamentally transform the way NPs are synthesised and 
can accelerate their commercialization and end-use in the clinic. This goal requires 
the integration of fabricated thin, robust nanoporous membranefs into microfluidic 
platforms which allows a systematic filtration process that is simple, fast and 
reproducible. 
4.3.2. Experimental setup 
The experiments presented in this section were performed in collaboration with 
Kilean Lucas from the University of Rochester. 
4.3.3. Before filtration 
The sample used in this study was the highly polydisperse iron oxide (γ-Fe2O3, 
maghemite) from a commercial source from the previous section. These nanoparticles 
are highly polydisperse, as shown under TEM in Figure 4.11a and its interplanar 
distance is 0.25 nm displayed under HRTEM in Figure 4.11b. The NPs were used from 
a stock solution (200 mg/ml) at which they present strong aggregation and 
agglomeration due to the ferrimagnetic behaviour of the particles of the sample larger 
than 20 nm. Reduction of both polydispersity and aggregation are key challenges that 
most scientists working with magnetic NPs have to deal with, particularly those 
working with fully or partially ferrimagnetic samples. As a first step, to achieve a more 
monodisperse and less aggregated colloidal solution, the sample concentration was 
reduced and redispersed with ultrasound for over 10 min. This helped to reduce 





aggregates. Hence, further membrane filtration steps were implemented to achieve 
higher purity and monodispersity.  
The γ-Fe2O3 NPs have an average size of 34.3 ± 0.1 nm with an extremely high 
polydispersity (Figure 4.11c), analysed over a population of 250 NPs. As shown in 
Figure 4.11d, the sizes fit reasonably well to a Lorentzian behaviour with some 
deviation that can be due to not using a sample representative enough, having 1 nm 
bias and the roundoff error while removing all decimals for the bar plot representation.  
 
Figure 4.11 | a) TEM image of the polydisperse γ-Fe2O3 (<50 nm) NPs over a carbon-
coated TEM grid. b) HR-TEM image of the γ-Fe2O3 material. c) Histogram of 250 NPs 
sizes counted from TEM images of the polydisperse sample before filtration. d) 
NanoSight measurements of averaged finite track length adjusted (FTLA) 
concentration (particles/ml) versus size (nm) of polydisperse γ-Fe2O3 (<50 nm) NPs 
before filtration. The average values were calculated from three measurements. 
Therefore, this semi-Lorentzian trend achieves values in the right-side tail that 





are indeed a problem for any biomedical application since they act as highly intense 
ferrimagnetic attractors of the other magnetic NPs. The NanoSight measurements 
provide insightful information about the behavior of the NPs while they are suspended 
as colloidal NPs. Unfortunately, these results have significant uncertainty and a limited 
range of size readings. Further details of the crystallographic structure are displayed 
in the Figure 4.11b and 4.6. The peaks from the XRD pattern confirm that the iron 
oxide phase present in this material is solely maghemite (γ-Fe2O3). 
The Lorentzian fit follows formula displayed below:  




4(x − xc)2 +w2
 (4.3.1) 
Lorentzian fit parameters from Figure 4.11c: A (amplitude) = 289 ± 46, xc 
(center) = 23.8567 ± 0.040, w (width) = 29.1 ± 6.7, y0 (offset) = 0.67 ± 0.55, R2 = 0.68. 
Comparing results from Figure 4.11c and d, it can be inferred that the NPs suffer 
high aggregation and agglomeration. Most of the NPs are found forming aggregates 
and agglomerated regions around 127 nm and 231 nm, while there is only a small 
number of non-aggregated NPs smaller than 50 nm. However, the NanoSight 
measurements only can detect NPs sized from 10 nm to 1 µm in optimal conditions 
which include non-aggregated samples and optimised concentration to differentiate 
NPs from each other.  However, the TEM image in Fig 4.12.a shows that there exist 
NPs smaller than 10 nm. Therefore, these smaller NPs cannot be detected using 
NanoSight, neither some large magnetic NPs that are close to the micron range. Most 
aggregates are caused by large NPs that display stronger effective magnetization and 
ferrimagnetic behaviour which leads to permanent magnetic forces that attract 





account for a small quantity of them; however, they are likely to be the many sources 
of both aggregation and subsequent agglomeration. For most biomedical applications, 
these large NPs will need to be removed before proceeding any further to prevent high 
toxicity. That is the reason for us to conduct the investigation of particle filtrations.  
4.3.4. After filtration 
To effectively filter these NPs, the NPN membranes displayed in Figure 4.12a 
and b were used. Mainly, to have two-step filtration that shows its effectiveness, the 
hole diameter profiles of each membrane must be significantly different from each 
other. This means minimised overlap between holes diameter distribution of all 
membranes and high monodispersity of each membrane individually.  
Figure 4.12c,d shows how the holes present Gaussian distributions with 
minimal overlapping and low polydispersity. Moreover, our sample’s distribution 
(Figure 4.11c) is broader and polydisperse enough to cover both hole diameter 
distributions. The approximated Lorentzian fit that the NPs size distribution follows in 






Figure 4.12 | a) SEM image of the NPN membrane with 37 nm average pore diameter. 
b) SEM image of the NPN membrane with a 60 nm average pore diameter. c) 
Histogram of 250 nanopores counted from SEM images of 37 nm nanopore size NPN 
membranes applying a gaussian fit under the scaled Levenberg-Marquardt algorithm. 
d) Histogram of 250 nanopores counted from SEM images of 60 nm nanopore size 
NPN membranes applying Gaussian fit under the scaled Levenberg-Marquardt 
algorithm. Results obtained with TESCAN VEGA3 SEM. 













The Gaussian fit parameters using scaled Levenberg-Marquardt algorithm with 
tolerance = 0.0001 in the range x = 1 - 200 nm for the 37 nm nanopore membrane are 
the following: A (amplitude) = 242.3 ± 6.3, xc (center) = 39.53 ± 0.15, w (width) = 10.93 
± 0.31, y0 (offset) = 0.039 ± 0.083, R2 = 0.93. For the 60 nm nanopore membrane, the 
parameters are the following: A (amplitude) = 226 ± 13, xc (center) = 56.95 ± 0.48, w 
(width) = 17.2 ± 1.0, y 0 (offset) = 0.12 ± 0.13, R2 = 0.82. 
Therefore, by filtrating this sample with first the larger pores, subsequently 
followed by the smaller pores, the sample can separate in different size ranges. Figure 
4.13 from the supporting information provides further insights about the topology of 
the membrane. Besides the NPN membrane nanopores are not fully represented 
under the AFM profile, the depth of the membrane appears to be around 40 nm which 





difference in this value is due to high uncertainties in the tips due to their large diameter, 
similar to the holes themselves. 
 
Figure 4.13 | 3D AFM topographic profile for the 60 nm nanoporous membrane 
obtained in collaboration with Iago Fernandez. 
The NPN membranes shown in Figure 4.14 were used to filter the sample from 
Figure 4.13, and the resulting samples are displayed in Figures 4.14 and 4.15. 
Comparing the filtered samples from figure 4.12b-e and the original sample (Figure 
4.12a), it is clear that the NPs were highly filtered through all the processes. Figure 
4.12a shows how the hydrodynamic diameter of the colloidal magnetic NPs is 
significantly reduced from every filtration step in NFF. These results show a consistent 
and reproducible size filtration and agglomeration reduction in both normal and 
tangential flow filtration, but each of them present advantages in some aspects and 
drawbacks in others. Comparatively, to reduce agglomeration and the number of 
aggregates, the TFF results in one-step filtration in water with 60 nm pore size are as 
good as the two-step filtration in water with NFF SepConsTM using first 60 nm and the 
37 nm pore size, and better than using ethanol as the liquid media. Although the TFF 
device does a better job reducing agglomeration of NPs once filtered, this process is 





columns, but it allows potential series tandem filtration. To maximise the quality of the 
filtration process, a reasonable approach would be applying a series of TFF filtration 
steps incorporated in a microfluidic device. On the other hand, cake formation played 
a significant role in both TFF and NFF in stopping the sample from being filtered. In 
NFF, this effect resulted in the membrane breaking due to accumulated mechanical 
stress as previously reported in these types of membranes [328]. Hence, all filtrations 
had to be performed at very low concentrations for both modes and solvents. 
Interestingly, ethanol, which has lower surface tension than water, offers slightly worse 
filtration but was found to be much faster and simpler by not requiring centrifugation. 
When using ethanol, gravity is strong enough to overcome the surface tension for the 
solution to pass through the membrane and perform the filtration of the sample. It 
would be beneficial to not only obtain the DLS results from the filtered samples but 
also their NP concentration versus size profiles from NanoSight. Unfortunately, this 
was not possible due to ending with a very diluted sample that was not readable using 
Nanosight. An iterative process of filtrating and concentration of the sample could be 






Figure 4.14 | (a) Bar chart of average dynamic light scattering (DLS) value of three 
measurements that represent the hydrodynamic diameter of polydisperse Fe2O3 (<50 
nm) NPs at different filtration steps. The error bars presented are the standard 
deviation of 3 repeats for each value. U: Unfiltered NPs in EtOH. NF1 EtOH: Filtered 
gravitationally via SepConTM with 60 nm nanopores in EtOH. NF2 EtOH: Filtered 
gravitationally via SepConTM with 37 nm (gravity) in EtOH after 60 nm. NF1 H2O: 
Filtered at 500g centrifugation speed for 4 minutes via SepConTM with 60 nm 
nanopores in H2O. NF1 H2O: Filtered at a500g centrifugation speed for 4 minutes via 
SepConTM with 37 nm in H2O after SepConTM after 60 nm. TF1 H2O: Tangential flow 
60 nm in H2O. TEM images of polydisperse Fe2O3 (<50 nm) NPs resulting after 
filtration over a carbon-coated TEM grid: (b) SepConTM of ~60 nm holes centrifuged at 
500 g (g-force) in water; (c) SepConTM of ~60 nm holes first and ~37 nm holes after 
centrifuged at 500 g (g-force) both in water; (d) Tangential flow with ~60 nm 
membranes in water; (e) SepConTM of ~60 nm holes first and ~37 nm after without 
centrifuging in EtOH, filtered just by gravity.  
By analysing multiple TEM images from the filtered NPs, 25 NPs were identified 
per filtered sample to compare relative filtration between two-step filtration in NFF 
SepConTM and one-step filtration in TFF. These results can be seen in Figure 4.15.a-
c and lead to a deeper understanding of the filtration process. The hydrodynamic 
radius from one-step TFF filtration in water with 60 nm nanopores is reduced similarly 
to two-step NFF filtration in water with 60 and 37 nm nanopores and better than in 
ethanol with 60 and 37 nm nanopores. However, the actual NPs appear to be 
significantly better filtered from both two-step SepConTM NFF filtrations (see Figure 
4.14a and b) than from one-step TFF filtration. The NP agglomeration and aggregates, 





single NPs remain dependent exclusively on the size of the nanopores and not on the 
filtration mode. 
Interestingly, in TFF using a 60 nm NPN membrane only (Figure 4.15c), no NP 
larger than 37 nm was found which suggests that larger NPs tend to aggregate and 
get captured on the nanomembrane surface and holes. Contrarily, using SepConTM 
under two-step NFF filtration with 60 and 37 nm in series (Figures 4.15a and b), there 
exist some NPs larger than 37 nm which might be due to the excessive pressure when 
using water under centrifugation and low surface tension when using ethanol as a 
medium. Moreover, when using two-step filtration in NFF most NP sizes range from 4 
to 24 nm in water with local maximum values at 10 nm and 20 nm, and 8 to 35 nm in 
ethanol with a maximum value at 11 nm. Meanwhile, after one-step TFF filtration, the 
sizes were concentrated in the range of 17 to 37 nm with a maximum value at 27 nm. 
These results emphasise the idea that the actual NP size filtration depends primarily 
on the nanopore size but seems better-filtered underwater which is consistent with the 
DLS results from Fig 4.15a.  
 
Figure 4.15 | Histogram of 25 NPs sizes counted from TEM images of the polydisperse 





(a) NFF SepConTM two-step filtration in ethanol by gravity under 60 nm 
nanomembrane followed by 37 nm nanomembrane.  (b) NFF SepConTM two-step 
filtration in water by centrifugation under 60 nm nanomembrane followed by 37 nm 
nanomembrane. (c) TFF one-step filtration in water by centrifugation under 60 nm 
nanomembrane. 
Moreover, a comparison between Figure 4.11c and Figure 4.15a-c shows the 
much lower concentration of filtered samples compared to the stock. Both filtration 
modes required low NP concentration before filtration and produced an even lower 
concentration after filtering the sample. Therefore, there are some limitations to apply 
this method at the early steps during the synthesis of NPs since most of them require 
high concentrations that would be diluted in the final steps. Working at low 
concentrations in early synthetic steps require a posterior concentrating method that 
might lead to further aggregation would substantially increase the synthesis time. 
Furthermore, washing steps during the synthesis of NPs by using decantation usually 
includes sample loss and reduction in concentration, therefore working at very low 
concentrations would be a risk and disadvantage if it were required after filtering using 
the membranes.  However, this filtration would be beneficial for final steps during the 
synthesis when there is no need to work at high concentrations.  
Finally, Figure 4.16 shows another important of the membranes - not only for 
the filtration of aggregates and selective reduction of NP sizes but also for purification 
of the samples by removing unwanted microscopic contamination. Figure 4.16 
displays two zooming sequences of SEM images taken at different magnifications 
without coating the membranes with Au to achieve better contrast between different 





nanopore size after filtration and was obtained after using a NP concentration of 20 
mg/ml (1:10 from the stock solution). Figure 4.16 shows more in detail how the 
captured NPs on the membrane looks like after filtration. 
 
Figure 4.16 | SEM images of the bare nanoporous membrane after NP filtration in NFF 
SepConTM devices. Using TESCAN VEGA3 SEM: (a-d) 60 nm average nanopore size 
from low magnification to high magnification, respectively. Using Zeiss Auriga FIB-
SEM and 4 nm Au coating: (e) Low magnification image of the full membrane covered 
on NPs. (f) Sample contamination. 
4.4. Summary 
In summary, WO3 NPs were coloured by an apparent hydrogenation process 
by performing heat treatment under H2+Ar gas atmosphere. The resulting NPs were 
stable for long periods of time. Forγ-Fe2O3 NPs, following the same procedure, there 
is an apparent reduction to pure α-Fe NPs at 320 °C which contains a mixture of both 





as long as were tracked (over several months) and presented substantial magnetic 
properties compared to the original γ-Fe2O3 NPs. α-Fe NPs dispaly notably higher heat 
rate than γ-Fe2O3 NPs when applying fields over 100 Oe and 111 kHz, the pure Fe 
has a significant heat rate reaching 120 ºC in less than 10 seconds. This opens the 
door to tuned heat rate by obtaining particular ratios of γ-Fe2O3 and α-Fe in the same 
NP. 
In terms of NP filtration, two nanoscale size-controlled filtration methods in NFF 
and TFF have been implemented and compared for polydisperse colloidal magnetic 
NPs using ultrathin nanoporous membranes in microfluidic devices. These methods 
can be applied for automated biomedical NP filtration during NP synthesis and 
purification purposes after the synthesis to obtain monodisperse samples with better 
biomedical applicability prospects. This filtration is effective when no high 
concentrations of NPs are required in subsequent synthetic steps. TFF brings a higher 
degree of filtration but at the expense of higher complexity for the assembly, longer 
filtration time and not currently commercially available. These advantages make these 
TFF and NFF filtration devices promising micro platforms for size selectivity and 
purification of biomedical magnetic NPs. Concretely,  monodispersity can help improve 
consistency in various techniques including SERS, MRI, CT and magnetic 
hyperthermia. Different degrees of dispersity of magnetic nanoparticles are evaluated 






















5. Novel WO3-SiO2-Au 
5.1. Introduction 
This chapter presents the successive steps to produce a new composite NP 
(see Figure 5.2) that displays prominent biomedical properties. These composite NPs 
were prepared by following modifications of the Stöber process for the intermediate 
SiO2 shell formation and the Turkevich method for the external Au coating generation. 
4-mercaptobenzoic acid (4-MBA) molecules Raman reporters are attached over this 
Au final layer that enhance the Raman signal via surface plasmons (SP) over the metal 
substrate. 
Currently, there is a lack of variety in diagnostic NPs to form the core of a 
diagnostic agent. The only clinically approved material is IONPs, although the body 
cannot break them down and need to be excreted to avoid toxic effects. Furthermore, 
this material has a toxicity problem related to strong magnetic NPs aggregation. This 
severe aggregation also appear when synthesising a single-core magnetite composite. 
Besides the fact that some methods can achieve very small individual monodisperse 
magnetite NPs which reduce the magnetization, the need for elaborating tuning of the 
physiochemical and surface properties generate complications to keep small sizes. 
This fact brings the needs of designing and synthesising new alternative composite 
NPs for diagnosis.  
Combining different functionalities in the same nanoscaled object has become 
one of the main goals for nanotechnology medical applications, bringing the need to 
fabricate nanocomposites which are a combination of different NPs to merge their 
individual phases. Indeed, the most extended and reliable kind of nanocomposites for 
SERS is the colloidal core-shell nanocomposites with a magnetic core and 
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functionalized surface, as described in Figure 5.1[329]. A magnetic core is needed to 
achieve hyperthermia after SERS imaging and then having a theranostic material. 
WO3 have shown low magnetic susceptibility, and thus a high magnetic field is 
required for magnetic heating. However, this could lead to better-controlled form of 
heating than high thermal damage produced with IONPs [330] which frequently also 
damage healthy cells [331].  
WO3 is a semiconductor what leads to the possibility of being easily doped to 
change several functional properties. Doped WO3 species have displayed even more 
promising electrochromic and magnetic properties so an alternative core could be 
easily introduced in the scheme from Figure 5.2 to satisfy any particular need such as 
magnetic susceptibility for hyperthermia treatment and magnetic delivery[332]. The SiO2 
nanoshell reduces its cytotoxicity drastically, and the finally AuNS makes it non-
cytotoxic while retaining the capacity of getting good SERS under near-infrared light. 
The external Au behaves in such a way that there is a significant Raman signal 
enhancement without generating photoinduced heating. Also, the chosen core could 
be electrically activated to display electrochromism if the SiO2 shell is thin enough to 
let electron transmission or if some Au NPs were in touch with the core. Besides, some 
studies have shown certain links between colour change and static magnetic fields 
that need to be better understood. Moreover, big sizes (larger than 100 nm) are hard 
to excrete by humans and this increase drastically their toxicity as described in section 
2.3. Liver accumulation suggests that the hepatobiliary system is the primary site for 
agent clearance for AuNPs from 10-250 nm [333]. It has been found that reduction in 
size for the most used type of iron oxide-based nanocomposites for delivery is 
challenging and, therefore, its toxicity is higher than for smaller composite NPs. 
Nonetheless, WO3 that has been reduced to sizes of 20 nm with a significant reduction 




in renal toxicity during the elimination process[334]. These are the main reasons to 
explore new possible options to overcome this critical issue such as WO3.  
Figure 5.1 shows the final composite core-shell WO3-SiO2-Au NP proposed for 
synthesis in this chapter that potentially will be attached to the cancer cells external 
surface or endocytosed in a human body for SERS imaging. For this configuration, the 
maximum of absorption in the Au surface is supposed to shift from 532 nm light, which 
would be plasmonic resonant for green light laser, to redder wavelengths closer to NIR. 
For biomedical imaging through biological tissue, it is necessary switching to NIR 
lasers in order to penetrate all the layers and reach the NPs.  
 
Figure 5.1 | Diagram of the final WO3-SiO2-Au NPs for SERS imaging and their most 
relevant characteristics for biomedical imaging. 
In the last decade, AuNSs with SiO2 cores have been prepared and 
characterised, obtaining desirable properties[335]. The SiO2 synthesis was firstly 
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reported by Stöber[151], and our procedure is a modification of this method to wrap a 
third material core, the final nanocomposite is WO3-SiO2-Au NPs where WO3 is the 
core. In Figure 5.2, the description of the full process is displayed. The election of a 
specific core relies on its individual properties such as small size, semiconductivity and 
magnetic susceptibility. WO3 is an electrochromic material whose nanopowder non-
calcinated version has a yellow colour, and in the presence of an electrical current can 
change it, this ability has been widely studied previously[336,337]. The WO3 core can be 
easily substituted by other semiconductor material with for instance magnetic moment. 
Characteristics of toxicity, biocompatibility, light absorption, plasmonic generation, 
electrochromic effect and easy fabrication reproducibility need to be discussed in detail 
to understand the benefits of using this novel structure. 
5.2. WO3-SiO2-Au synthesis method 
Materials: All the following reagents were purchased from Sigma-Aldrich: 
Gold(III) chloride hydrate (HAuCl4.xH2O, 99.999% trace metals basis MW 339.79 
g/mol), Tetrakis (hydroxymethyl)phosphonium chloride solution (THPC, 80% in H2O), 
(3-Aminopropyl)triethoxysilane (APTES), potassium carbonate (K2CO3, 99.995% 
trace metals basis MW 138.21 g/mol), sodium hydroxide (NaOH, Sigma-Aldrich), 
potassium carbonate (K2CO3), formaldehyde (CH2O (H-CHO)), 4-mercaptobenzoic 
acid (MBA), deionised water, ethanol and formaldehyde solution. The WO3 NPs were 
purchased from China, Chang Sha Na Ro Mei Nanomaterials Ltd, with a purity of 
99.9% and an average size of 40 nm. 





Figure 5.2 | Diagram of the WO3-SiO2-Au core-shell composite NPs synthesis process 
with 4-MBA Raman reporters. 
SiO2 nanoshell formation: The first step was the synthesis of the WO3-SiO2 
core-shell nanocomposite NPs (Figure 5.2), following the Stober process. A liquid 
suspension made of 10 mL deionised (DI) water, 20 mL ethanol and 0.015 g WO3 NPs 
were first prepared, then a modified Stöber process promoted the formation of the 
SiO2 shell via the sol-gel method. In this method, consecutive hydrolysis and 
condensation of alkoxysilanes in an aqueous-alcoholic solution in the presence of a 
base catalyst was involved, using tetraethyl orthosilicate (TEOS) as alkoxysilane and 
ammonia as the base catalyst. 
In this thesis, a different route from other Stöber-based versions was taken to 
perform the SiO2 synthesis while in parallel coating the core. WO3 NPs were coated 
with SiO2 by adding 1 mL ammonia and 5 drops of TEOS while stirring the WO3 
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suspension with a time interval of 10 sec between each TEOS drop. This was the key 
to create the SiO2 coating because by changing the concentration of TEOS the SiO2 
thickness could be modified. After that, the mixture was stirred continuously for 30 
more min. The ammonia concentration catalysed this reaction by increasing the 
reaction rate. Finally, the suspension was washed with deionised water and Ethanol 
by centrifugation to separate the NPs from the liquid in 50 mL Eppendorf tubes.  
Amine functionalisation: The WO3-SiO2 core-shell nanocomposite surfaces 
were functionalized with an amine group. First, 0.015 g WO3-SiO2 core-shell 
nanocomposites (Figure 5.2) was dispersed in 20 mL of ethanol in a beaker and 
subjected to 30 min ultrasonic probe treatment. Then, 500 μL of APTES was added to 
the suspension which was heated to 70 °C under the magnetic stirring for 5 h. To 
remove the excess reactants, the suspension of 25 ml ethanol was centrifuged for 3 
times (10 min per cycle at 6,000 rpm) without washing and redispersed by ultrasonic 
probe treatment. 
The critical aspect of this functionalization was the NH2 ending on top[169]. These 
NH2 ligands reacted with Au after breaking it in two parts by heating. On one hand, H2 
was released on one side when the H atoms absorbed higher energy than the bond. 
On the other hand, a firm bond was created between the N and the Au atoms that 
were close enough to be attracted by the electric force of the N2- ions and the Au 
electron cloud. This fact made it possible to attach Au nanoseeds and to stabilise 
subsequent Au growth on top with homogeneous distribution. 
Colloidal WO3-SiO2-Au NPs fabrication: Colloidal Au NPs can be obtained 
following different methods, which are based on the work of Turkevich et al.[132]. Herein 
they were NP obtained by reducing Au salts (HAuCl4) in the presence of surfactants, 




tetrakis (hydroxymethyl) phosphonium chloride (THPC, C4H12ClO4P)[282]. During the 
formation of the metallic solution, a massive excess of NaOH was formed. The 
reactions between THPC and NaOH produced formaldehyde as the reducing agent 
for Au. After the amine functionalisation, the Au coating process is implemented.  
By dissolving 0.098 g of HAuCl4·3H2O in 10 mL of deionised water, a 25.0 mM 
Au stock solution was prepared, called chloroauric acid. By typical reducing the 
chloroauric acid with THPC, the colloidal Au NPs (13 nM) was prepared. In detail, 3 
mL of 1 M NaOH (0.2 g in 5 mL deionised water) and 1 mL of diluted THPC (12 µL of 
80% THPC per 1 mL of deionised water, 50mM) were added to 44 mL of deionised 
water while being stirred. The solution was magnetically stirred for 5 min and 2 mL of 
the 25 mM Au stock solution was rapidly added in and the colour quickly changed to 
dark red or brown. The final Au colloidal was stored at 5 °C for 12 h, prior to being 
used for later Au coating process.  
5 mL of the amine functionalised SiO2 core-shell nanocomposites suspension 
of 70 °C was added to 20 mL of magnetically stirred Au colloidal NP of 100 °C, and 
then continuously stirred for 10 min. The resulting colloidal suspension NP was 
washed with deionised water under centrifugation for 3 times at 6,000 rpm for 10 min 
each time, to remove the excess of reactants.  
Au shell synthesis: Once the Au nanoseeds were attached to the SiO2 
nanoshell, the Au started to grow to form the final out layer[136]. The alkaline growth 
solution was prepared by dissolving 0.025 g potassium carbonate (K2CO3) in 100 mL 
deionised water (0.18 mM). Then 1.5 mL of 25 mM (1% w/v) of the Au stock solution 
was added to the growth solution, and the mixture was stirred until the yellow colloidal 
suspension became clear (transparent). 20 mL of this clear solution was injected with 
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1 mL of the WO3-SiO2-Au NPs suspension, then 100 µL of formaldehyde was added, 
and a colour change from colourless to purple was observed which is characteristic of 
the Au nanoshell formation. The resultant suspension was then centrifuged and 
redispersed in water, for later UV-vis spectrophotometry and Raman spectroscopy 
characterization. 
Adding reporter molecule for SERS: The Au nanoshell bioconjugation was 
achieved by mixing 4-mercaptobenzoic acid (4-MBA) diluted in ethanol with the WO3-
SiO2-Au nanocomposites[338]. After these synthesis steps, Thiolated WO3-SiO2-Au 
core-shell nanocomposites were obtained. Figure 5.2 (see additional information) 
describes the entire synthesis steps. 1 mM of 4-MBA solution was prepared by diluting 
an appropriate mass of the solid in ethanol. For the collection of SERS spectra, 100 
μL of 1 mM solution of 4-MBA was mixed with 1 mL of colloidal Au NPs. After 5 min 
stirring, the mixture was centrifuged 3 times for 7 min at 4,000 rpm in 1.5 mL Eppendorf 
tubes, and the supernatant was re-dissolved in deionised water. 






Figure 5.3 | Characterization of the nanocomposites. (a) XRD profiles of the WO3, 
WO3-SiO2, WO3-SiO2-Au and Au. (b) HRTEM images of WO3 and (c) Au. (d-h) STEM-
EDX element mapping of Au nanoshell on WO3-SiO2-Au: STEM image, RGB overall, 
W, Au and Si, respectively. (i-m) STEM-EDX element mapping of Au nanoseeds on 
WO3-SiO2-Au: STEM image, RGB overall, W, Au and Si, respectively. (n-r) STEM-
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EDX element mapping of WO3-SiO2: STEM image, RGB overall, W, O and Si, 
respectively. 
Figure 5.3 displays the XRD patterns of the NPs from each synthesis step. The 
peaks in each XRD pattern reveal the crystal structure of these materials. Along with 
the progression, the original monoclinic WO3 (Blue line) peaks are accompanied with 
lumps of the amorphous SiO2 at 23.1° (002), 23.6° (020) and 24.4° (200) (black line), 
and then the cubic Au peaks appear (red line) in the composite, benchmarked against 
the plain Au NPs at 38.1° (111) and 44.3° (200) (Green line). The three main fingerprint 
peaks of monoclinic WO3 at 23.1°, 23.6° and 24.4° are always present. This result 
confirms the bulk composite phase structures. 
The phases identified by XRD are also verified by HRTEM imaging. The lattice 
spacing is 0.265 nm (Figure 5.3b) for the Monoclinic WO3 (020) core, and 0.235 nm 
for the Au (111) on top of the intermediate SiO2 shell (Figure 5.3b and c). Figure 5.3d-
r shows the STEM images of the composite NPs and their corresponding energy-
dispersive EDX elemental mapping results. These maps reveal the detailed 
distribution features of each element at the nanoscale. Figure 5.3n-r represents the 
first step of the synthesis and shows that the core contains W and O, while the first 
shell being Si and O. This is consistent with the expected WO3 wrapped by SiO2. 
Figure 5.3i-m is the Au seeding step, in which Au in green color is found surrounding 
the SiO2 shell with a homogeneous distribution of small Au seeds. Figure 5.3d-h 
demonstrates the thick Au shell growth in green color as compared with that shown 
previously for the attached Au nanoseeds. Finally, the STEM-EDX and HRTEM results 
both confirm an average diameter of 3.5 ± 1.0 nm for the particulate Au nanoseeds.  





Figure 5.4 | a) Colloidal NPs solutions made of Au, WO3-SiO2 and WO3-SiO2-Au 
covered with Au seeds and Au shells within thick layers respectively. b) WO3-SiO2-Au 
NPs solutions with various Au thickness obtained by using different Au stock solution 
during the shell formation.  
The WO3 core used in this material is polydisperse and add a significant 
uncertainty in the final shape and size, especially for thin layers of SiO2 and Au. Also, 
the purity of the source can be refined to avoid crosslinked WO2 contamination or use 
WO2 cores directly during the synthesis which has smaller energy bandgap for 
displaying electrochromic behavior. The reduction of the final overall size can help to 
improve excretion rates of the NPs after imaging [32–35]. 




Figure 5.5 | TEM images of WO3-SiO2 samples with different ratios of ammonia:TEOS. 
a) 4:1, b) 6:1, c) 8:1, d) 10:1, e) 20:1 and f) 50:1. 
Control of SiO2 shell thickness: Figure 5.5 shows the SiO2 thickness 
dependency on the ratio of ammonia:TEOS. To achieve thickness control, the volume 
of ammonia remains constant at 1 mL for all the displayed coatings in Figure 5.5. This 
follows the principles of the Stöber process that describes the growth of SiO2 NPs [36]. 
When the amount of TEOS increases over the ammonia, the coating is thicker, and 
vice versa (Figure 5.5a-f). This has been previously addressed using different cores 
by several authors [37–39]. The thickness of the SiO2 can be minimised down to 3 nm. 
However, the relationship between the thickness and the concentration of TEOS is 
non-linear. On the other hand, the current core has been found to exhibit some 
potential cytotoxicity for certain cells[40–42], so it needs to be wrapped thick enough to 
ensure it never directly interacts with healthy cells. TEOS concentration is the main 
parameter determining the SiO2 layer thickness. 





Figure 5.6 | TEM images of Au nanoseeds attachment. WO3-SiO2-Au NPs synthesised 
with different APTES additions: a) 50 μL. b) 200 μL. 
Attachment of Au NPs: There are several very important optical and chemical 
properties of Au NPs that depend strictly on the type of ligand and ligand-metal bond. 
3-aminopropyltrimethoxysilane (APTES) is one of the most common chemicals used 
to amine functionalised surfaces for successive Au attachment due to its stable 
bonding with Au, fast attachment, and low cost.  
Figure 5.6a displays the sample prepared with 4 times lower APTES 
concentration than the one used to prepare the sample shown in Figure 5.6b during 
the amine functionalisation process. Figure 5.6b shows that an increment of the 
APTES content leads to a more homogeneous Au seeding over the SiO2 surface. The 
concentration of APTES used in this study produced Au NPs of 3.5 nm ± 1.0 nm in 
diameter. Quantification of Au seeds from TEM images was attempted by counting the 
number of gold seeds visible in these images over many samples. Unfortunately, due 
to the high polydispersity of the core and the overall diameter, no consistent number 
of seeds was found for the same synthetic steps. 




Figure 5.7 | UV-vis absorption spectra of various colloidal NPs: a) WO3, WO3-SiO2, Au 
seeded WO3-SiO2-Au, Au shelled WO3-SiO2-Au (and aggregated batch, after 2 weeks 
stored in room temperature) and Au alone (and aggregated batch, after 2 weeks stored 
in room temperature). b) WO3-SiO2-Au shelled with different Au stock solution (X) used 
during the shell formation. 
Plasmonic light absorption: Figure 5.7a shows the ultraviolet-visible (UV-vis) 
absorption spectra of various synthesis stages, which reveals the plasmon excitation 
wavelengths and the maximum absorption peak of Au, and the visible colour displayed 
by the colloid. The plain Au colloidal appears as red, with maximum absorption at 510 
nm; whilst the colloidal nanoshell version of WO3-SiO2-Au appears purple with an 
absorption peak at 532 nm[43]. Figure 5.7b, which corresponds to the colloidal NPs 
displayed in Figure 5.3d, displays the evolution of the absorption spectra during the 
nanoshell formation in which X represents the volume of 25 mM Au stock solution as 
explained in the methods section. Also, there is a clear redshift when the aggregation 
of the Au and WO3-SiO2-Au NPs takes place. The optimal scenario is a maximum 
peak in the near-infrared regime to have the highest plasmonic oscillations for the 
SERS application with near-infrared laser illumination, which is analysed in Figure 5.8. 
There are no maximum local peaks for the non-metallic materials, as expected since 




they do not have plasmon resonances. Also, the contribution of SiO2 is negligible but 
starts to be relevant for increased wavelengths.  
5.4. Cell viability 
Materials: Dulbecco’s Modified Eagle’s Medium (DMEM), trypsin-EDTA 
solution and cell proliferation reagent WST-1. Culture cell serum-supplement and 
penicillin-streptomycin were purchased from Gibco. 
Cell culture: The MDA-MB 231 human breast cancer cells were cultured in 
DMEM with 10% serum-supplement and 1% penicillin-streptomycin. Cells were grown 
under standard conditions of 5% CO2 and 37 °C in a controlled humidified incubator to 
reach 70-80 % confluence. Cells were routinely sub-cultured using 0.25% trypsin-
EDTA solution. 
Cell viability: Cell viability experiments were performed in 96-well plates, and 
imaging experiments were performed in 6-well plate. Cells were seeded in 96-well 
plate at the density of 1 x 104 cells per well while cells were seeded onto the 6-well 
plates at a density of 1 × 106 cells per well and incubated for 24 h prior to the 
experiments. After overnight incubation, cells were treated with and without 100, 250, 
500 and 1000 µg/ml of 4 types of NPs for 24 h. Cell viability after NP treatment was 
determined using WST-1 assay (Roche Applied Biosystems) according to the 
manufacturer’s instructions with modifications to adapt for NP-treated cells. Briefly, 
cells were seeded in a 96-well plate with a density of 1 x 104 cells per well, 
differentiated and incubated with NPs (3 replicates per concentration). After 24 h, 
WST-1 reagent was added to the cells, and after the colour reaction, the plate was 
then kept for shaking and then absorbance was measured at a wavelength of 450 nm 
using a plate reader (Clariostar plate reader, BMG lab tech). The results were 
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expressed as percentage cell viability. Three independent experiments were 
performed for each study, and all measurements were performed in triplicate.  
Statistical analysis: The data were statistically analysed using GraphPad Prism 
5.04 to assess the effects of NPs treatment on cell viability and were expressed as % 
cell count ± SD, Mann Whitney. * (p < 0.05) was considered statistically significant. 
Results were presented as the mean ± standard deviation (SD). 
Cytotoxicity profile in a triple-negative human breast cancer cell line MDA-MB 
231: Figure 5.9a shows the in vitro cytotoxicity profile of the selected concentrations 
(100, 250, 500 and 1000 μg/ml) of four different batches (A1, A2, B1, B2) of WO3-
SiO2-Au NPs in a triple-negative human breast cancer cell line MDA-MB 231. A1, A2, 
B1, B2 represent The NPs concentration range was selected from the minimum 
concentration showing low toxicity to concentration showing maximum toxicity. A live-
dead assay for a period of 24 h was performed to confirm the suitability of the NPs for 
biomedical applications. Statistical analysis was performed with three batches per 
sample and concentration of which the mean and standard deviation were calculated. 
The results show no statistical significance (ns, p ≥ 0.05) for concentrations 500 μg/ml, 
while for concentrations of 100, 250 and 1000 μg/ml the results are statistically 
significant (*, p < 0.01 to 0.05) as shown in Figure 5.9a.  Among the statistically 
significant results, low cytotoxicity (>75% alive cells) after 24 h was found for 
concentrations of 100 μg/ml indicating their suitability for cell imaging purposes. 




5.5. Raman spectroscopy applications 
 
Figure 5.8 | (a-c) SERS spectra of 4-MBA molecule peaks at 1,078 and 1,589 cm-1 
with 830 nm laser and d-f) Raman maps with 785 nm and 830 nm of different samples 
with 4-MBA Raman reporter over a silicon wafer with its characteristic reference peak 
at 520 cm-1. (a) Au shelled WO3-SiO2-Au. (b) Au seeded WO3-SiO2-Au. c) Plain 4-
MBA molecules. (d-f) Optical microscopy image, Raman maps under PC1 (66.09%) 
taken with 785 nm and 830 nm lasers, respectively. 
 
SERS maps with 4-MBA reporter: Figure 5.8a-c shows the Raman spectra of 
4-MBA molecules bound to the shelled WO3-SiO2-Au, seeded WO3-SiO2-Au and 4-
MBA alone, respectively. 100 µL of sample at 1 mg/L was pipetted on a substrate and 
dried at 60 °C until the liquid fully evaporates. The substrate that holds the dried 
samples is a Si wafer and acts as a reference to control the intensity performance of 
the vibrational resonance peaks from the fixed concentration and volume of 4-MBA 
molecules, and therefore, the SERS effect quality. It is clear from Figure 5.8a-c that 
for Au content there is a boost in these peaks against the 4-MBA molecule alone in 
Figure 5.8c[44]. This boost could also be caused by local hot spots even though the 
work was performed at low concentrations. The maximum enhancement of 771 times 
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over the original signal is achieved for the core-shell NPs nanoshelled with Au twice 
as shown in Figure 5.10b. This factor is more than 4 times achieved value with the 3.5 
nm Au nanoseeds on the SiO2 surface from Figure 5.8.b. This implies that for better 
contrast, the complete nanoshell is essential. All the enhancement factor calculations 
have been carried out using the same Raman reporter molecule concentrations. A 
quick comparison with previous results using bare Au NPs for the same overall size 
shows that these composite NPs achieved lower enhancement factors, mainly due to 
the bluer maximum absorption peak position [45,46]. Smaller monodispersed cores and 
thinner SiO2 shells can be the key for a substantial improvement to match the surface 
plasmon resonance wavelength. Larger enhancements can be more readily achieved 
by increasing the Au nanoshell thickness while keeping non-smooth surfaces. It can 
also be improved with the addition of another external Au layer on top of the Raman 
molecules to create hot spots. 
4-MBA is a thiol that contains a benzene ring in the R part which forms the 
aromatic ring. This ring provides a substantial Raman scattering cross-section with 
characteristics peaks of 1,078 cm-1 and 1,589 cm-1 (see Figure 5.8). This molecule 
was chosen due to its features of stable sulfur bond with Au, easy attachment and pH 
sensitivity in the Raman spectra [47]. Depending on the intensity and position of the 
peaks, different thiolated reporter molecules can be investigated to find the most 
suitable Raman reporters for potential use when labeling specific cell types such as 
cancer cells. The NPs synthesised in this paper achieve easily improvable 10 and 103 
SERS EFs for one Au shell and double Au shell, respectively, in dried samples over 
Si wafers (see Figures 5.8.a and 5.10.b). Also, several orders of magnitude were found 
for the double Au layer for liquid samples (see Figure 5.10.a), which is very promising 
for future in vivo applications due to including optical absorption similar to organic 




human soft tissue. All these values were obtained by dividing the SERS signal by the 
background silicon peak to normalise them and subsequently measuring the ratio of 
the SERS peak versus the molecule without plasmonic enhancement. Moreover, no 
Raman enhancement from the Au seeds without attaching to the SiO2 shell was 
included because the intensity of the 4-MBA peaks was as strong as the molecules 
alone for both near-infrared lasers. 
PCA is an adaptive data analysis technique that combines conventional 
imaging and spectroscopy to simultaneously obtain both spatial and spectral 
information from an object by reducing a broad set of possibly correlated variables to 
a small set of uncorrelated variables, called principal components that still contains 
most of the relevant information from the broad set [48,49]. The origin of the new 
coordinate system is located in the center of the data points, the first PCA step includes 
the points in the direction of the highest variance, the second PCA step includes the 
ones for the second-highest variance and the rest follow this trend. Using the first PCA 
which describes the highest variance in the dataset (66.09%) in the Raman maps, the 
4-MBA molecules location is found: dark red means 4-MBA and dark blue represents 
the Si wafer (Figure 5.8.e,f). This information is not obvious from the optical image 
(Figure 5.8.d); however, the Raman maps are able to identify the locations of these 
reporters. The SERS intensity of the aggregated areas is not only due to the 2D spatial 
distribution of the materials but also due to having several layers that lead to stronger 
hot spots [50] and cannot be seen with the optical microscope. After subsequent 
attachment of the NPs to or uptake into cancer cells, the cancer cells will be precisely 
located.  




Figure 5.9 | (a) Cytotoxicity tests after 24 h of samples A1 (single layer of Au), A2 
(single layer of Au coated with 4MBA), B1 (double layer of Au) and B2 (double layer 
of Au coated with 4MBA). The values represent the mean ± standard deviation of three 
experiments; * denotes p < 0.05 (statistical significance) and ns represent p ≥ 0.05 
(non-statistical significance). (b) Average values and standard deviations errors from 
CARS spectra from cells alone and cells with NPs. (c) Control cells CARS stack – z-
projection image in greyscale. (d) CARS 3D demonstration of NPs B1 within the cell 
in greyscale and (e) its z-projection of the entire stack (recoloured intensity-dependent 
with fire LUT in ImageJ). (f) NPs A2 in cells CARS imaging (recoloured intensity-
dependent with fire LUT in ImageJ). g) z-stacking of CARS images from cells and NPs 
stack A1 (recoloured intensity-dependent with fire LUT in ImageJ). The cytotoxicity 
results were obtained in collaboration with Dr. Tanveer Tabish and the CARS imaging 
with Dr. Jessica Mansfield. 
Cell imaging using coherent Anti-stokes Raman spectroscopy: CARS imaging 
was carried by using dual-wavelength output from an InSight X3 ultrafast fs laser 
(Newport SpectraPhysics) with 800 nm for the pump and probe beam and 1045 nm 
as the Stokes beam. The beams where chirped to produced ps pulses and spatially 




overlaid in the Spectral Focusing Timing and Recombination Unit (SF-TRU, Newport 
SpectraPhysics). The temporal overlap between the pump and Stokes beams was 
scanned via the SF-TRU unit to allowing us to rapidly change which Raman vibration 
was probed and acquire spectral data [58]. 3D submicron resolution imaging was 
performed on a modified confocal microscope (Olympus FV3000), with a 60 x water- 
immersion objective (1.2NA, UPlanSApo, Olympus). The anti-stokes light at 648 nm 
from CARS was collected in the forward direction using a water immersion objective 
(Olympus LUMPlanFLN 60 x ). The anti-Stokes light was separated from the laser 
fundamentals by using a long pass dichroic beamsplitter (Chroma DC/T760lpxr) 
followed by 2 filters (Chroma ET650/45x) and detected using a PMT (Hamamatsu 
R3896). The samples were mounted between 2 coverslips. To avoid photo-damage 
to the samples the laser intensities were attenuated to give 9mW and 18mW for the 
pump and Stokes beams in the sample plane, respectively. 
Cell imaging in human MDA-MB 231 breast cancer cells: The cancer cells were 
visualised by imaging the CARS signal generated from the CH molecular vibrations 
within the cells, this signal was chemically specific with a peak around 2940 cm-1. The 
NPs within the cells also exhibited a very strong signal within the CARS channel, 
however, this was from a four-wave mixing process which was not chemically specific. 
Figure 5.9b compares the spectra of the cells to the spectral of the WO3-SiO2-Au NPs 
within the cells. The average value and standard deviation of three measurements 
were taken and plotted for both the cells only and the cells with the NPs. The intensity 
of the signal in cells with NPs is a few times higher than cells alone which indicates 
high sensitivity to locate the NPs. Figures 5.9c-g show the cell imaging results 
obtained with CARS. The control label-free human MDA-MB 231 breast cancer cells 
without NPs are shown in Figure 5.9c, this image is a z-projection of a CARS image 
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stack and the contrast is from the CH vibrations within the cells. Then, in Figure 5.9d, 
CARS 3D cross-sections of NPs with a double layer of Au (white color) within the cells 
(grey color) in grey confirms that the NPs were uptaken by the cells and can be seen 
from the inside of the cells. Additionally, the z-projection of the entire stack of CARS 
images was implemented in Figure 5.9e by applying the color filter fire LUT in ImageJ 
over the original intensity-dependent greyscale. This recolored image shows the NPs 
(white) located inside the cells (purple) at different z-positions. Similarly, Figure 5.9f 
and d show the z-projection of the entire stack with fire LUT recoloration for NPs with 
a single layer of Au coated with 4MBA and without 4MBA, respectively. These results 
along with the cytotoxicity profiles confirm the viability for these NPs to be used in 
cancer cell imaging. 
Targeting and localization of cancer cells can be achieved in future studies by 
functionalising the Au nanoshell with cancer ligands such as antibodies which are 
customised for each type of cancer. One type of promising ligand is the anti-HER 
monoclonal antibodies for the treatment of various types of cancers including HER-2+ 
metastatic breast, colorectal, NSCLC, pancreatic, breast, HNSCC, ovarian and renal 
tumours [51,52]. Should these core-shell NPs provide sufficient signals in combination 
with bright Raman reporters in the near-infrared, the SERS signals could be readout 
using microscopy in individual cancer cells. Moreover, they also could visualise in vivo 
tissues with Raman fibre probes or SESORS. 




5.6. Raman in liquid samples 
 
Figure 5.10 | Raman spectra of 4-MBA peaks which are boosted by the SERS effect 
on the external double Au shell of the colloidal WO3-SiO2-Au NPs with 10 nm SiO2 
intermediate shell thickness dispersed in a mixture of 80% water and 20% ethanol 
solvent. These measurements were performed in collaboration with Dr. Benjamin 
Gardner. a) Liquid sample that includes the background measurements of the plastic 
cuvette and solvent; b) dried sample over a silicon wafer with the characteristic 520 
cm-1 peak. c,d) TEM images of the doubly Au shelled colloidal WO3-SiO2-Au NPs. 
Figure 5.10a shows a strong SERS signal obtained in an aqueous liquid media, 
which does not attenuate light as much as human tissues but reduces substantially 
the concentration. Measurements with only 4-MBA molecules within the solution were 
also taken, but there was not visible signal compared to background only. Other 
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samples with thinner Au shells were measured, but no 4-MBA peaks were found for 
the liquid samples Raman spectra besides having visible SERS in their dried 
counterpart. Therefore, the Raman spectra from these WO3-SiO2-Au NPs in Figure 
5.10.a is several orders of magnitude bigger than the bare molecules proving a truly 
strong SERS effect for both 4-MBA resonance peaks. Looking at dried samples over 
a silicon wafer with the well defined 520 cm-1 peak, it is easy to obtain accurately the 
enhancement factor. And for this batch the SERS EF is bigger than for measurements 
in liquid due to not having dilution from the aqueous media as displayed in Figure 
5.10b. The SERS EF reached a value of 771 for the main 4-MBA peak at 1078 cm-1 
without removing fluorescence due to being inexistent. This batch of NPs was 
prepared growing two layers of Au before to attach the 4-MBA molecules. The second 
layer was grown by repeating the Au shell synthesis step but using 0.050 g potassium 
carbonate and 3.0 mL of 25 mM of the Au stock solution. The NPs have a very thick 
double layer of Au and look as shown in Figure 5.10c and d, which is clearly enhancing 
both the plasmon generation and subsequently 4-MBA vibrations. Some hot spots for 
agglomerations may have also occurred in this batch and contributed to boosting the 
signal. This strong SERS signal for a liquid media leads to believe that other 3D liquid 
media such human organ-on-a-chips could also provide a fundamental understanding 
of 3D human cell behaviour and interactions in the presence of colloidal NPs. 
5.7. Summary 
In summary, these studies have demonstrated a size-tunable synthesis method 
to obtain novel WO3-SiO2-Au NPs. Higher APTES concentrations result in attachment 
of larger numbers of seeding Au NPs over the SiO2 layer. Along with the synthesis, 
modifications in the intensity of the ultrasonication and speed in the centrifugation can 
be introduced to refine the washing process and avoid NPs agglomerations. On the 




one hand, by repeating the Au shell growth step, several Au shells are created, and 
stronger SERS is achieved when using the 785 nm laser. This ability to increase the 
enhancement factor is crucial for translational biomedical applications that involve 
scattering media that attenuates the near-infrared laser intensity. On the other hand, 
the main parameter for the SiO2 thickness growth is the ratio between TEOS and 
ammonia. Higher ratios of ammonia:TEOS lead to thinner SiO2 thickness which 
reduces the potential toxicity in the human body through a faster excretion. The 
minimum thickness was down to 3 nm. The ratios 4:1, 6:1, 8:1, 10:1, 20:1 and 50:1 
lead to SiO2 thicknesses of 60, 44, 36, 28, 26 and 13 nm, respectively. However, it 
could increase the risk of displaying cytotoxicity related to partially uncoated WO3 
cores. The final WO3-SiO2-Au NPs have been systematically obtained in more than 10 
batches by following the synthetic procedure; this reflects the high reproducibility of 
the synthesis.  
The optimal thickness of the SiO2 and Au nanoshells for both strong SERS and 
low toxicity has yet to be determined. However, preliminary results from various 
configurations show NPs detection in 2D human breast cancer cell culture and liquid 
media, which leads to believe in vivo cell imaging can be achieved.  
Moreover, cytotoxicity tests after 24 h show >75% living cells (against approx. 
90% in the control batch) from statistically significant cell viability at concentrations of 
100 μg/ml which is higher than needed for detection. This is a promising translational 
result that encourages the use of these NPs in future live human cancer cells imaging 
and 3D human cell culture models such as spheroids, organoids and organ-on-a-chip 
technologies to have the full picture of how beneficial these NPs can be in the clinical 
stage. Further improvements could be obtained by using a monodisperse source for 
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the core and working with smaller NPs that present similar toxicity but can better 
penetrate the cell. 
  













6. Magnetic-plasmonic composite nanoparticles 
6.1. Introduction 
In this chapter, a similar approach to the one used in the previous chapter is 
followed in terms of the NP synthesis design; the only difference lies in the core. Since 
most proposed magnetic NPs developed to replace the highly toxic gadolinium-based 
compounds used in the clinic are Fe3O4, the use of other magnetic NPs with slightly 
weaker magnetic properties such as γ-Fe2O3 can provide a safer approach thanks to 
a reduced aggregation tendency. Looking into biocompatibility, Au NPs are also 
clinically approved and bring high opacity (absorption) against X-rays for CT and 
plasmonic properties for SERS and potential light-induced hyperthermia. Therefore, 
composite NPs that contain both materials seem promising for both strong theranostic 
capabilities and clinical viability.  
This chapter presents the design and critical synthetic steps for the creation of 
a new class of composite core-shell NPs, named Fe2O3-SiO2-Au that displays 
desirable properties for cancer theranostics following the ideas mentioned previously. 
Figure 6.1 shows how the NPs could effectively use multifunctionality to image and kill 
cancer cells by combining clinically relevant functionalities. The NPs have a magnetic 
core made of γ-Fe2O3 which has a superparamagnetic or ferrimagnetic behaviour 
depending on the size, a SiO2 coating over the surface and an external Au nanoshell 
which brings the plasmonic behaviour[32] 




Figure 6.1 | Overview of the multifunctional NP in vivo applications for cancer 
nanotheranostics. 
In cancer nanotheranostics, there are multiple routes to obtain fully operational 
and multifunctional agents by mixing properties that arise from the nanoscale. 
Concretely, SERS can be used to obtain single-molecule detection[339], in combination 
with CT and MRI for a multifunctional detection of malignant regions. On the other 
hand, magnetic heat is generated by flipping continuously and rapidly the material’s 
nuclear spins inefficiently via external AMFs. Composite NPs made of both plasmonic 
and magnetic materials that combine these four functionalities are promising 
candidates for effective detection and treatment of early cancers. 
6.2. Experimental synthesis 
Materials: All reagents are purchased from Sigma-Aldrich: Gold(III) chloride 
hydrate (HAuCl4.xH2O, 99.999% trace metals basis MW 339.79 g/mol), Tetrakis 
(hydroxymethyl)phosphonium chloride solution (THPC, 80% in H2O), (3-
Aminopropyl)triethoxysilane (APTES), potassium carbonate (K2CO3, 99.995% trace 




metals basis MW 138.21 g/mol), sodium hydroxide (NaOH, Sigma-Aldrich), potassium 
carbonate (K2CO3), formaldehyde (CH2O (H-CHO)), 4-mercaptobenzoic acid (MBA), 
deionised water, ethanol and formaldehyde solution. Pericyte Medium (PM) consists 
of 500 ml of basal medium, 10 ml of fetal bovine serum (FBS, Product Code SC-0010), 
5 ml of pericyte growth supplement (PGS, Product Code SC-1252), and 5 ml of 
penicillin/streptomycin solution (P/S, Product Code SC-0503).   
These NPs were prepared by modifying the Stöber process to create the 
intermediate SiO2 shell over the core, amine functionalising the SiO2 surface and using 
the Turkevich method to attach Au nanoseeds over the SiO2 surface and grow them 
to form the external Au nanoshell. In terms of the core, two distinctive cores are 
presented in this chapter which were already analysed in Chapter 4: monodisperse 
and highly polydisperse commercial γ-Fe2O3 NPs. Moreover, the Au was thiolised with 
benzene rings to produce strong Raman signals. The resulting NPs were thoroughly 
characterised by transmission electron microscopy, powder X-ray diffraction, Raman 
spectroscopy and ultraviolet-visible spectrophotometry. Light absorption and 
plasmonic generation tests have been carried out to understand the benefits of these 
novel composite NPs. 
SiO2 nanoshell formation: The first step was the synthesis of the γ-Fe2O3-SiO2 
core-shell nanocomposites (Figure 6.2), NP following the Stober process. A liquid 
suspension made of 10 ml deionised (DI) water, 20 ml ethanol and 0.015 g γ-Fe2O3 
NPs was first prepared, then a modified Stöber process promoted the formation of the 
SiO2 shell via the sol-gel method. The Stöber-based process used follows the same 
steps described for WO3-SiO2 in section 5.2.  
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Amine functionalisation: The γ-Fe2O3-SiO2 core-shell composite NP surface 
was functionalized with an amine group following the same method used for WO3-SiO2 
in section 5.2.  
Colloidal γ-Fe2O3-SiO2-Au NPs: Colloidal γ-Fe2O3-SiO2-Au NPs with Au 
nanoseeds were obtained following the same method used for WO3-SiO2-Au in section 
5.2.  
Au shell synthesis: Colloidal γ-Fe2O3-SiO2-Au NPs with Au nanoshells were 
obtained following the same method used for WO3-SiO2-Au in section 5.2.  
Adding reporter molecule for SERS: The Au nanoshell bioconjugation with 4-
MBA over γ-Fe2O3-SiO2-Au core-shell nanocomposites was obtained following the 
same method used for WO3-SiO2-Au in section 5.2.  
 
Figure 6.2 | Diagram of (a) synthetic steps and (b) the theranostic combination of 
functionalities: SERS, MRI, CT and magnetic hyperthermia.  




To summarise, Figure 6.2a represents the synthetic process of these core-shell 
composite NPs where the core can be either monodisperse and polydisperse to 
fabricate two distinctive types of NPs, but the rest of the steps are identical for both. 
The idea is understanding if there are improvements or drawbacks of working with a 
highly monodisperse core against a polydisperse counterpart. Hence, the four 
functionalities described in Figure 6.2b are analysed for both cases. 
6.3. Characterization 
When trying to understand the composition, TEM images and XRD spectra are 
used to verify that the core-shell composite nanostructure is achieved following the 
same approach followed in chapter 5. Figure 6.3a presents the solutions obtained 
during the synthesis when creating 1 layer of Au and 2 layers of Au as performed in 
chapter 5. These solutions once again present a transition from dark red/purple to 
purple/blue when increasing thee Au content. Similar results are obtained for 
monodisperse and polydisperse in terms of solution apparent colour. This consistency 
is independent of the core material but dependent on substantial fluctuations of its 
size; which is a pivotal result to design and predict future NPs. 




Figure 6.3 | (a) Photographs of the colloidal NPs solutions γ-Fe2O3-SiO2-Au NPs with 
1 Au layer and 2 layers (b) XRD spectra of γ-Fe2O3-SiO2-Au NPs with 1 Au layer and 
γ-Fe2O3 NPs. (c) STEM element mapping analysis of γ-Fe2O3-SiO2-Au NPs with 1 Au 
layer. (d) STEM element mapping analysis of γ-Fe2O3-SiO2-Au NPs with Au 
nanoseeds. 
NPs material composition: Figure 6.3b-d presents the analysis of the 
composition in the NP design, proving the correct configuration of the different layers 
portrayed in Figure 6.2. Figure 6.3a verifies that the colour change when growing the 
outer layer of Au follows the same procedure already reported in Chapter 5 and Figure 
6.4 also corroborates that the plasmonic behaviour is almost identical as the displayed 
in chapter 5.  





Figure 6.4 | UV-vis absorption spectra of various colloidal NPs: Au, γ-Fe2O3-SiO2-Au 
nanoseeded and γ-Fe2O3-SiO2-Au nanoshelled with one Au nanoshell step (multiplied 
5 times the spectrum).  
Plasmonic light absorption: Figure 6.4 shows the UV-vis absorption spectra of 
various synthesis stages, which reveals the plasmon excitation wavelengths and the 
maximum absorption peak of Au, and the visible colour displayed by the colloidal. The 
plain Au colloidal appears as red, with maximum absorption at 525.9 nm; whilst the 
colloidal of nanoshell version of γ-Fe2O3-SiO2-Au appears purple with an absorption 
peak at 637.5 nm[43].  This shift will allow us to obtain a more efficient SERS when 
working at longer laser wavelengths.  
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6.3.1. Polydisperse commercial core 
 
Figure 6.5 | (a) HR-TEM image of γ-Fe2O3 NPs (b) TEM image of γ-Fe2O3 NPs (c) 
TEM image of γ-Fe2O3-SiO2 NPs (d) TEM image of γ-Fe2O3-SiO2-Au NPs with Au 




seeds (e) TEM image of γ-Fe2O3-SiO2-Au NPs with 1 Au layer nanoshell (f) TEM image 
of γ-Fe2O3-SiO2-Au NPs with 2 Au layers nanoshell. 
The polydispersity of the core for these samples was already analysed in 
chapter 4. Here, the synthetic steps of the polydisperse γ-Fe2O3-SiO2-Au NPs imaged 
under TEM are presented, including HR-TEM, to verify the atomic structure (see 
Figure 6.5). 
6.3.2. Monodisperse core 
First of all, it is necessary to understand these samples from the inside out, 
starting from the core. In chapter 4, a comprehensive study on dispersity for the 
commercial polydisperse γ-Fe2O3 cores. This chapter shows a more straightforward 
study of their monodisperse 11 nm NPs counterpart synthesised in the lab following 
the procedure explained chapter 4. 
  
Figure 6.6 | (a) TEM images of monodisperse γ-Fe2O3 NPs. (b) Statistical analysis of 
the size distribution in the monodisperse γ-Fe2O3 NPs. These results were obtained 
in collaboration with Irene Morales and Prof. Patricia de la Presa. 
Figure 6.6 displays a dispersity analysis under TEM. This image shows how 
NPs size range from 4 to 26 nm following a gaussian distribution with a centred 
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maximum peak value at 11 nm. This is a drastic reduction in dispersity compared to 
commercial NPs. Therefore, during the rest of this chapter, this NPs will be referred to 
as ‘monodisperse‘. 
 
Figure 6.7 | (a) TEM image of γ-Fe2O3-SiO2-Au NPs with Au seeds, (b) HR-TEM image 
of γ-Fe2O3-SiO2-Au NPs with 1 Au layer nanoshell, (c) TEM image of γ-Fe2O3-SiO2-
Au NPs with 1 Au layer nanoshell, and (d) TEM image of γ-Fe2O3-SiO2-Au NPs with 2 
Au layers nanoshell. 
Figure 6.7 shows how the growth of Au structures from seeds to seeded shell 
to Au shell has a redshift in the maximum of absorption as previously described in 
Chapter 6 and in the study published by Martinez Pancorbo et al. In 2019 [11]. 




6.4. Detection Results 
6.4.1. Liquid Raman 
Raman spectroscopy measurements: The measured Raman signal follows the 
same procedure discussed in section 5.6.  As shown in Figure 6.8, results confirm a 
strong SERS effect in liquid samples containing water, ethanol, and Raman reporters 
for the 1,077.8 cm-1 and 1,589.4 cm-1 peaks from 4-MBA.  
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Figure 6.8 | Liquid sample Raman spectra of 4-MBA peaks which are boosted by the 
SERS effect on the external double Au shell of the colloidal γ-Fe2O3-SiO2-Au NPs in 
a mixture of 80% water and 20% ethanol solvent in plastic cuvettes. These results 
were obtained in collaboration with Dr. Benjamin Gardner. 
Figure 6.8 shows a strong SERS signal obtained in an aqueous liquid media 
that is easily overcoming the background signal. The solvent attenuates the Raman 
activity to mimic body fluids which are primarily made of water. These results show 
that monodisperse cores with double Au shell provide the best SERS effect reaching 
a SERS EF of 33 for removed fluorescence for the 1,077.8 cm-1 peak. Measurements 
with only 4-MBA molecules within the solution were referred to as “background”.  





Figure 6.9 | MicroCT 3D imaging of aggregated samples from different relevant 
synthetic steps, all at the same mass (20 mg) and in the same volume (1.5 mL) of DI 
water. (a) Shadow cross-section of the aggregated γ-Fe2O3-SiO2-Au NPs. (b) 
Photographs of the three synthetic steps samples used for MicroCT imaging. (c) 
Manipulable 3D volume at low X-rays opacity of both the carbon fibre, plastic sticky 
tape and sample in microcentrifuge tubes. (d) Manipulable 3D volume at medium X-




rays opacity of both the carbon fibre, plastic sticky tape and sample in microcentrifuge 
tubes. (e) Manipulable 3D volumes at variable X-rays opacity of both the three 
aggregated liquid samples in microcentrifuge tubes. All tomographical measurements 
were taken at 125 ms per projection; and for 2400 projections in total, from 0 to 360 
degrees. These results were obtained in collaboration with Dr Hong Chang. 
NPs materials’ CT contrast: Results from Figure 6.9 confirm the capabilities of 
γ-Fe2O3-SiO2-Au NPS to be used as CT contrast agents for aggregated NPs, not for 
single-cell imaging, due to their spatial resolution limitation. MicroCT measurements 
were performed following the configuration displayed in Figure 3.5. Standard CT 
usually provides less resolving power and, therefore, the results obtained from this 
experimental setup will outperform the spatial resolution from clinical CT 
measurements. However, any values obtained from MicroCT come from smaller 
voxels than in clinical CT, which carry a weaker signal per voxel for the same X-rays 
emitter intensity. Hence, the contrast per voxel will be higher in the 3D region of the 
NPs if the voxel size is not larger than the aggregates. Figure 6.9a-e compile the 
results obtained under MicroCT for γ-Fe2O3 NPs, γ-Fe2O3-SiO2-Au NPs with Au 
nanoseeds and γ-Fe2O3-SiO2-Au NPs with Au nanoshell. These results confirm that 
the more Au included in the sample, the better CT contrast agent, i.e., more Au 
absorbs Z-rays, and this creates X-rays contrast when performing X-rays CT. 
Unfortunately, to achieve strong contrast, the samples had to be aggregated at the 
bottom on the microcentrifugation tube. This issue makes this modality not suitable for 
single-cell imaging but still useful for submillimeter sized tumour regions which are still 
better than most current early-stage detections in the clinic, including not only CT but 
also using any other clinically approved in vivo imaging technique. 
 




All the MRI results in this section were obtained in collaboration with Dr 
Abdelmalek Benattayallah. 
MRI measurements: The volume used for all the measurements is 600 uL while 
varying concentrations: 200, 100 ug/mL, 50, 20, 10 and 5 µg/mL. Results were 
measured for monodisperse γ-Fe2O3 NPs, monodisperse γ-Fe2O3-SiO2-Au NPs and 
polydisperse γ-Fe2O3-SiO2-Au NPs.  
For fresh NPs, 3D signals without modality were taken at TE = 1 min, 
TR/TE=25/2 and with dimensions of the coronal slices to measure of 2x2x2 mm 
(spatial resolution). T2 measurements were taken with a total scan of 5 minutes. 
Dimensions of the coronal slices to measure: 1x1x5 mm (spatial resolution). TR=3000 
ms. TE values are 13, 26, 39, 52, 65, 78, 91 and 104 ms. T1 measurements were 
taken with a total scan of time for each TI (point) is 2.5 minutes. Dimensions of the 
coronal slices to measure: 1x1x5 mm (spatial resolution). TR=10000 ms. TI values are 
50, 100, 200, 300, 500, 800, 1000, 1300, 1500, 1800, 2000, 2500 ms. 
For NPs after 2 months, 3D signals without modality were taken at TE = 1 min, 
TR/TE=.25/7. ms. Dimensions of the coronal slices to measure: 0.5x0.5x2 mm. For T1 
measurements, the total scan time for each TI is 5 min 20 seconds. The dimensions 
of the coronal slices to measure are 0.5x0.5x5 mm (spatial resolution). TR is 10000 
ms and eight TI measurements (50, 100, 200, 300, 500, 800, 1000, 1300, 1500, 1800, 
2000 and 2500 ms) are performed. For T2 measurements, the total scan time is 9.6 
minutes. The dimensions of the coronal slices to measure are 0.5x0.5x5 mm (spatial 
resolution). TR is 3000 ms, and TE values were measured at 14, 28, 42, 56, 70, 84, 
98 and 112 ms. 





Figure 6.10 | (a) Zoomed area where our samples are placed during the  MRI 
measurement, (b) Philips Gyroscan Intera 1.5T MRI, (c) Picture of the sample holder 
with a zoomed area over the samples analysed in this chapter, including 3D signals of 
the samples from the top recoloured intensity-dependent with fire LUT in ImageJ and 
from the side with no filter. 
MRI was performed to evaluate whether the γ-Fe2O3-SiO2-Au NPs are suitable 
for being MRI contrast agents. Figure 6.10a-b shows how the sample was located in 
the MRI to be measures and 6.10c displays that the liquid samples dispersed in DI 
water kept in microcentrifugation tubes are being measured using a silicon holder 
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encapsulated in a polystirine box. Moreover, the samples are imaged in 3D to verify 
the location and orientation of what is being detected. 
 
Figure 6.11 | (a) T1-weighted MR images at TI of 200 ms. 1300 ms, 1500 and 200 ms. 
(2) T2-weighted MR images at TE of 16 ms. 65 ms and 104 ms. 
MRI T1 and T2 weighted images were taken and used for all the following 
calculations, some of these modal images are displayed in Figure 6.11 at various 
concentrations, all as low or below the concentrations used for cytotoxicity and cell 
viability tests so that the results obtained in MRI are automatically translated to a safe 
cellular exposure. 
MRI T1-weighted images from 6.11 have high contrast for just the core and 
moderate contrast for full core-shell NPs independently of the core dispersity. However, 




it is essential to consider that the core-shell NP have a minimal amount of magnetic 
material since the core present a small fraction of the entire NP. For the monodisperse 
core, this difference is bigger than for the polydisperse sample. Therefore, lower 
contrast in the sample cannot be inferred as a consequence of a weaker signal from 
each NP but an effect of having less magnetic material. 
 
Figure 6.12 | T1 (left) and T2 (right) profiles from the center of the microcentrifugation 
tubes containing monodisperse γ-Fe2O3 NPs at concentrations of 200, 100, 50, 20, 10 
and 5 µg/mL. (a) T1 measured at TI of 50, 100, 200, 300, 500, 800, 1000, 1300, 1500, 
1800, 2000 and 2500 ms. (b) T2 is measured at TE of 14, 28, 42, 56, 70, 84, 98 and 
112 ms. 
Figure 6.12 displays the signal obtained for both T1 and T2 weighted images. 
There is an evident diminution in contrast for both modes when decreasing the signal. 
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them is already a promising result. “Fresh” means same day synthesis and 
ultrasonically redispersed. “2 months” means stored in the fridge at 5 °C for 2 months 
which resulted in most of the sample aggregated and decantated at the bottom of the 
microcentrifugation tube and strongly sonicated afterwards, plus allowing a few hours 
to seat at room temperature that will lead to decantation when the particles still remain 
aggregated.  
 
Figure 6.13 | T1 and T2 profiles from the center of the microcentrifugation tubes 
containing monodisperse γ-Fe2O3-SiO2-Au NPs at concentrations of 200, 100, 50, 20, 
10 and 5 µg/mL. T1 is measured at TI of 50, 100, 200, 300, 500, 800, 1000, 1300, 
1500, 1800, 2000 and 2500 ms. T2 is measured at TE of 14, 28, 42, 56, 70, 84, 98 






















































































































































In the same line, Figure 6.13 shows moderate contrast at 200 µg/mL and low 
for any value below 50 µg/mL. This means that single cancer cells might not be 
detected using this NP but clusters of them could be detected.  
 
Figure 6.14 | First time T1 and T2 profiles from the centre of the micro centrifugation 
tubes containing polydisperse γ-Fe2O3-SiO2-Au NPs at concentrations of 200, 100, 50, 
20, 10 and 5 µg/mL. T1 is measured at TI of 50, 100, 200, 300, 500, 800, 1000, 1300, 
1500, 1800, 2000 and 2500 ms. T2 is measured at TE of 14, 28, 42, 56, 70, 84, 98 
and 112 ms. 
Comparing these results from monodisperse nanoparticles with the 
polydisperse counterparts presented in Figure 6.14, it is clear that the polydisperse 
sample performs worse as a contrast agent than the monodisperse sample. Not only 
the results are worse, but also the polydisperse sample contains a higher magnetic 
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to compensate. However, this is not the case, and therefore the performance is clearly 
poorer. 
By using the profiles displayed in Figures 6.12-14, Table 1 was obtained where 
the T1 and T2 values are reported for each concentration in the fresh and 2 months 
formats using equations A3 and A5 from the Appendix, along with an estimation of 
how well the fit the exponential decay model.  













200 0.97 0.32 36 0.62 
100 0.96 0.35 21 1.00 
50 3.89 0.01 57 1.00 
20 -0.37 0.73 883 0.79 
10 -0.37 0.72 837 0.84 
5 -0.22 0.72 615 0.93 
2 months 
200 1.29 0.32 69 0.45 
100 1.07 0.27 28 0.94 
50 -1.09 0.14 114 0.99 
20 -0.40 0.74 1492 0.33 
10 -0.40 0.73 2099 0.17 




200 -0.37 0.73 328 0.95 
100 -0.35 0.73 526 0.90 
50 -0.32 0.72 870 0.78 
20 -0.32 0.74 2365 0.40 
10 -0.39 0.71 682 0.88 
5 -0.32 0.72 2279 0.45 
2 months 
200 -0.39 0.71 824 0.65 
100 -0.40 0.69 1142 0.54 
50 -0.24 0.69 1732 0.31 
20 -0.40 0.72 1848 0.28 
10 -0.24 0.74 2753 0.11 




200 -0.37 0.74 704 0.83 
100 -0.39 0.70 576 0.90 
50 -0.37 0.72 655 0.87 
20 -0.32 0.75 1938 0.43 
10 -0.32 0.74 1450 0.69 




5 -0.32 0.74 2108 0.47 
2 months 
200 -0.38 0.64 2013 0.30 
100 -0.39 0.64 2852 0.14 
50 -0.40 0.66 3670 0.09 
20 -0.40 0.65 2417 0.13 
10 -0.42 0.66 3315 0.30 
5 -0.40 0.65 1925 0.19 
Table 1: T1 and T2 values calculated using the linear regression included in the 
Appendix. 
Previously, Jun et al. reported that the T2 results have an intrinsic relationship 
with the size of the Fe3O4 NPs. Concretely, they obtained values of 350-400 ms at 4 
nm, 150-200 ms at 6 nm, 150 nm at 9 nm and 100 ms at 12 nm [340]. Similar NPs to 
the ones used in our study were synthesised before by other authors also for contrast-
enhanced MRI without including an intermediate layer of SiO2 (direct coating). That 
approach seems to decrease the saturation magnetization, hence reducing the 
relaxivity of the IONP core and reducing its ability to act as an MRI contrast agent 
[235,341,342]. Therefore, the intermediate thin SiO2 shell plays a strategic role in 
preventing this avoidable loss in relaxivity. 
Our composite NPs display strong contrast negative for both T1 and T2 modes. 
These results are consistent with the literature [343]; IONPs tend to display a negative 
contrast for T2. The T2 decay time of water and cerebrospinal fluid (CSF) is 2000-
2500 ms while in fat is around 60-70 ms [344]. In contrast, the T1 decay time of water 
and CSF is about 4000 ms while in fat is 250 ms. Knowing the value is very important 
for medical imaging, but in our analysis, water is also essential to evaluate the contrast 
of the NPs since they are redispersed in deionised water. This means that negative 
contrast agents will be useful for water and CSF but not for fatty tissue. On the contrary, 
positive contrast agents will be more useful for both modes than negative contrast 
agents in theory. However, our T1 values from Table 1 are so low that they are close 
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to 0 in the approximated exponential fit and this can bring good contrast for both modes 
in water. 
Dispersity in sizes for the magnetic core of a core-shell NP is not affecting 
significantly in the contrast capabilities at the same concentrations of the composite 
NP. However, since the polydisperse samples have much larger cores, the proportion 
of magnetic amount of magnetic material is much higher than in the monodisperse 
samples at the same NP concentrations. Therefore, the monodisperse samples seem 
to match the same contrast displayed in the polydisperse samples while having less 
magnetic material. This could be indicative of a higher contrast of the polydisperse 
sample. Overall, the concentration of the magnetic material in the composite structure 
is critical to obtain strong or weak contrast as seen by reducing the NPs concentration. 
6.5. Magnetic nanoparticles’ micromagnetic simulations results 
All the following magnetic simulations in this section were performed by Conor 
McKeever using the micromagnetics theory with mumax3. The simulations were run 
on the GPU card: CUDA 9010 GeForce GTX 1080 Ti, from the online information there 
are 3584 CUDA cores. 
Figure 6.15 shows the hysteresis loop using micromagnetics under single 
domain approximation for one maghemite NP. This result shows a high potential 
magnetic heat since thanks to the wide hysteresis loop area. However, these results 
are not an accurate representation of our system because there are many interacting 
NPs that will display emergent behaviour from these interactions. 





Figure 6.15 | Hysteresis loop Simulation of a 11 ± 1 nm NP using micromagnetics 
Figure 6.16 shows a snapshot of 40 NPs like the ones used previously to obtain 
figure 6.15. Here, small variations in the size are introduced to include small 
polydispersity in the sample which is more realistic and adjust better to the 
monodisperse maghemite NPs used experimentally in this chapter.  
 
Figure 6.16 | High contrast simulation snapshot of 11 ± 1 nm NPs. 
These simulated NPs present 11 ± 1 nm diameter. The polydispersity is 
included by adding up to 1 nm of random fluctuations around 11 nm, which is the 
average value of the monodisperse NPs used experimentally. This small 
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polydispersity is very similar to the experimentally present fluctuations in diameter from 
the experiments.  
As a computationally affordable approximation, a single net magnetic spin is 
used to describe each NP within the ensemble, which is subject to both inter- and 
intraparticle magnetic interactions. Figure 6.17.(a-c) shows the hysteresis loop 
comparison between the simulations and the experimental results. Figure 6.17.(d) 
displays the spin direction of the single domain magnetic NPs at a different intensity 
of the applied magnetic field. 
 
Figure 6.17 | (a) Comparison between simulated and experimental data for maghemite 
NPs, indicating close agreement between simulated and experimental values for the 
coercivity and remanence 5 K. (b) Comparison between numerical hysteresis obtained 
from a single simulation of 40 NPs and 800 NPs obtained by averaging over 20 




simulations at 5 K. A smoothened hysteresis loop is observed due to particle 
averaging. (c) Hysteresis loop of interacting NP system at 300 K (room temperature). 
Superparamagnetic behaviour is observed at room temperature. (d) Magnetic 
configurations obtained for 40 strongly interacting maghemite NPs at different field 
strengths, corresponding to (b). The NPs are below the single domain limit allowing 
the magnetisation to be represented by a single net magnetic spin. These results were 
obtained by Conor McKeever using micromagnetics. 
The saturation magnetization was that of maghemite at low temperatures [345] 
msat = 3.8 × 105 A/m with an exchange constant of C = 1 × 10−11 J/m in the magnetic 
regions and C = 0 in non-magnetic regions. Uniaxial magnetocrystalline anisotropy 
was used with an estimated value of Ku = 8 × 103 J/m3 based on fitting to experimental 
data (see Figure 6.10.(a)), which is in reasonable agreement with the effective 
magnetic anisotropy of maghemite, e.g. 7.8 × 103 J/m3 ± 12%  for 13 nm maghemite 
NPs, which is known to be generally larger than the bulk magnetocrystalline anisotropy 
4.6 × 103 J/m3 [346–348]. The magnetocrystalline anisotropy axis was oriented along a 
direction chosen randomly on the unit sphere. To incorporate the material variation 
present in actual samples, a 10% uniform variation of the material parameters was 
introduced into the simulations. Moreover, due to the random choice of 
magnetocrystalline anisotropy direction for each particle, there is an infinite number of 
unique magnetic NPs which can be modelled. As a result, each simulation was 
repeated multiple times with different random number generator seed values, and the 
resulting hysteresis loops were averaged. The particles were randomly populated 
within the grid and prevented from overlapping to study a system of non-agglomerated 
particles. A cell-size of 0.4 nm was adopted for NPs of 11.1 nm in diameter, which is 
below the single domain limit for maghemite NPs [349,350]. A 10% uniform variation in 
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particle size was introduced to account for the size disparity of experimental samples. 
Brown’s thermal equation was incorporated into the simulation by running the 
stochastic Landau-Lifshitz (sLL) equation in the time-domain with high-damping (α = 
1.0). The impact of thermal energy on the hysteretic behaviour is very large at room 
temperature due to the small size of the NPs, leading to superparamagnetic behaviour 
(see Figure 6.10.(c)). At low temperatures, the simulated coercivity and remanence of 
the hysteresis loop are found to agree closely with experimental values (see Figure 
6.10.(a)). However, the experimental measurements show a longer hysteresis tail. 
Such a discrepancy could potentially result from the effect of particle agglomeration 
leading to more complex domain configurations with larger nucleation fields [351]. 
6.6. Magnetic heating results 
 
Figure 6.18 | NanoHeat from NanoScience Laboratories experimental setup (a) from 
the inside and (b) from the outside. (c) Polystyrene holder. (d) Sample configuration 
during readings. 
Figure 6.18 displays the experimental setup used to obtain the magnetic 
heating profiles of the monodisperse core and its core-shell counterpart. The device 




was calibrated before taking the measurements with a 9 nm magnetite sample. This 
system works in a range of 50kHz to 1,000kHz, which is optimal to cover most 
biologically relevant magnetic heating tests.  
Figure 6.19 shows that the magnetic heating profiles of γ-Fe2O3 and γ-Fe2O3-
SiO2-Au NPs at 515 kHz and 170 Oe seem promising for cellular applications. The 
temperature rise is 30 °C in 18 min for γ-Fe2O3 and 7 °C in 23 min for γ-Fe2O3-SiO2-
Au. Human body temperature is usually at 37 °C in normal conditions, and magnetic 
hyperthermia is achieved at 40-48 °C. Therefore, both heating profiles quickly increase 
by 3 °C to reach the range. 
 
Figure 6.19 | Magnetic heating profiles of γ-Fe2O3 and γ-Fe2O3-SiO2-Au NPs at 515 
kHz and 170 Oe. 
6.7. In vitro toxicity results 
All the cell viability and toxicity assays are performed in close collaboration with Dr 
Julia Sero, Dr Dyan Ankrett and Marziyeh Belal. 
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Cell viability in human kidney cells:  Monodisperse Fe2O3-SiO2-Au NPs cytotoxicity 
against eukaryotic cells was determined using human embryonic kidney HEK293A 
cells (ThermoFisher, UK) and utilising the MTT assay. HEK293A cells were 
sequentially adapted to serum-free media, followed by routine culture in Pro293™ 
chemically defined, serum-free media (Lonza, Slough, UK) and supplemented with 1% 
v/v Insulin-Transferrin-Selenium (ITS, Gibco, UK), 4.5 g/L glucose, 2 mM L-glutamine 
and 1% Penicillin Streptomycin (Sigma-Aldrich, Dorset, UK). Media and all 
supplements were free of animal-derived components. The cells were maintained 
37°C in 5% CO2. For cytotoxicity assays, HEK293A cells were seeded in 96‐well plates 
at a density of 1×105 cells mL−1 and incubated for 24 hours at 37 °C in 5% CO2.  
NPs were diluted in Pro293™media to produce a final concentration range of 100 
– 2000 µg/mL−1 when added to cells in individual wells (final volume, 200 µL per well).  
Cells exposed to NPs were then incubated for a further 24 or 48 hrs. Upon termination 
of the incubation time, MTT (20 µL of 5 mg/mL in PBS) was added to all wells and 
incubated for a further 4 hours.  All wells were then aspirated, followed by the addition 
of 200 µL DMSO, at room temperature and under subdued light, for 15-20 minutes. 
DMSO solubilised the MTT formazan product, which was produced by live-cell 
mitochondrial succinate dehydrogenase. The absorbance of the solubilised formazan 
product was read at 590 nm using ClarioStar microplate reader (BMG LABTECH Ltd, 
Bucks, UK). 
Cell viability in human pericytes: The pericyte cells derived from human foetus 
provided by ScienceCell Company were cultured in T75 flasks and maintained in 5% 
CO2 incubator at 37 °C. After a few days of culturing once the flasks were fully covered 
by the cells and reached the confluency of >80% the monodisperse Fe2O3-SiO2-Au 




NPs were added to the flasks in series of dilutions. After 48 hours, the cell viability was 
evaluated using the Trypan blue exclusion method. The NPs added in the flasks were 
initially soluble in the Pericyte Medium but not anymore after being left for 48 hours. 
As a result, after the aspiration of the medium from flasks, the NPs were not present 
in the medium; instead, they were bound to the pericyte cells and make them look dark 
after centrifugation. 
Cell viability in human breast epithelial cells: Cells were cultured in 96-well plates 
in 100 μL of growth medium were treated with 10 μL of DI H2O or 1:10 dilutions of 
washed NP supernatant (carrier liquid) or NPs in suspension (for a final dilution of 
1:100). The initial concentration of NPs prior to two washes was ~20 mg/μL. Plates 
were fixed and stained to label nuclei (DAPI), 5 fields of view per well were imaged at 
20X using a high-content wide-field fluorescence microscope, (InCell Analyser 2000), 
and cells were detected and measured using automated image analysis (CellProfiler). 
The tube was centrifuged for 10 min at 4 °C, and the supernatant was removed.  
MCF10A (non-tumour) human breast epithelial cell plate was incubated at 37 °C 
(5% CO2) for 24 h. Then, it was fixed with 2% formaldehyde and permeabilised with 
2% Triton X-100, washed with phosphate-buffered saline, and incubated with 10 ug/ml 
Hoeschst to stain DNA (label nuclei). Imaged 9 fields of view per well (20X) - most of 
the wells covered by these fields and automatically detected and counted nuclei/well 
using CellProfiler. Dead/dying cells not removed by washing were filtered out based 
on morphology and staining. 




Figure 6.20 | Cell viability and cytotoxicity assays for monodisperse γ-Fe2O3-SiO2-Au 
NPs in healthy cells. Cell viability assay in human kidney cells was performed by Dr. 
Dyan Ankrett, in human pericytes by Marziyeh Belal and in human breast epithelial 
cells was performed by Dr. Julia Sero. 
Figure 6.20 displays the cell viability assays results from kidney cells and pericytes. 
None of the concentrations leads to high levels of cytotoxicity even at 2000 ug/mL, 
which is the high most drugs and NPs are usually tested at. This is incredibly 
encouraging since these are healthy cells that usually survive worse than cancer cells 
when exposed to nanoscale agents. Also, kidney cells died faster after 24 h than after 
48 h which is beneficial for long term exposure and could be an effect NP corona 
formation. Breast epithelial cells showed very variable toxicity, but not significant since 
the standard deviation was high. Nevertheless, the no substantial cytotoxicity was 
found for these cells. For human pericytes, using single factor ANOVA, p-value is more 




than 0.05% which shows there is no significant difference between groups in terms of 
the viability. Based on the pericyte assay, we can state that FBS does not display clear 
benefits. 
The main issue with the use of NPs in vivo as a diagnostic or therapeutic tool 
is that it is an invasive technique which brings potential side effects to the patient. 
These concerns could be outweighed for terminal patients. However, high 
concentrations of NPs would be required to deal with the metastasised tumours, and 
high concentrations of any NPs also lead to longer excretion time and small excretion 
ratios.  High concentrations that remain for more extended periods in the human 
organism have been found toxic even for safely engineered NPs[352]. Therefore, the 
primary target patient for the use of these NPs are those whose potential tumour is 
small, and subsequently, only small volumes at low concentration of these NPs would 
be required to find and treat the malignancy. The optimal patients that match these 
criteria are early stage and reemission patients. Hence, assessing their toxicity in 
physiologically relevant microenvironments is essential to pursue a commercialization 
plan while actively avoiding the use of non-human animals for preclinical trials. 
6.8. Summary 
In summary, chapter 6 presented magneto plasmonic core-shell γ-Fe2O3-SiO2-Au 
NPs with monodisperse and polydisperse cores. The monodisperse sample presented 
a better performance in all the imaging techniques, and subsequently, its magnetic 
hyperthermia capabilities and cytotoxicity were analysed. These NPs displayed 
promising magnetic hyperthermia capabilities within the scope of 20 minutes of 
heating time. No significant toxicity was found in any of the three types of cells tested 
either. γ-Fe2O3-SiO2-Au NPs have therefore shown combined capabilities for strong 
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SERS effect in liquid samples, CT contrast for aggregated NPs, MRI contrast at low 
concentration and hyperthermia capabilities without presenting significant toxicity at 
the cellular level for healthy cells. This NPs present a promising approach for cancer 
cell nanotheranostics. 
  
















In this thesis, several nanoparticles were designed and successfully 
synthesised, followed by the testing of their cancer nanotheranostics functionalities. 
Multiple NPs were synthesised and compared in Chapter 4 to evaluate potential 
functionalities for a core in a core-shell structure. WO3 and γ-Fe2O3 were reduced 
under heat treatment in an H2+Ar gas atmosphere showing material transition at 
different temperatures. For WO3, a colouration process to dark blue probably due to 
hydrogenation is achieved with complete colouration at approximately 340 °C. For γ-
Fe2O3 NPs, a customizable mixture ratio of α-Fe and γ-Fe2O3 is obtained. This mixture 
presents different magnetic properties, obtaining only α-Fe as a product at 
approximately 320 °C. Filtration of NPs was performed with heavily polydisperse γ-
Fe2O3 NPs to identify synthetic methods that improve sample homogeneity, purity and 
monodispersity. Consistent reduction in both hydrodynamic and NP diameter was 
found after filtration for both NFF and TFF using 37 nm and 60 nm pore size NPN. 
While TFF brings a higher degree of filtration than NFF, it is also more complex to 
assemble, requires longer filtration time, and it is not currently commercially available. 
These results bring valuable insights for automated microfluidic NP synthesis and 
purification platforms. 
In chapter 5, a novel type of core-shell composite NP that contains WO3 in its 
core was synthesised. This core was first shelled with SiO2 and subsequently with Au 
that grew from an intermediate seeding step. This chapter reports how to control the 
SiO2 shell formation, Au seeding process and Au shell formation over the WO3 with 
SiO2 and Au tunable shell thicknesses. SiO2 was from 3 nm to 60 nm with potential to 




shell thickness by repeating the Au shell formation step and morphology is controlled 
by the varying the density of Au seeds on the SiO2 shell which is increased by 
increasing the APTES concentration. These NPs displayed auspicious properties for 
clinical in vivo single cancer cell imaging. However, no therapeutic nor imaging 
capabilities were proven arising from the core. These NPs were tested using cell 
viability assays which showed low toxicity for concentrations below 100 µg/mL (after 
24 h, >75% alive cells from statistically significant cell viability). These concentrations 
are low but still higher than the values other authors have used previously, which can 
go as low as 5 µg/mL. 
The last multifunctional type of NP – the magnetic-plasmonic composite core-
shell γ-Fe2O3-SiO2-Au NP – combined effectively magnetic and plasmonic behaviours 
for cancer diagnosis and treatment while minimising toxicity and aggregation. This 
thesis showed a performance analysis of four different functionalities from this NP: 
SERS, MRI, microCT and magnetic heating. These functionalities are highly desirable 
for cancer theranostics from a clinical point of view. Furthermore, their cytotoxicity was 
analysed in various types of human cells, including healthy kidney cells, healthy 
pericytes and breast cells. These results showed extremely low toxicity in vitro using 
2D assays for all the tested cells at all concentrations. These results lead to expect 
highly promising results in 3D in vitro models and human trials. 
Refinement methods and material phase transitions were performed to study 
other potential NPs. Some of these methods display some limitations, such as the 
need to work at low concentrations or working with dried samples. Converting NPs 
from a higher oxidation state to a lower stable phase is highly demanded in materials 




these NPs during the heat treatment, particularly with magnetic NPs. On the other 
hand, working with nanoporous membranes brought to our attention some vital issues 
during the NPs’ size filtration. The NPs need to be filtered at a significantly lower 
concentration to prevent aggregation that will accumulate on the membrane surface 
building the cake effect – which tends to break the membranes. Low concentrations 
during filtration translate to long filtration periods. Moreover, both tangential and 
normal filtration have low efficiencies – many NPs that could be filtered never cross 
the membrane, which leads to high sample loss. Moreover, future tests of 
electrochromic properties in realistic microphysiological mimicking environments could 
help to better understand the usefulness of the electrochromic behaviour. 
In conclusion, the final type of NPs, monodisperse γ-Fe2O3-SiO2-Au, presents 
highly desirable properties for potential cancer theranostics by offering a combination 
of SERS, MRI and CT imaging capabilities as well as extremely low cytotoxicity for all 
types of healthy and cancer cells in vitro tested which are representative of different 
regions of the human body. Furthermore, magnetic heat was obtained from these NPs 
using AMF at 515 kHz and 170 Oe, obtaining an increment of 7 °C in 23 min. Since a 
healthy human body is usually at 37 °C, in 23 min temperatures of 44 °C can be 
reached, which are in the optimal hyperthermia range (42-46 °C). This implies a 
potential combination of four functionalities (three diagnostic and one therapeutic) 

















8. Future prospect 
Further studies should be performed to understand their behaviour in a 
dynamical environment and without 2D movement restrictions as well as being under 
gradients of temperature, pressure, and pH. For a selective targeting, these NPs can 
be functionalized with antibodies that target specific antigens from the cancer cell 
surface. However, as long the surface is negatively charged, targeting can be 
achieved to only cancer cells [97]. This could be better in cases of dealing with multiple 
types of cancers or when the identification of the type of cancer is not possible. In this 
regard, working with personalised 3D microfluidic assays is the safest and most ethical 
approach to understand the future behaviour of the NPs for a particular cancer patient. 
Additional functionalities can be further studied with the same materials used in 
this thesis such as NIR fluorescence, ultrasound and terahertz imaging along with 
photothermal treatment. This is possible thanks to the fact that the materials of types 
of core (WO3 and γ-Fe2O3) and the Au shells used in this study are good contrast 
agents for ultrasound imaging and terahertz imaging, except SiO2 which would bring 
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Furnace oven calibration: The differences in temperatures are plotted in 4.3 to 
evaluate the trend. 
 
Figure A.1 | Contrast between the furnace temperature and the thermometer 
temperature. 
Figure A.1 clearly concludes that there is approximately a linear correlation 
between the furnace temperature and measured with the thermometer. This to 
estimate the future temperatures along with ensuring reproducibility. 
T1 and T2 calculations: T1 and T2 decay times calculations from converting the 
exponential decay formulas into a linear formula by applying a Napierian logarithmic 
reduction approach which then is adjusted into a linear regression to obtain both T1 
and T2. The steps used are the following. 
For T1 mode, T1 and S0 are calculated by using the following formula: 
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With the rapid development of nanotechnology during the last decades, the 
ability to detect and control individual objects at the nanoscale has enabled 
us to deal with complex biomedical challenges. In cancer imaging, novel 
nanoparticles (NPs) offer promising potential to identify single cancer cells 
and precisely label larger areas of cancer tissues. Herein, a new class of size 
tunable core–shell composite (Au–SiO2–WO3) nanoparticles is reported. 
These nanoparticles display an easily improvable ≈103 surface-enhanced 
Raman scattering (SERS) enhancement factor with a double Au shell for dried 
samples over Si wafers and several orders of magnitude for liquid samples. 
WO3 core nanoparticles measuring 20–50 nm in diameter are sheathed by an 
intermediate 10–60 nm silica layer, produced by following the Stöber-based 
process and Turkevich method, followed by a 5–20 nm thick Au outer shell. By 
attaching 4-mercaptobenzoic acid (4-MBA) molecules as Raman reporters to 
the Au, high-resolution Raman maps that pinpoint the nanoparticles’ location 
are obtained. The preliminary results confirm their advantageous SERS prop-
erties for single-molecule detection, significant cell viability after 24 h and in 
vitro cell imaging using coherent anti-stokes Raman scattering. The long-term 
objective is to measure SERS nanoparticles in vivo using near-infrared light.
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the 2000s, positron emission tomog-
raphy (PET) combined with computed 
tomography (CT) was commercialized 
and started to be used worldwide due to 
its enhanced precision in the location of 
areas with highly active cells compared 
to older techniques. Its appearance had 
a great impact on cancer diagnosis until 
today, remaining the main technique for 
precise tumor location in the clinical stage 
for most types of cancers.[1] Unfortunately, 
this technique does not provide single cell 
detection and involves radioactive agents. 
More recent advances in optical imaging 
techniques such as deep Raman spectros-
copy-based approaches have enabled the 
potential to find single cancer cells inside 
of the human body without involving ion-
izing radiation. These novel techniques 
allow higher precision via light–molecule 
interactions by measuring biomarkers in 
the microscale, such as microcalcifications 
in breast cancer tissue.[2] More precise 
measurements using nanoscale objects 
labeled with Raman reporters could achieve single cell resolu-
tion for an optimal early stage cancer detection.[3]
In modern cancer imaging, the best personalized medical 
techniques are based on delivering nanoscale agents to cancer 
cells location while minimizing any undesirable interactions. 
However, many nanostructures do not arrive at the target 
and can induce toxicity. Hence, it is crucial to develop bio-
compatible nanoscale objects that contain clinically approved 
materials. Among many inorganic nanomaterials used, only 
iron-oxide (Fe3O4), silica (SiO2), and gold (Au) NPs are cur-
rently clinically accepted.[4] Iron oxide is used in imaging 
and thermal ablation of tumors; silica for fluorescent cancer 
imaging;[5] and gold for both surface-enhanced Raman spec-
troscopy (SERS) and photothermal ablation of tumors.[6] Plas-
monic nanoparticles (gold or silver) coated with Raman agents 
provide a platform for the emission of measurable Raman 
signals to optically locate the nanoparticles in the body, and 
therefore the cancer cells too.
The combination of different materials in the same particle 
to perform medical diagnosis and therapy in the same agent 
has become an important research topic, known as theranos-
tics. The most extensively studied composite nanoparticles 
SERS
1. Introduction
Cancer is the second main cause of death globally after car-
diovascular diseases, which are preventable via low-fat diet. 
Currently, the approach for cancer diagnosis is still based on 
nineteenth and twentieth century methodologies, which were 
supported in a limited knowledge of the cancer biology. In 
Adv. Funct. Mater. 2019, 29, 1903549
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in medical diagnosis are the colloidal ferromagnetic Fe3O4 
wrapped by functionalized Au core–shell NP for X-rays, SERS, 
and MRI imaging.[7] However, there are some important limi-
tations in all these applications. Medium to high energy X-rays 
can penetrate through the soft tissue in the human body but 
can induce new tumors and have poor contrast between soft 
tissues.[8] MRI uses Fe3O4 as a contrast agent due to favorable 
superparamagnetic properties, biodegradability, and easily 
modified surface properties for improved in vivo kinetics 
and multifunctionality.[9] Although MRI has a penetration 
depth only limited by the magnetic field, it has a low contrast 
between bound and unbound water molecules.[10] Further 
contrast is typically provided by injecting gadolinium-based 
enhancing agents. However, gadolinium has shown certain 
mechanisms for cytotoxicity.[11] The alternative, Fe3O4, is non-
cytotoxic but carries the risk of magnetic aggregation, forming 
very large particles that will not be excreted.[12] Au SERS uses 
nonionizing radiation that requires specific wavelengths in 
the near-infrared to penetrate the soft tissue, but penetration 
depth is typically up to only several centimeters.[13] However, it 
is one of the few techniques that allow achieving single cancer 
cell detection.
On the one hand, Au NPs have been extensively used as 
nanoprobes for SERS cancer imaging.[14] Their recent extension 
to Au nanoshells (Au NSs) covering in a core–shell structure 
has shown rather promising results for future biosensing,[15] 
by using specific molecules with benzene rings on top as the 
Raman reporters.[16] Spherical Au NPs have a range of surface 
plasmonic resonance wavelength excitations ranging from 
510 to 572 nm for particle sizes from 3 to 100 nm, and from 
520 to 932 nm excitations for Au NSs with different combina-
tions of internal diameters and external shell thickness, respec-
tively.[17,18] Apparently, thinner shells and larger internal diameters 
of nanoshells bring redshifts in the plasmonic generation.[18–20] 
Both Au NPs and Au NSs are well known for their good bio-
compatibility, ready bioconjugation,[21] and optical properties 
via plasmons.[22] On the other hand, Fe3O4 presents a behavior 
from superparamagnetic to ferromagnetic for 20 nm size 
or above of the nanoparticles which leads to significant mag-
netic nanoparticle aggregation.[23,24] Therefore, there is a drive 
to develop new materials that integrate alternative cores for 
Au nanoshells core–shell nanoparticles without magnetic 
aggregation.
Here we have explored the use of tungsten trioxide (WO3) 
that has excellent sensing properties,[25] including unique 
chromic behavior activated via thermal changes, electrical cur-
rents, and gases.[26] Additionally, some studies have previously 
shown potential oxygen vacancy induced ferromagnetism that 
brings magnetic hyperthermia capabilities,[27,28] and both bio-
compatibility and antibacterial properties.[29] Ultrasmall WO3-x 
nanodots have also been used recently for in vivo studies for 
multimodality imaging tumor imaging through computed 
tomography and photoacoustic imaging, and effective cancer 
treatment combining both photothermal therapy and radia-
tion therapy.[30] WO3 and WO2 transparency can be tuned by 
inducing a difference of electric potential or electric current, 
which can enhance or reduce the plasmonic generation of an 
external Au shell. However, Au and WO3 are not easily bound 
together, therefore an intermediate interface that helps to bind 
both the Au NPs and the WO3 core is needed. This interme-
diate layer needs to have low cytotoxicity for the human cells 
and should be able to accommodate the Au NPs easily. Porous 
silica (SiO2) NPs have previously been utilized to accommodate 
Au and have shown very low toxicity in the human body.[31] The 
synthetic steps are displayed in Figure S1 (Supporting Informa-
tion). To validate this design (Figure 1a), we will use the well-
established Raman reporter on Au, 4-mercaptobenzoic acid 
(4-MBA), to acquire the SERS signals. The schematic of the 
SERS process in the Au shell surface is explained in Figure 1b. 
It also shows that 785 and 830 nm are the two wavelengths 
used to obtain the Raman signals and maps, which are in the 
near-infrared region of the electromagnetic spectra. These 
wavelengths allow human tissue penetration while standard 
SERS that uses visible light would be fully absorbed by the 
organic tissues.
2. Results and Discussion
2.1. Characterization of Au–SiO2–WO3 Nanocomposites
Figure 2a displays the X-ray powder diffraction (XRD) patterns 
of the nanoparticles from each synthesis step. The peaks in 
each XRD pattern reveal the crystal structure of these mate-
rials. Along with the progression, the original monoclinic 
WO3 (Blue line) peaks are accompanied with lumps of the 
amorphous SiO2 at 23.1° (002), 23.6° (020), and 24.4° (200) 
(Black line), and then the cubic Au peaks appear (Red line) 
in the composite, benchmarked against the plain Au NPs at 
38.1° (111) and 44.3° (200) (Green line). The three main finger-
print peaks of monoclinic WO3 at 23.1°, 23.6°, and 24.4° are 
always present. This result confirms the bulk composite phase 
structures.
The phases identified by XRD are also verified by high-
resolution transmission electron microscopy (HRTEM) 
imaging. The lattice spacing is 0.265 nm (Figure 2b) for the 
monoclinic WO3 (020) core, and 0.235 nm for the Au (111) on 
top of the intermediate SiO2 shell (Figure 2b,c). Figure 2d–r 
shows the scanning transmission electron microscopy (STEM) 
images of the composite nanoparticles and their corresponding 
energy-dispersive X-ray spectroscopy (EDX) elemental mapping 
results. These maps reveal the detailed distribution features of 
each element at the nanoscale. Figure 2n–r represents the first 
step of the synthesis and shows that the core contains W and O, 
while the first shell being Si and O. This is consistent with the 
expected WO3 wrapped by SiO2. Figure 2i–m is the Au seeding 
step, in which Au in green color is found surrounding the 
SiO2 shell with a homogeneous distribution of small Au seeds. 
Figure 2d–h demonstrates the thick Au shell growth in green 
color as compared with that shown previously for the attached 
Au nanoseeds. Finally, the STEM-EDX and HRTEM results 
both confirm an average diameter of 3.5 ± 1.0 nm for the par-
ticulate Au nanoseeds.
The WO3 core used in this material is polydispersed and 
add a big uncertainty in the final shape and size, especially for 
thin layers of SiO2 and Au. Also, the purity of the source can 
Adv. Funct. Mater. 2019, 29, 1903549
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be refined to avoid crosslinked WO2 contamination or use WO2 
cores directly during the synthesis, which has smaller energy 
bandgap for displaying electrochromic behavior. The reduction 
of the final overall size can help to improve excretion rates of 
the nanoparticles after imaging.[32–35]
2.2. Control of SiO2 Shell Thickness
Figure 3 shows the SiO2 thickness dependency on the ratio 
of ammonia:TEOS. To achieve thickness control, the volume 
of ammonia remains constant at 1 mL for all the displayed 
coatings in Figure 3. This follows the principles of the Stöber 
process that describes the growth of SiO2 NPs.[36] When the 
amount of TEOS increases over the ammonia, the coating is 
thicker, and vice versa (Figure 3a–f). This has been previously 
addressed using different cores by several authors.[37–39] The 
thickness of the SiO2 can be minimized down to 3 nm. How-
ever, the relationship between the thickness and the concentra-
tion of TEOS is nonlinear. On the other hand, the current core 
has been found to exhibit some potential cytotoxicity for certain 
cells,[40–42] so it needs to be wrapped thick enough to ensure it 
never directly interacts with healthy cells. TEOS is the main 
parameter determining the SiO2 layer thickness.
2.3. Attachment of Au NPs
There are several very important optical and chemical properties 
of Au NPs that depend strictly on the type of ligand and ligand-
metal bond. 3-Aminopropyltrimethoxysilane (APTS) is one of 
the most common chemicals used to amine-functionalized 
surfaces for successive Au attachment due to its stable bonding 
with Au, fast attachment, and low cost.
Figure 4a displays the sample prepared with 4 times fewer 
APTS concentration than the one used to prepare the sample 
shown in Figure 4b during the amine functionalization pro-
cess. Figure 4 shows that an increment of the APTS content 
leads to a more homogeneous Au seeding over the SiO2 sur-
face. The concentration of APTS used in this study produced 
Au NPs of 3.5 nm ± 1.0 nm in diameter.
2.4. Plasmonic Light Absorption
Figure 5a shows the ultraviolet–visible (UV–vis) absorption 
spectra of various synthesis stages, which reveals the plasmon 
excitation wavelengths and the maximum absorption peak 
of Au, and the visible color displayed by the colloidal. The 
plain Au colloidal appears as red, with maximum absorption 
Adv. Funct. Mater. 2019, 29, 1903549
Figure 1. a,b) Schematic of the composite NP design and SERS effect over the gold nanoshell, respectively. c) Colloidal nanoparticles solutions made 
of Au, SiO2–WO3, and Au–SiO2–WO3 covered with Au seeds and Au shells within thick layers, respectively. d) Au–SiO2–WO3 nanoparticles solutions 
with various Au thickness obtained by using different Au stock solution during the shell formation.
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at 510 nm; whilst the colloidal of nanoshell version of Au–
SiO2–WO3 appears purple with an absorption peak at 532 nm.[43] 
Figure 5b, which corresponds to the colloidal nanoparticles dis-
played in Figure 1d, displays the evolution of the absorption 
spectra during the nanoshell formation in which X represents 
the volume of 25 × 10−3 m Au stock solution as explained in the 
methods section. Also, there is a clear redshift when the aggrega-
tion of the Au and Au–SiO2–WO3 NPs takes place. The optimal 
scenario is a maximum peak in the near-infrared regime to have 
the highest plasmonic oscillations for the SERS application with 
near-infrared laser illumination. There are no local maximum 
peaks for the nonmetallic materials, as expected since they do 
not have plasmon resonances. Also, the contribution of SiO2 is 
negligible but starts to be relevant for increased wavelengths.
2.5. SERS Maps with 4-MBA Reporter
Figure 6a–c shows the Raman spectra of 4-MBA molecules 
bound to the shelled Au–SiO2–WO3, seeded Au–SiO2–WO3 and 
Adv. Funct. Mater. 2019, 29, 1903549
Figure 2. Characterization of the nanocomposites. a) XRD profiles of the WO3, SiO2–WO3, Au–SiO2–WO3 and Au. b) HRTEM images of WO3 and c) Au. 
d–h) STEM-EDX element mapping of Au nanoshell on Au–SiO2–WO3: STEM image, RGB overall, W, Au, and Si, respectively. i–m) STEM-EDX element 
mapping of Au nanoseeds on Au–SiO2–WO3: STEM image, RGB overall, W, Au, and Si, respectively. n–r) STEM-EDX element mapping of SiO2–WO3: 
STEM image, RGB overall, W, O, and Si, respectively.
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4-MBA alone, respectively. The substrate that holds the sam-
ples is a Si wafer and acts as a reference to control the intensity 
performance of the vibrational resonance peaks from the fixed 
concentration and volume of 4-MBA molecules, and therefore, 
the SERS effect quality. It is clear from Figure 6a–c that for Au 
content there is a boost in these peaks against the 4-MBA mole-
cule alone in Figure 6c.[44] The maximum enhancement of 771 
times over the original signal is achieved for the core–shell NPs 
nanoshelled with Au twice as shown in Figure S2b (Supporting 
Information). This factor is more than four times achieved 
value with the 3.5 nm Au nanoseeds on the SiO2 surface from 
Figure 6b. This implies that for higher resolution and detection 
power, the complete nanoshell is essential. All the enhance-
ment factor calculations have been carried out using the same 
Raman reporter molecule concentrations. A quick compar-
ison with previous results using bare Au nanoparticles for the 
same overall size shows that these composite nano particles 
achieved lower enhancement factors, mainly due to the bluer 
maximum absorption peak position.[45,46] Smaller monodis-
persed cores and thinner silica shells can be the key for a sub-
stantial improvement to match the surface plasmon resonance 
wavelength. Larger enhancements can be easily achieved by 
increasing the gold nanoshell thickness while keeping non-
smooth surfaces. It can also be improved with the addition of 
another external Au layer on top of the Raman molecules to 
create hot spots.
4-MBA is a thiol that contains a benzene ring in the R part, 
which forms the aromatic ring. This ring provides a strong 
Raman scattering cross-section with characteristics peaks 
of 1078 cm−1 and 1589 cm−1 (see Figure 6). We chose this 
mole cule due to its features of stable sulfur bond with Au, 
easy attachment, and pH sensitivity in the Raman spectra.[47] 
Adv. Funct. Mater. 2019, 29, 1903549
Figure 3. TEM images of SiO2–WO3 samples with different ratios of ammonia:TEOS. a) 4:1, b) 6:1, c) 8:1, d) 10:1, e) 20:1, and f) 50:1.
Figure 4. TEM images of Au nanoseeds attachment. Au–SiO2–WO3 NPs synthesized with different APTS additions: a) 50 µL. b) 200 µL.
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Depending on the intensity and position of the peaks, dif-
ferent thiolated reporter molecules can be investigated to find 
the most suitable Raman reporters for potential use when 
labeling specific cell types such as cancer cells. The nano-
particles synthesized in this paper achieve easily improvable 
10 and 103 SERS EFs for one Au shell and double Au shell, 
respectively, in dried samples over Si wafers (see Figure 6a 
and Figure S2b, Supporting Information). Also, several orders 
of magnitude were found for the double Au layer for liquid 
samples (see Figure S2a, Supporting Information), which is 
very promising for future in vivo applications due to including 
optical absorption similar to organic human soft tissue. All 
these values were obtained by diving the SERS signal by the 
background silicon peak to normalize them and subsequently 
measuring the ratio of the SERS peak versus the molecule 
without plasmonic enhancement. Moreover, we have not dis-
played the Raman enhancement from the Au seeds without 
attaching to the silica shell because the intensity of the 4-MBA 
peaks was as strong as the molecules alone for both near-
infrared lasers.
Principal component analysis (PCA) is an adaptive data 
analysis technique that combines conventional imaging 
and spectroscopy to simultaneously obtain both spatial and 
spectral information from an object by reducing a large set 
of possibly correlated variables to a small set of uncorrelated 
variables, called principal components that still contains 
most of the relevant information from the large set.[48,49] The 
origin of the new coordinate system is located in the center 
Adv. Funct. Mater. 2019, 29, 1903549
Figure 6. a–c) SERS spectra of 4-MBA molecule peaks at 1078 and 1589 cm−1 with 830 nm laser and d–f) Raman maps with 785 and 830 nm of 
different samples with 4-MBA Raman reporter over a silicon wafer with its characteristic reference peak at 520 cm−1. a) Au shelled Au–SiO2–WO3. 
b) Au seeded Au–SiO2–WO3. c) Plain 4-MBA molecules. d–f) Optical microscopy image, Raman maps under PC1 (66.09%) taken with 785 nm and 
830 nm lasers, respectively.
Figure 5. UV–vis absorption spectra of various colloidal nanoparticles: a) WO3, SiO2–WO3, Au seeded Au–SiO2–WO3, Au shelled Au–SiO2–WO3 (and 
aggregated batch, after 2 weeks stored in room temperature) and Au alone (and aggregated batch, after 2 weeks stored in room temperature). b) Au–
SiO2–WO3 shelled with different Au stock solution (X) used during the shell formation.
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of the data points, the first PCA step includes the points in 
the direction of the highest variance, the second PCA step 
includes the ones for the second-highest variance and the 
rest follow this trend. Using the first PCA, which describes 
the greatest variance in the dataset (66.09%) in the Raman 
maps, we can find where the 4-MBA molecules are located: 
dark red means 4-MBA and dark blue represents the Si wafer 
(Figure 6e,f). This information is not obvious from the optical 
image (Figure 6d); however, the Raman maps are able to 
identify the locations of these reporters. The SERS intensity 
of the aggregated areas is not only due to the 2D spatial dis-
tribution of the materials but also due to having several layers 
that lead to stronger hot spots[50] and cannot be seen with the 
optical microscope. After subsequent attachment of the nano-
particles to or uptake into cancer cells, the cancer cells will be 
precisely located.
Targeting and localization of cancer cells can be achieved by 
functionalizing the Au nanoshell with cancer ligands such as 
antibodies, which are customized for each type of cancer. One 
type of promising ligand is the anti-HER monoclonal anti-
bodies for the treatment of various types of cancers including 
HER-2+ metastatic breast, colorectal, NSCLC, pancreatic, 
breast, HNSCC, ovarian and renal tumors.[51,52] Should these 
core–shell nanoparticles provide sufficient signals in combi-
nation with bright Raman reporters in the near-infrared, the 
SERS signals could be readout using microscopy in individual 
cancer cells. Moreover, they also could visualize in vivo tissues 
with Raman fiber probes or surface-enhanced spatially offset 
Raman spectroscopy (SESORS).
2.6. Cytotoxicity Profile in a Triple-Negative Human Breast 
Cancer Cell Line MDA-MB 231
Figure 7a shows the in vitro cytotoxicity profile of the selected 
concentrations (100, 250, 500, and 1000 µg mL−1) of four dif-
ferent batches (A1, A2, B1, B2) of Au–SiO2–WO3 nanoparticles 
in a triple-negative human breast cancer cell line MDA-MB 231. 
A1, A2, B1, B2 represent single layer of Au, single layer of Au 
coated with 4MBA, double layer of Au and double layer of Au 
coated with 4MBA, respectively. The NPs concentration range 
was selected from the minimum concentration showing low 
toxicity to concentration showing maximum toxicity. A live–
dead assay for a period of 24 h was performed to confirm the 
suitability of the nanoparticles for biomedical applications. Sta-
tistical analysis was performed with three batches per sample 
and concentration of which the mean and standard deviation 
were calculated. The results show no statistical significance (ns, 
p ≥ 0.05) for concentrations 500 µg mL−1, while for concentra-
tions of 100, 250, and 1000 µg mL−1 the results are statistically 
significant (*, p < 0.01 to 0.05) as shown in Figure 7a. Among 
the statistically significant results, low cytotoxicity (>75% alive 
cells) after 24 h was found for concentrations of 100 µg mL−1 
indicating their suitability for cell imaging purposes.
2.7. Cell Imaging in Human MDA-MB 231 Breast Cancer Cells
The cancer cells were visualized by imaging the CARS signal 
generated from the CH molecular vibrations within the 
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Figure 7. a) Cytotoxicity tests after 24 h of samples A1 (single layer of Au), A2 (single layer of Au coated with 4MBA), B1 (double layer of Au) and 
B2 (double layer of Au coated with 4MBA). The values represent the mean ± standard deviation of three experiments; * denotes p < 0.05 (statistical 
significance) and ns represents p ≥ 0.05 (nonstatistical significance). b) Average values and standard deviations errors from CARS spectra from cells 
alone and cells with nanoparticles. c) Control cells CARS stack—z-projection image in grayscale. d) CARS 3D demonstration of nanoparticles B1 within 
the cell in grayscale and e) its z-projection of the entire stack (recolored intensity-dependent with fire LUT in ImageJ). f) Nanoparticles A2 in cells 
CARS imaging (recolored intensity-dependent with fire LUT in ImageJ). g) z-stacking of CARS images from cells and nanoparticles stack A1 (recolored 
intensity-dependent with fire LUT in ImageJ).
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cells, this signal was chemically specific with a peak around 
2940 cm−1. The nanoparticles within the cells also exhibited a 
very strong signal within the CARS channel, however, this was 
from a four-wave mixing process, which was not chemically spe-
cific. Figure 7b compares the spectra of the cells to the spectral 
of the Au–SiO2–WO3 NPs within the cells. The average value 
and standard deviation of three measurements were taken and 
plotted for both the cells only and the cells with the NPs. The 
intensity of the signal in cells with NPs is a few times higher 
than cells alone, which indicates high sensitivity to locate the 
NPs. Figure 7c–g shows the cell imaging results obtained with 
CARS. The control label-free human MDA-MB 231 breast 
cancer cells without nanoparticles are shown in Figure 7c, this 
image is a z-projection of a CARS image stack and the contrast 
is from the CH vibrations within the cells. Then, in Figure 7d, 
CARS 3D cross-sections of NPs with a double layer of Au 
(white color) within the cells (gray color) in gray confirms that 
the nanoparticles were uptaken by the cells and can be seen 
from the inside of the cells. Additionally, the z-projection of the 
entire stack of CARS images was implemented in Figure 7e 
by applying the color filter fire look-up-tables (LUT) in ImageJ 
over the original intensity-dependent greyscale. This recolored 
image shows the nanoparticles (white) located inside the cells 
(purple) at different z-positions. Similarly, Figure 7f,d shows 
the z-projection of the entire stack with fire LUT recoloration 
for nanoparticles with a single layer of Au coated with 4MBA 
and without 4MBA, respectively. These results along with the 
cytotoxicity profiles confirm the viability for these nanoparticles 
to be used in cancer cell imaging.
3. Conclusion
In summary, we have demonstrated a size tunable synthesis 
method to obtain novel Au–SiO2–WO3 NPs. Higher APTS con-
centrations result in attachment of larger numbers of seeding 
Au NPs over the SiO2 layer. Along with the synthesis, modifica-
tions in the intensity of the ultrasonication and speed in the 
centrifugation can be introduced to refine the washing process 
and avoid nanoparticles agglomerations. On the one hand, by 
repeating the Au shell growth step, several gold shells are cre-
ated and stronger SERS is achieved as displayed in Figure S2a 
(Supporting Information). This ability to increase the enhance-
ment factor is crucial for translational biomedical applications 
that involve media that attenuates the near-infrared laser inten-
sity. On the other hand, the main parameter for the SiO2 thick-
ness growth is the ratio between TEOS and ammonia. Higher 
ratios of ammonia:TEOS lead to thinner SiO2 thickness, which 
reduces the potential toxicity in the human body through a 
faster excretion. However, it could increase the risk of dis-
playing cytotoxicity related to partially uncoated WO3 cores. The 
final Au–SiO2–WO3 NPs have been systematically obtained in 
more than 10 batches by following the synthetic procedure, this 
reflects the high reproducibility of the synthesis. The optimal 
thickness of the SiO2 and Au nanoshells for both strong SERS 
and low toxicity has yet to be determined. However, preliminary 
results from various configurations show highly reproducible 
accurate nanoparticles detection in 2D human breast cancer 
cell culture and liquid media which leads to believe in vivo cell 
imaging can be achieved. Moreover, cytotoxicity tests after 24 h 
show >75% alive cells from statistically significant cell viability 
at concentrations of 100 µg mL−1. This is a very promising 
translational result that encourages the use of these nanoparti-
cles in future live human cancer cells imaging and 3D human 
cell culture models such as spheroids, organoids and organ-on-
a-chip technologies to have the full picture of how beneficial 
these nanoparticles can be in the clinical stage.
4. Experimental Section
Materials: All the following reagents were purchased from Sigma-
Aldrich: gold(III) chloride hydrate (HAuCl4.xH2O, 99.999% trace metals 
basis MW 339.79 g mol−1), tetrakis (hydroxymethyl)phosphonium 
chloride solution (THPC, 80% in H2O), (3-aminopropyl)triethoxysilane 
(APTS), potassium carbonate (K2CO3, 99.995% trace metals basis 
MW 138.21 g mol−1), sodium hydroxide (NaOH, Sigma-Aldrich), 
potassium carbonate (K2CO3), formaldehyde (CH2O (HCHO)), 
4-mercaptobenzoic acid (MBA), deionized water, ethanol, formaldehyde 
solution, Dulbecco’s modified Eagle’s medium (DMEM), trypsin–EDTA 
solution, and cell proliferation reagent WST-1. The WO3 nanoparticles 
were purchased from China, Chang Sha Na Ro Mei Nanomaterials 
Ltd, with a purity of 99.9% and an average size of 40 nm. Culture cell 
serum-supplement and penicillin–streptomycin were purchased from 
Gibco.
Cell Culture: The MDA-MB 231 human breast cancer cells were 
cultured in DMEM with 10% serum-supplement and 1% penicillin–
streptomycin. Cells were grown under standard conditions of 5% 
CO2 and 37 °C in a controlled humidified incubator to reach 70–80% 
confluence. Cells were routinely subcultured using 0.25% trypsin–EDTA 
solution.
Characterization Instruments and Conditions: The nanoparticles were 
characterized by using the Thermo Scientific Evolution Array UV–vis 
spectrophotometer to obtain the light absorption spectra of the colloidal 
composite nanoparticles suspended in ethanol at mild conditions. For 
the electron microscopy images and the EDX element maps, the JEOL 
2100 TEM/STEM system was used. The XRD patterns were obtained with 
the Bruker D8 advanced XRD machine working at 0.03° step per second 
of 2θ from 10° to 80° at room temperature. Raman signals, maps, and 
optical images for dried samples were obtained from samples dried on 
top of silicon wafers by using 785 and 830 nm lasers integrated into the 
Renishaw Invia Raman system and with its internal optical microscope 
at standard room conditions.
Silica Nanoshell Formation: The first step was the synthesis of 
the SiO2–WO3 core–shell nanocomposites (Figure S1, Supporting 
Information), NP following the Stober process. A liquid suspension made 
of 10 mL deionized (DI) water, 20 mL ethanol, and 0.015 g WO3 NPs was 
first prepared, then a modified Stöber process promoted the formation 
of the SiO2 shell via the sol–gel method. In this method, consecutive 
hydrolysis and condensation of alkoxysilanes in an aqueous-alcoholic 
solution in the presence of a base catalyst were involved, using tetraethyl 
orthosilicate (TEOS) as alkoxysilane and ammonia as the base catalyst.
In this paper, a different route from other Stöber-based versions was 
taken to perform the silica synthesis while in parallel coating the core. 
WO3 NPs were coated with SiO2 by adding 1 mL ammonia and 5 drops 
of TEOS while stirring the WO3 suspension with a time interval of 10 s 
between each TEOS drop. This was the key to create the SiO2 coating 
because by changing the concentration of TEOS the SiO2 thickness could 
be modified. After that, the mixture was stirred continuously for 30 more 
min. The ammonia concentration catalyzed this reaction by increasing 
the reaction rate. Finally, the suspension was washed with deionized 
water and Ethanol by centrifugation to separate the nanoparticles from 
the liquid in 50 mL Eppendorf tubes.
Amine Functionalization: The SiO2–WO3 core–shell nanocomposite 
surfaces were functionalized with an amine group. First, 0.015 g 
www.afm-journal.dewww.advancedsciencenews.com
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SiO2–WO3 core–shell nanocomposites (Figure S1, Supporting 
Information) was dispersed in 20 mL of ethanol in a beaker and 
subjected to 30 min ultrasonic probe treatment. Then, 500 µL of 
APTS was added to the suspension, which was heated to 70 °C under 
the magnetic stirring for 5 h. To remove the excess reactants, the 
suspension of 25 mL ethanol was centrifuged for three times (10 min 
per cycle at 6 000 rpm) without washing and redispersed by ultrasonic 
probe treatment.
The key aspect of this functionalization was the NH2 ending on 
top.[53] These NH2 ligands reacted with Au after breaking it in two parts 
by heating. On the one hand, H2 was released on one side when the H 
atoms absorbed higher energy than the bond. On the other hand, a very 
strong bond was created between the N and the Au atoms that were 
close enough to be attracted by the electric force of the N2− ions and the 
Au electron cloud. This fact made it possible to attach Au nanoseeds and 
to stable subsequent Au growth on top with homogeneous distribution.
Colloidal Au–SiO2–WO3 NPs Fabrication: Colloidal Au NPs can be 
obtained following different methods, which are based on the work of 
Turkevich et al.[54] Herein they were NP obtained by reducing Au salts 
(HAuCl4) in the presence of surfactants, tetrakis (hydroxymethyl) 
phosphonium chloride (THPC, C4H12ClO4P).[55] During the formation of 
the metallic solution, a huge excess of NaOH was formed. The reactions 
between THPC and NaOH produced formaldehyde as the reducing 
agent for Au. After the amine functionalization, the gold coating process 
is implemented.
By dissolving 0.098 g of HAuCl4·3H2O in 10 mL of deionized water,a 
25.0 × 10−3 m Au stock solution was prepared, called chloroauric acid. By 
typical reducing the chloroauric acid with THPC, the colloidal Au NPs 
(13 × 10−9 m) was prepared. In detail, 3 mL of 1 m NaOH (0.2 g in 5 mL 
deionized water) and 1 mL of diluted THPC (12 µL of 80% THPC per 
1 mL of deionized water, 50 × 10−3 m) were added to 44 mL of deionized 
water while being stirred. The solution was magnetically stirred for 5 min 
and 2 mL of the 25 × 10−3 m Au stock solution was rapidly added in and 
the color quickly changed to dark red or brown. The final Au colloidal was 
stored at 5 °C for 12 h, prior to being used for later Au coating process.
5 mL of the amine-functionalized SiO2 core–shell nanocomposites 
suspension of 70 °C was added to 20 mL of magnetically stirred Au 
colloidal NP of 100 °C, and then continuously stirred for 10 min. The 
resulting colloidal suspension NP was washed with deionized water 
under centrifugation for three times at 6000 rpm for 10 min each time, 
to remove the excess of reactants.
Au Shell Synthesis: Once the Au nanoseeds were attached to the SiO2 
nanoshell, the Au started to grow to form the final out layer.[56] The 
alkaline growth solution was prepared by dissolving 0.025 g potassium 
carbonate (K2CO3) in 100 mL deionized water (0.18 × 10−3 m). Then 
1.5 mL of 25 × 10−3 m (1% w/v) of the Au stock solution was added to 
the growth solution, and the mixture was stirred until the yellow colloidal 
suspension became clear (transparent). 20 mL of this clear solution was 
injected with 1 mL of the Au–SiO2–WO3 NPs suspension, then 100 µL 
of formaldehyde was added, and a color change from colorless to purple 
was observed which is characteristic of the Au nanoshell formation. 
The resultant suspension was then centrifuged and redispersed in 
water, for later UV–vis spectrophotometry and Raman spectroscopy 
characterization.
Adding Reporter Molecule for SERS: The Au nanoshell bioconjugation 
was achieved by mixing 4-mercaptobenzoic acid (4-MBA) diluted 
in ethanol with the Au–SiO2–WO3 nanocomposites.[57] After these 
synthesis steps, thiolated Au–SiO2–WO3 core–shell nanocomposites 
were obtained. Figure S1 (Supporting Information) describes the entire 
synthesis steps. 1 × 10−3 m of 4-MBA solution was prepared by diluting 
an appropriate mass of the solid in ethanol (or aqueous). For the 
collection of SERS spectra, 100 µL of 1 × 10−3 m solution of 4-MBA was 
mixed with 1 mL of colloidal Au NPs. After 5 min stirring, the mixture 
was centrifuged three times for 7 min at 4000 rpm in 1.5 mL Eppendorf 
tubes, and the supernatant was redissolved in deionized water.
Cell Viability: Cell viability experiments were performed in 96-well 
plates and imaging experiments were performed in six-well plate. Cells 
were seeded in a 96-well plate at the density of 1 × 104 cells per well 
while cells were seeded onto the six-well plates at a density of 1 × 106 
cells per well and incubated for 24 h prior to the experiments. After 
overnight incubation, cells were treated with and without 100, 250, 
500, and 1000 µg mL−1 of four types of NPs for 24 h. Cell viability after 
nanoparticle treatment was determined using WST-1 assay (Roche 
Applied Biosystems) according to the manufacturer’s instructions 
with modifications to adapt for nanoparticle-treated cells. Briefly, cells 
were seeded in a 96-well plate with a density of 1 × 104 cells per well, 
differentiated and incubated with nanoparticles (three replicates per 
concentration). After 24 h, WST-1 reagent was added to the cells, and 
after the color reaction, the plate was then kept for shaking and then 
absorbance was measured at a wavelength of 450 nm using a plate reader 
(Clariostar plate reader, BMG labtech). The results were expressed as 
percentage cell viability. Three independent experiments were performed 
for each study and all measurements were performed in triplicate.
Statistical Analysis: The data were statistically analyzed using 
GraphPad Prism 5.04 to assess the effects of NPs treatment on cell 
viability and were expressed as % cell count ± SD, Mann Whitney. 
*(p < 0.05) was considered statistically significant. Results were 
presented as the mean ± standard deviation (SD).
Cell Imaging Using Coherent Antistokes Raman Spectroscopy: Coherent 
anti-Stokes Raman scattering (CARS) imaging was carried by using 
dual-wavelength output from an InSight X3 ultrafast fs laser (Newport 
SpectraPhysics) with 800 nm for the pump and probe beam and 1045 nm 
as the Stokes beam. The beams where chirped to produced ps pulses 
and spatially overlaid in the Spectral Focusing Timing and Recombination 
Unit (SF-TRU, Newport SpectraPhysics). The temporal overlap between 
the pump and Stokes beams was scanned via the SF-TRU unit to allowing 
us to rapidly change which Raman vibration was probed, and acquire 
spectral data.[58] 3D submicron resolution imaging was performed on 
a modified confocal microscope (Olympus FV3000), with a 60× water-
immersion objective (1.2NA, UPlanSApo, Olympus). The anti-Stokes light 
at 648 nm from CARS was collected in the forward direction using a water 
immersion objective (Olympus LUMPlanFLN 60X). The anti-Stokes light 
was separated from the laser fundamentals by using a long pass dichroic 
beamsplitter (Chroma DC/T760lpxr) followed by two filters (Chroma 
ET650/45x) and detected using a PMT (Hamamatsu R3896). The 
samples were mounted between two coverslips. To avoid photodamage 
to the samples, the laser intensities were attenuated to give 9 and 18 mW 
for the pump and Stokes beams in the sample plane, respectively.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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